Compositions and methods for delivering transgenes

JP2024161350A5Inactive Publication Date: 2024-12-05CRISPR THERAPEUTICS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024110847
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-17
Filing Date
2024-07-10
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current genome editing technologies suffer from inaccuracies and off-target editing, limiting their effectiveness in precisely manipulating genes at specific genomic loci, particularly for treating conditions like hemophilia A and hereditary angioedema.

Method used

The use of guide RNAs (gRNAs) with specific sequences, such as those listed in Table 3, combined with Cas9 endonucleases and donor templates, to target and integrate therapeutic genes like FVIII or SERPING1 into the albumin locus in hepatocytes, enhancing precision and efficacy.

Benefits of technology

This approach allows for precise integration and expression of therapeutic proteins, such as FVIII or SERPING1, reducing the need for frequent injections and providing a potentially permanent treatment for conditions like hemophilia A and hereditary angioedema.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000136_0000
    Figure 00000136_0000
  • Figure 00000136_0001
    Figure 00000136_0001
  • Figure 00000136_0002
    Figure 00000136_0002
Patent Text Reader

Abstract

To provide compositions, methods, and systems for targeted delivery of nucleic acids, including DNA and RNA, to a target cell.SOLUTION: The present invention provides a system comprising: a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding the DNA endonuclease; a guide RNA (gRNA) comprising a spacer sequence from any one of specific sequences, or a nucleic acid encoding the gRNA; and a donor template comprising a nucleic acid sequence encoding a gene-of-interest (GOI) or a functional derivative thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 747,128, filed October 17, 2018, which is expressly incorporated by reference herein in its entirety, including any drawings.

[0002] Incorporating a sequence listing The contents of the attached Sequence Listing are incorporated by reference into this application. The attached Sequence Listing text file entitled 052984-535001WO_Sequence Listing.txt was created on October 8, 2019, and is 125 KB.

[0003] The present disclosure provides compositions, methods, and systems for targeted delivery of nucleic acids to target cells, such as human cells. Some embodiments of the present invention relate to compositions, methods, and systems for expressing a transgene in a cell by genome editing. [Background technology]

[0004] Recent advances in genome sequencing technology and analytical methods have significantly accelerated our ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable the systematic reverse engineering of causal genetic variations by enabling the selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnology, and medical applications.

[0005] Gene editing using engineered site-specific nucleases has recently emerged as a technology for both basic biomedical research and therapeutic development. In recent years, various platforms based on four major types of endonucleases have been developed for gene editing: meganucleases and their derivatives, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced palindromic repeats (CRISPR)-associated endonuclease 9 (Cas9). Each nuclease type can induce DNA double-strand breaks (DSBs) at specific DNA loci, thereby triggering two DNA repair pathways. The non-homologous end joining (NHEJ) pathway generates random insertion / deletion (indel) mutations at DSBs, whereas the homology-directed repair (HDR) pathway repairs DSBs with the genetic information carried on the donor template. These gene editing platforms are therefore capable of manipulating genes at specific genomic loci in multiple ways, including disrupting gene function, successfully repairing mutated genes, and inserting DNA material.

[0006] However, currently available genome editing technologies can suffer from many disadvantages, such as precision, unacceptable levels of off-target editing, etc. Therefore, there remains a need for new genome gene editing platforms that can manipulate genes at specific genomic loci in multiple ways, such as disrupting gene function, successfully repairing mutated genes, and / or inserting heterologous DNA material at specific loci, such as safe harbor loci, within the genome of target cells. Summary of the Invention

[0007] Provided herein are, among others, compositions, methods and systems for targeted delivery of nucleic acids, including DNA and RNA, to target cells, for example, human cells.Also provided are compositions, methods and systems for expressing transgenes in cells by integrating the transgene into the cell genome in a targeted manner through genome editing.Certain aspects and embodiments of the present disclosure relate to compositions, methods and systems for knocking in a gene of interest (GOI) into a specific safe harbor location in the genome, particularly into or near the endogenous albumin locus.Furthermore, provided are compositions, methods and systems for treating subjects who have or are suspected of having a disorder or health condition using ex vivo and / or in vivo genome editing.

[0008] In one aspect, provided herein is a guide RNA (gRNA) sequence having a sequence complementary to a genomic sequence within or near an endogenous albumin locus.

[0009] In some embodiments, the gRNA has a sequence selected from those listed in Table 3, and variants thereof having at least 85% homology to any of those listed in Table 3.

[0010] In another aspect, provided herein is a composition comprising any of the above gRNAs.

[0011] In one aspect, provided herein is a system comprising a guide RNA (gRNA) or a nucleic acid encoding a gRNA disclosed herein. In some embodiments, the gRNA of the system has a sequence selected from those listed in Table 3, and variants thereof having at least 85% homology to any of those listed in Table 3.

[0012] In some embodiments, the system further comprises one or more of the following: a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding a DNA endonuclease, and a donor template having a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 22, 21, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0013] In some embodiments, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide, or a functional derivative thereof, or a functional derivative thereof. In some embodiments, the DNA endonuclease is a type II Cas endonuclease or a functional derivative thereof.

[0014] In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 is derived from Streptococcus pyogene (spCas9). In some embodiments, the Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0015] In some embodiments, the nucleic acid encoding the DNA endonuclease is codon-optimized for expression in the host cell.

[0016] In some embodiments, the nucleic acid sequence encoding the gene of interest (GOI) is codon-optimized for expression in a host cell. In some embodiments, the GOI encodes a polypeptide selected from the group consisting of a therapeutic polypeptide and a prophylactic polypeptide. In some embodiments, the GOI encodes a protein selected from the group consisting of a factor VIII (FVIII) protein, a factor IX protein, alpha-1-antitrypsin, a factor XIII (FXIII) protein, a factor VII (FVII) protein, a factor X (FX) protein, protein C, serine protease inhibitor G1 (serpin G1), or a functional derivative of any thereof. In some embodiments, the GOI encodes a FVIII protein or a functional derivative thereof. In some embodiments, the GOI encodes a FIX protein or a functional derivative thereof. In some embodiments, the GOI encodes a serpin G1 protein or a functional derivative thereof.

[0017] In some embodiments, the nucleic acid encoding the DNA endonuclease is a deoxyribonucleic acid (DNA) sequence.

[0018] In some embodiments, the nucleic acid encoding the DNA endonuclease is a ribonucleic acid (RNA) sequence.

[0019] In some embodiments, the RNA sequence encoding the DNA endonuclease is covalently linked to the gRNA.

[0020] In some embodiments, the composition further comprises a liposome or lipid nanoparticle.

[0021] In some embodiments, the donor template is encoded by an adeno-associated virus (AAV) vector.

[0022] In some embodiments, the DNA endonuclease is formulated in a liposome or lipid nanoparticle.

[0023] In some embodiments, the liposome or lipid nanoparticle also carries a gRNA.

[0024] In some embodiments, the DNA endonuclease is pre-complexed with the gRNA to form a ribonucleoprotein (RNP) complex.

[0025] In another aspect, provided herein is a kit having any of the above compositions, further comprising instructions for use.

[0026] In another aspect, provided herein is a method for editing a genome in a cell. The method includes providing a cell with: (a) any of the gRNAs or nucleic acids encoding the gRNAs described herein, (b) a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding a DNA endonuclease, and (c) a donor template having a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 22, 21, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0027] In some embodiments, the gRNA has a sequence selected from those listed in Table 3, and variants thereof having at least 85% homology to any of those listed in Table 3.

[0028] In some embodiments, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or a functional derivative thereof. In some embodiments, the DNA endonuclease is a Type II Cas endonuclease or a functional derivative thereof.

[0029] In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 is derived from Streptococcus pyogene (spCas9). In some embodiments, the Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0030] In some embodiments, the nucleic acid encoding the DNA endonuclease is codon optimized.

[0031] In some embodiments, the nucleic acid sequence encoding the gene of interest (GOI) is codon-optimized. In some embodiments, the GOI encodes a polypeptide selected from the group consisting of a therapeutic polypeptide and a prophylactic polypeptide. In some embodiments, the GOI encodes a protein selected from the group consisting of a FVIII protein, a FIX protein, alpha-1-antitrypsin, a FXIII protein, a FVII protein, a FX protein, protein C, serpin G1, or any functional derivative thereof.

[0032] In some embodiments, the nucleic acid encoding the DNA endonuclease is a deoxyribonucleic acid (DNA) sequence.

[0033] In some embodiments, the nucleic acid encoding the DNA endonuclease is a ribonucleic acid (RNA) sequence.

[0034] In some embodiments, the RNA sequence encoding the DNA endonuclease is covalently linked to the gRNA.

[0035] In some embodiments, the donor template is encoded by an AAV vector.

[0036] In some embodiments, one or more of (a), (b), and (c) are formulated in a liposome or lipid nanoparticle.

[0037] In some embodiments, the DNA endonuclease is formulated in a liposome or lipid nanoparticle.

[0038] In some embodiments, the liposome or lipid nanoparticle also carries a gRNA.

[0039] In some embodiments, the DNA endonuclease is pre-complexed with the gRNA to form an RNP complex prior to delivery to the cell.

[0040] In some embodiments, (a) and (b) are provided to the cell after (c) is provided to the cell.

[0041] In some embodiments, (a) and (b) are provided to the cell about 1 to 14 days after (c) is provided to the cell.

[0042] In some embodiments, a nucleic acid sequence encoding a gene of interest (GOI) is inserted into the genomic sequence of the cell.

[0043] In some embodiments, the insertion is at, within, or near an albumin gene or an albumin gene regulatory element in the genome of the cell.

[0044] In some embodiments, the insertion is within the first intron of the albumin gene.

[0045] In some embodiments, the insertion is at least 37 bp downstream of the end of the first exon of the human albumin gene in the genome and at least 330 bp upstream of the start of the second exon of the human albumin gene in the genome.

[0046] In some embodiments, the nucleic acid sequence encoding the gene of interest is expressed under the control of the endogenous albumin promoter.

[0047] In some embodiments, the cells are hepatocytes.

[0048] In another aspect, provided herein is a genetically modified cell, wherein the genome of the cell is edited by any of the above methods.

[0049] In some embodiments, a nucleic acid sequence encoding a gene of interest is inserted into the genomic sequence of the cell.

[0050] In some embodiments, the insertion is at, within, or near an albumin gene or an albumin gene regulatory element in the genome of the cell.

[0051] In some embodiments, the insertion is within the first intron of the albumin gene.

[0052] In some embodiments, the insertion is at least 37 bp downstream of the end of the first exon of the human albumin gene in the genome and at least 330 bp upstream of the start of the second exon of the human albumin gene in the genome.

[0053] In some embodiments, the nucleic acid sequence encoding the gene of interest is expressed under the control of the endogenous albumin promoter.

[0054] In some embodiments, the nucleic acid sequence encoding the gene of interest is codon-optimized.

[0055] In some embodiments, the cells are hepatocytes.

[0056] In another aspect, provided herein is a method of treating a disorder or condition in a subject, the method comprising administering to the subject any of the genetically modified cells described above.

[0057] In some embodiments, the subject is a patient with or suspected of having hemophilia A, hemophilia B, or HAE.

[0058] In some embodiments, the subject has been diagnosed with hemophilia A, hemophilia B, or at risk for HAE.

[0059] In some embodiments, the genetically modified cells are autologous.

[0060] In some embodiments, the cells are hepatocytes.

[0061] In some embodiments, a nucleic acid sequence encoding a gene of interest is inserted into the genomic sequence of the cell.

[0062] In some embodiments, the insertion is at, within, or near an albumin gene or an albumin gene regulatory element in the genome of the cell.

[0063] In some embodiments, the insertion is within the first intron of the albumin gene.

[0064] In some embodiments, the insertion is at least 37 bp downstream of the end of the first exon of the human albumin gene in the genome and at least 330 bp upstream of the start of the second exon of the human albumin gene in the genome.

[0065] In some embodiments, the nucleic acid sequence encoding the gene of interest is expressed under the control of the endogenous albumin promoter.

[0066] In some embodiments, the method further includes obtaining a biological sample from the subject, the biological sample having hepatocyte cells, and editing the genome of the hepatocyte cells by inserting a nucleic acid sequence encoding the gene of interest into the genomic sequence of the cells, thereby producing genetically modified cells.

[0067] In another aspect, the present invention provides a method for treating a disorder or a health condition in a subject. The method includes: obtaining a biological sample from a subject, the biological sample comprising hepatocyte cells; providing the hepatocyte cells with the following: (a) any of the above-mentioned gRNAs or nucleic acids encoding gRNAs; (b) deoxyribonucleic acid (DNA) endonucleases or nucleic acids encoding DNA endonucleases; and (c) a donor template comprising a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof; thereby generating a genetically modified cell; and administering the genetically modified cell to a subject.

[0068] In some embodiments, the subject is a patient having or suspected of having a disorder or condition selected from the group consisting of FVIII deficiency (hemophilia A), FIX deficiency (hemophilia B), Hunter syndrome (MPS II), Hurler syndrome (MPS1H), alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and hereditary angioedema (HAE). In some embodiments, the subject is a patient having or suspected of having hemophilia A. In some embodiments, the subject is a patient having or suspected of having hemophilia B. In some embodiments, the subject is a patient having or suspected of having HAE.

[0069] In some embodiments, the subject has been diagnosed as being at risk for a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE. In some embodiments, the subject has been diagnosed as being at risk for hemophilia A. In some embodiments, the subject has been diagnosed as being at risk for hemophilia B. In some embodiments, the subject has been diagnosed as being at risk for HAE.

[0070] In some embodiments, the genetically modified cells are autologous.

[0071] In some embodiments, the gRNA has a sequence selected from those listed in Table 3, and variants thereof having at least 85% homology to any of those listed in Table 3.

[0072] In some embodiments, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or a functional derivative thereof. In some embodiments, the DNA endonuclease is a Type II Cas endonuclease or a functional derivative thereof.

[0073] In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 is derived from Streptococcus pyogene (spCas9). In some embodiments, the Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0074] In some embodiments, the nucleic acid encoding the DNA endonuclease is codon optimized.

[0075] In some embodiments, the nucleic acid sequence encoding the gene of interest (GOI) or a functional derivative thereof is codon-optimized.

[0076] In some embodiments, the nucleic acid encoding the DNA endonuclease is a deoxyribonucleic acid (DNA) sequence.

[0077] In some embodiments, the nucleic acid encoding the DNA endonuclease is a ribonucleic acid (RNA) sequence.

[0078] In some embodiments, the RNA sequence encoding the DNA endonuclease is covalently linked to the gRNA.

[0079] In some embodiments, one or more of (a), (b), and (c) are formulated in a liposome or lipid nanoparticle.

[0080] In some embodiments, the donor template is encoded by an AAV vector.

[0081] In some embodiments, the DNA endonuclease is formulated in a liposome or lipid nanoparticle.

[0082] In some embodiments, the liposome or lipid nanoparticle also carries a gRNA.

[0083] In some embodiments, the DNA endonuclease is pre-complexed with the gRNA to form an RNP complex prior to delivery to the cell.

[0084] In some embodiments, (a) and (b) are provided to the cell after (c) is provided to the cell.

[0085] In some embodiments, (a) and (b) are provided to the cell about 1 to 14 days after (c) is provided to the cell.

[0086] In some embodiments, a nucleic acid sequence encoding the (GOI) or a functional derivative is inserted into the genomic sequence of the cell.

[0087] In some embodiments, the insertion is at, within, or near an albumin gene or an albumin gene regulatory element in the genome of the cell.

[0088] In some embodiments, the insertion is within the first intron of the albumin gene.

[0089] In some embodiments, the insertion is at least 37 bp downstream of the end of the first exon of the human albumin gene in the genome and at least 330 bp upstream of the start of the second exon of the human albumin gene in the genome.

[0090] In some embodiments, the nucleic acid sequence encoding the (GOI) or functional derivative is expressed under the control of the endogenous albumin promoter.

[0091] In some embodiments, the cells are hepatocytes.

[0092] In another aspect, provided herein is a method of treating a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE in a subject. The method comprises providing to a cell in the subject: (a) any of the gRNAs described above, (b) a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding a DNA endonuclease, and (c) a donor template having a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof.

[0093] In some embodiments, the subject is a patient having or suspected of having a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE.

[0094] In some embodiments, the subject has been diagnosed as being at risk for a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE.

[0095] In some embodiments, the gRNA has a sequence selected from those listed in Table 3, and variants thereof having at least 85% homology to any of those listed in Table 3.

[0096] In some embodiments, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or a functional derivative thereof. In some embodiments, the DNA endonuclease is a Type II Cas endonuclease or a functional derivative thereof.

[0097] In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 is derived from Streptococcus pyogene (spCas9). In some embodiments, the Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0098] In some embodiments, the nucleic acid encoding the DNA endonuclease is codon optimized.

[0099] In some embodiments, the nucleic acid sequence encoding the GOI or a functional derivative thereof is codon-optimized.

[0100] In some embodiments, the nucleic acid encoding the DNA endonuclease is a deoxyribonucleic acid (DNA) sequence.

[0101] In some embodiments, the nucleic acid encoding the DNA endonuclease is a ribonucleic acid (RNA) sequence.

[0102] In some embodiments, the RNA sequence encoding the DNA endonuclease is covalently linked to the gRNA.

[0103] In some embodiments, one or more of (a), (b), and (c) are formulated in a liposome or lipid nanoparticle.

[0104] In some embodiments, the donor template is encoded by an AAV vector.

[0105] In some embodiments, the DNA endonuclease is formulated in a liposome or lipid nanoparticle.

[0106] In some embodiments, the liposome or lipid nanoparticle also carries a gRNA.

[0107] In some embodiments, the DNA endonuclease is pre-complexed with the gRNA to form an RNP complex prior to delivery to the cell.

[0108] In some embodiments, (a) and (b) are provided to the cell after (c) is provided to the cell.

[0109] In some embodiments, (a) and (b) are provided to the cell about 1 to 14 days after (c) is provided to the cell.

[0110] In some embodiments, the nucleic acid sequence encoding the GOI or a functional derivative is inserted into the genomic sequence of the cell.

[0111] In some embodiments, the insertion is at, within, or near an albumin gene or an albumin gene regulatory element in the genome of the cell.

[0112] In some embodiments, the insertion is within the first intron of the albumin gene in the genome of the cell.

[0113] In some embodiments, the insertion is at least 37 bp downstream of the end of the first exon of the human albumin gene in the genome and at least 330 bp upstream of the start of the second exon of the human albumin gene in the genome.

[0114] In some embodiments, the nucleic acid sequence encoding the GOI or a functional derivative is expressed under the control of the endogenous albumin promoter.

[0115] In some embodiments, the cells are hepatocytes.

[0116] In some embodiments, the nucleic acid sequence encoding the GOI, such as a nucleic acid sequence encoding a FVIII protein or functional derivative, is expressed in the liver of the subject.

[0117] In another aspect, provided herein are methods for treating hemophilia A, hemophilia B, or HAE in a subject. The method includes administering genetically modified cells disclosed herein. In some embodiments, the genetically modified cells are autologous to the subject. In some embodiments, the method includes (i) obtaining a biological sample from the subject, the biological sample comprising hepatocytes, and preparing genetically modified cells from the hepatocytes.

[0118] Each of the aspects and embodiments described herein can be used together unless expressly or specifically excluded from the context of the embodiment or aspect.

[0119] The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the exemplary embodiments and features described herein, further aspects, embodiments, objects, and features of the present disclosure will become more fully apparent from the drawings and detailed description, and from the claims. [Brief explanation of the drawings]

[0120] An understanding of the particular features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0121] [Figure 1] Figure 1 shows a multiple alignment of different codon-optimized FVIII-BDD coding sequences. Only the mature coding sequence is shown (the signal peptide region has been removed). The ClustalW algorithm was used. [Figure 2] 1 shows non-limiting exemplary designs of DNA donor templates. [Figure 3] 1 shows the results of TIDE analysis of the cleavage efficiency of mAlb gRNA-T1 in Hepa1-6 cells. [Figure 4] Figure 1 shows the INDEL frequency in the liver and spleen of mice 3 days after administration of lipid nanoparticles (LNPs) encapsulating different doses of Cas9 mRNA and mAlb gRNA_T1, or PBS control. N=5 mice per group, mean values ​​are plotted. [Figure 5]Figure 1 shows the design of the DNA donor template for targeted integration into albumin intron 1 used in Example 4. SA: splice acceptor sequence, LHA: left homology arm, RHA: right homology arm, pA: polyadenylation signal, gRNA site: target site of gRNA that mediates cleavage by gRNA-targeted Cas9 nuclease, Δfurin: deletion of the furin site in FVIII, FVIII-BDD: coding sequence of human FVIII with a B domain deletion (BDD) in which the B domain is replaced with an SQ-linked peptide. [Figure 6] Figure 1 shows the INDEL frequencies of seven candidate gRNAs targeting human albumin intron 1 in primary human hepatocytes from four donors. [Figure 7] INDEL frequencies in non-human primate (monkey) primary hepatocytes transfected with different albumin guide RNAs and spCas9 mRNA. [Figure 8] FIG. 1 shows a schematic diagram of an exemplary AAV-mSEAP donor cassette. [Figure 9] FIG. 1 shows a schematic diagram of an exemplary FVIII donor cassette used for packaging into AAV. [Figure 10] Blood FVIII levels in hemophilia A mice are shown over a time course following injection of AAV8-pCB056, followed by injection of LNPs encapsulating spCas9 mRNA and mAlbT1 guide RNA. [Figure 11] FVIII levels in hemophilia A mice 10 and 17 days after injection of LNPs encapsulating spCas9 mRNA and gRNA. LNPs were administered 17 days or 4 days after AAV8-pCB0056. [Figure 12] FIG. 1 shows a schematic diagram of exemplary plasmid donors containing the human FVIII gene and different polyadenylation signal sequences. [Figure 13]Figure 1 shows FVIII activity and FVIII activity / targeted integration ratios in mice after hydrodynamic injection of a plasmid donor with three different polyA signals, followed by LNP-encapsulated Cas9 mRNA and mAlbT1 gRNA. Groups 2, 3, and 4 received pCB065, pCB076, and pCB077, respectively. The table includes the FVIII activity values, targeted integration frequency, and FVIII activity / TI ratios (ratios) at day 10 for individual mice. [Figure 14] A schematic diagram of an exemplary AAV donor cassette used to assess targeted integration in primary human hepatocytes is shown. [Figure 15] SEAP activity in the culture medium of primary human hepatocytes transduced with AAV-DJ-SEAP virus with or without lipofection of spCas9 mRNA and hALb4 gRNA. Two cell donors (HJK and ONR) were tested and are indicated by black and white bars. The three pairs of bars on the left represent SEAP activity in the control condition of cells transfected with Cas9 and gRNA only (first pair of bars), AAV-DJ-pCB0107 (SEAP virus) alone at 100,000 MOI (second pair of bars), or AAV-DJ-pCB0156 (FVIII virus) alone at 100,000 MOI (third pair of bars). The four pairs of bars on the right represent SEAP activity in wells of cells transduced with AAV-DJ-pCB0107 (SEAP virus) at various MIOs and transfected with Cas9 mRNA and hAlbT4 gRNA. [Figure 16]Figure 1 shows FVIII activity in the medium of primary human hepatocytes transduced with AAV-DJ-FVIII virus with or without lipofection of spCas9 mRNA and hAlbT4 gRNA. Two cell donors (HJK, ONR) were tested and are represented by black and white bars. The two pairs of bars on the left represent FVIII activity in the control condition of cells transduced with AAV-DJ-pCB0107 (SEAP virus) alone at 100,000 MOI (first pair of bars) or AAV-DJ-pCB0156 (FVIII virus) alone at 100,000 MOI (second pair of bars). The four pairs of bars on the right represent FVIII activity in the medium from wells of cells transduced with AAV-DJ-pCB0156 (FVIII virus) at various MOIs and transfected with Cas9 mRNA and hAlbT4 gRNA. [Figure 17A] 1 shows a non-limiting exemplary design of a DNA template containing a codon-optimized sequence for blood clotting factor IX (F9, FIX). hFIX SA: hFIX splice acceptor, spA+: signal peptide, stuffer: stuffer fragment derived from a human microsatellite sequence, 18: 18 bp random sequence. [Figure 17B] The figure summarizes the targeted integration efficiency of the donor DNA template depicted in Figure 17A in the first intron of the albumin locus. [Figure 18A] 1 shows a non-limiting exemplary design of a DNA template containing the coding sequence of the human serpin G1 / C1 inhibitor gene (SERPING1). [Figure 18B] The figure summarizes the SERPING1 activity expressed from the donor DNA template depicted in Figure 18A at day 11 after insertion into the first intron of the albumin locus. DETAILED DESCRIPTION OF THE INVENTION

[0122] The present disclosure provides, inter alia, compositions, methods, and systems for targeted delivery of nucleic acids, including DNA and RNA, to specific locations, such as safe harbor loci in the genome of target cells, such as mammalian cells, e.g., human cells. Site-specific delivery of transgenes is an advantageous alternative to random integration because it can reduce the risk of insertional mutagenesis. Some aspects and embodiments of the present disclosure relate to compositions, methods, and systems for expressing transgenes integrated into the genome of cells in a targeted manner by genome editing. In some embodiments, the transgene can be inserted into a specific safe harbor location in the genome, utilizing a promoter found in the safe harbor locus, or allowing transgene expression to be regulated by an exogenous promoter fused to the transgene before insertion. In some embodiments, the transgene of interest is integrated in a targeted manner near or within the first intron of the albumin gene. In principle, there are no particular limitations on the transgene delivered to the safe harbor locus. Some particular aspects and embodiments relate to systems, compositions, and methods for genome editing to express a therapeutic protein of interest, such as the blood clotting proteins FIX and C1 inhibitor (C1INH), integrated into a genomic location within or near the endogenous albumin locus, which is used as a specific safe harbor locus in the genome of a target cell. The present disclosure also provides systems, compositions, and methods for treating, both ex vivo and in vivo, subjects having or suspected of having a disease or condition, such as hemophilia B or hereditary angioedema (HAE), among other conditions, including systems for use in the treatment of a disorder or condition, and systems for use in the manufacture of a medicament for the treatment of a disorder or condition.

[0123] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is to be understood that the detailed description is exemplary and explanatory only and is not intended to limit any claimed subject matter. In this application, the use of the singular includes the plural unless expressly stated otherwise. It should be noted that as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the use of the term "including" and other forms such as "include," "includes," and "included" is not limiting.

[0124] Although various features of the present disclosure may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the present disclosure may be described herein in the context of separate embodiments for clarity, the present disclosure may also be implemented in a single embodiment. Published patent applications and other published references, documents, manuscripts, and scientific literature cited herein are incorporated by reference for any purpose. In case of conflict, the present specification, including definitions, will control. Furthermore, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0125] As used herein, ranges and amounts can be expressed as "about" a particular value or range. About also includes the exact amount. Thus, "about 5 μL" also means "about 5 μL" and "5 μL." Generally, the term "about" includes amounts that are expected to be within experimental error, such as ±10%.

[0126] When a range of numerical values ​​is presented herein, each intervening value between the lower and upper limits of the range, the upper and lower limits of the range, and all values ​​recited along with that range are encompassed within the disclosure. All possible subranges within the lower and upper limits of the range are also contemplated by the disclosure.

[0127] The terms "polypeptide," "polypeptide sequence," "peptide," "peptide sequence," "protein," "protein sequence," and "amino acid sequence" refer to a linear series of amino acid residues linked to each other by peptide bonds, and the series may include proteins, polypeptides, oligopeptides, peptides, and fragments thereof. Proteins may be composed of naturally occurring amino acids and / or synthetic (e.g., modified or non-naturally occurring) amino acids. Thus, as used herein, "amino acid" or "peptide residue" refers to both naturally occurring and synthetic amino acids. The terms "polypeptide," "peptide," and "protein" encompass fusion proteins, including, but not limited to, fusion proteins with heterologous amino acid sequences, fusions with heterologous and homologous leader sequences with or without an N-terminal methionine residue, immunologically tagged proteins, and fusion proteins with detectable fusion partners, such as fluorescent proteins, β-galactosidase, luciferase, etc., as fusion partners. Furthermore, it should be noted that a dash at the beginning or end of an amino acid sequence indicates either a peptide bond to a further sequence of one or more amino acid residues or a covalent attachment to the carboxyl or hydroxyl terminal group. However, the absence of a dash should not be construed to imply the absence of such a peptide bond or covalent bond to the carboxyl or hydroxyl terminal group, as such omission is conventional in the representation of amino acid sequences.

[0128] The terms "polynucleotide," "polynucleotide sequence," "oligonucleotide," "oligonucleotide sequence," "oligomer," "oligo," "nucleic acid sequence," or "nucleotide sequence," used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.

[0129] The terms "derivative" and "variant" refer to, but are not limited to, any compound, such as a nucleic acid or protein, having a structure or sequence derived from a compound disclosed herein and whose structure or sequence is sufficiently similar to that disclosed herein such that it would be expected by one of ordinary skill in the art, based on such similarity, to exhibit the same or similar activity and utility as the referenced compound, and are therefore also referred to interchangeably as "functionally equivalent" or "functional equivalent." Alterations to obtain a "derivative" or "variant" can include, for example, addition, deletion, and / or substitution of one or more nucleic acid or amino acid residues.

[0130] In the context of proteins, functional equivalents or functionally equivalent fragments may have one or more conservative amino acid substitutions. The term "conservative amino acid substitution" refers to the substitution of an amino acid with another amino acid that has similar properties to the original amino acid. The groups of conservative amino acids are as follows: [Table 1]

[0131] Conservative substitutions can be introduced into any position of a given peptide or its fragment.However, it may also be desirable to introduce non-conservative substitutions, particularly non-conservative substitutions at any one or more positions, but this is not limited to this.Non-conservative substitutions that result in the formation of functionally equivalent fragments of peptides will be substantially different, for example, in polarity, charge, and / or steric volume, while maintaining the functionality of derivative or variant fragments.

[0132] "Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, and the portion of the polynucleotide or polypeptide sequence within the comparison window may have additions or deletions (i.e., gaps) compared to the reference sequence (which does not have additions or deletions) for optimal alignment of the two sequences. In some examples, the percentage can be calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences to produce the number of matched positions, dividing the number of matched positions by the total number of positions within the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity.

[0133] The terms "identical" or percent "identity" in the context of two or more nucleic acid or polypeptide sequences refer to two or more sequences or subsequences that are identical or have a specified percentage of identical amino acid residues or nucleotides (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identity over a particular region, e.g., an entire polypeptide sequence or an individual domain of a polypeptide), when compared and aligned for maximum correspondence over a comparison window or designated region, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the complement of a test sequence.

[0134] The terms "complementary" or "substantially complementary," as used interchangeably herein, mean that a nucleic acid (e.g., DNA or RNA) has a sequence of nucleotides that allows it to non-covalently bind, i.e., form Watson-Crick base pairs and / or G / U base pairs, with another nucleic acid in a sequence-specific antiparallel manner (i.e., the nucleic acid specifically binds to the complementary nucleic acid). As known in the art, standard Watson-Crick base pairing includes adenine (A) pairing with thymidine (T), adenine (A) pairing with uracil (U), and guanine (G) pairing with cytosine (C).

[0135] A DNA sequence that "encodes" a specific RNA is a DNA nucleic acid sequence that is transcribed into RNA when placed under the control of an appropriate regulatory sequence. A DNA polynucleotide can encode an RNA (mRNA) that is translated into protein, or a DNA polynucleotide can encode an RNA that is not translated into protein (e.g., tRNA, rRNA, or guide RNA, also known as "non-coding" RNA or "ncRNA"). A protein-coding sequence or a sequence that encodes a specific protein or polypeptide is transcribed into mRNA (in the case of DNA) and translated into a polypeptide in vitro or in vivo (in the case of mRNA) when placed under the control of an appropriate regulatory sequence.

[0136] As used herein, a "codon" refers to a sequence of three nucleotides that together form a unit of genetic code in a DNA or RNA molecule. As used herein, the term "codon degeneracy" refers to the property in the genetic code that permits variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide.

[0137] The term "codon-optimized" or "codon optimization" refers to the coding region of a gene or nucleic acid molecule for transformation into various hosts, and refers to the modification of codons in the coding region of a gene or nucleic acid molecule to reflect the typical codon usage of the host organism without altering the polypeptide encoded by the DNA. Such optimization involves replacing at least one, or two or more, or a significant number of codons with one or more codons more frequently used in the genes of that organism. Codon usage tables are readily available, for example, from the "Codon Usage Database" at www.kazusa.or.jp / codon / (accessed March 20, 2008). By utilizing knowledge of codon usage or codon preference in each organism, one skilled in the art can apply the frequency to any given polypeptide sequence and generate a nucleic acid fragment of a codon-optimized coding region that encodes the polypeptide but uses the optimal codons for a given species. Codon-optimized coding regions can be designed by various methods known to those skilled in the art.

[0138] For example, the terms "recombinant" or "engineered" when used with respect to a cell, nucleic acid, protein, or vector indicate that the cell, nucleic acid, protein, or vector has been modified by or is the result of a laboratory method. Thus, for example, a recombinant or engineered protein includes a protein produced by a laboratory method. A recombinant or engineered protein can contain amino acid residues not found in the native (non-recombinant or wild-type) form of the protein or can contain amino acid residues that have been modified, e.g., labeled. The terms can include any modification to a peptide, protein, or nucleic acid sequence. Such modifications include any chemical modification of a peptide, protein, or nucleic acid sequence, including one or more amino acids, deoxyribonucleotides, or ribonucleotides, the addition, deletion, and / or substitution of one or more amino acids in a peptide or protein, and the addition, deletion, and / or substitution of one or more nucleic acids in a nucleic acid sequence.

[0139] The term "genomic DNA" or "genomic sequence" refers to the DNA of an organism's genome, including, but not limited to, the DNA of a bacterial, fungal, archaeal, plant, or animal genome.

[0140] As used herein, "transgene," "exogenous gene," or "exogenous sequence," in the context of nucleic acids, refers to a nucleic acid sequence or gene that was not present in the genome of a cell but that has been artificially introduced into the genome, e.g., via genome editing.

[0141] As used herein, "endogenous gene" or "endogenous sequence" in the context of nucleic acids refers to a nucleic acid sequence or gene that is naturally present in the genome of a cell, without being introduced through artificial means.

[0142] The terms "vector" or "expression vector" mean a replicon, such as a plasmid, phage, virus, or cosmid, to which another DNA segment, or "insert," may be attached so as to bring about the replication of the attached segment in a cell.

[0143] The term "expression cassette" refers to a vector having a DNA coding sequence operably linked to a promoter. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. The terms "recombinant expression vector" or "DNA construct" are used interchangeably herein and refer to a vector and a DNA molecule having at least one insert. Recombinant expression vectors are typically generated for the purposes of expressing and / or propagating insert(s) or for the construction of other recombinant nucleotide sequences. The nucleic acid(s) may or may not be operably linked to a promoter sequence and may or may not be operably linked to a DNA regulatory sequence.

[0144] The term "operably linked" means that the nucleotide sequence of interest is linked to a regulatory sequence(s) in a manner that allows expression of the nucleotide sequence. The term "regulatory sequence" is intended to include, for example, promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are well known in the art and are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Those skilled in the art will understand that the design of an expression vector can depend on factors such as the selection of target cells, the desired expression level, etc.

[0145] A cell is "genetically modified" or "transformed" or "transfected" when exogenous DNA, such as by a recombinant expression vector, has been introduced into the cell. The presence of the exogenous DNA results in a permanent or transient genetic change. The transforming DNA may or may not be integrated (covalently linked) into the cell's genome. Genetically modified (or transformed or transfected) cells can be used with therapeutic activity, such as to treat hemophilia A, and are called therapeutic cells.

[0146] The term "concentration" as used in the context of a molecule such as a peptide fragment refers to the amount of the molecule present in a given volume of solution, e.g., the number of moles of the molecule.

[0147] The terms "individual," "subject," and "host" are used interchangeably herein and refer to any subject for whom diagnosis, treatment, or therapy is desired. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a patient. In some embodiments, the subject is a human patient. In some embodiments, the subject may have or is suspected of having a disorder or health condition associated with a gene of interest (GOI). In some embodiments, the subject may have or is suspected of having hemophilia A, and / or has one or more symptoms of hemophilia A. In some embodiments, the subject is a human diagnosed at or after diagnosis as being at risk for a disorder or health condition associated with the GOI. In some embodiments, the subject is a human diagnosed at or after diagnosis as being at risk for hemophilia A. In some examples, a diagnosis of being at risk for a disorder or health condition associated with the GOI can be determined based on the presence of one or more mutations in the endogenous GOI or genomic sequence near the GOI within the genome that can affect expression of the GOI.

[0148] The term "treatment" when used to refer to a disease or condition means that at least an improvement in the symptoms associated with the condition afflicting an individual is achieved, where improvement refers broadly to at least a reduction in a parameter associated with the condition being treated (e.g., hemophilia A), e.g., the magnitude of the symptoms. Thus, treatment also includes situations in which a pathological condition, or at least the symptoms associated therewith, are completely suppressed, e.g., prevented from occurring, or completely eliminated such that the host no longer suffers from the condition, or at least the symptoms characteristic of the condition. Thus, treatment includes (i) prevention, i.e., preventing clinical symptoms from developing, e.g., reducing the risk of developing clinical symptoms, including preventing disease progression, and (ii) inhibition, i.e., preventing the onset or further development of clinical symptoms, e.g., reducing or completely inhibiting active disease.

[0149] As used herein, the terms "effective amount," "pharmaceutical effective amount," or "therapeutically effective amount" refer to a composition sufficient to provide a desired benefit when administered to a subject with a particular condition. In the context of ex vivo treatment of hemophilia A, the term "effective amount" refers to the amount of a therapeutic cell population or their progeny necessary to prevent or alleviate at least one sign or symptom of hemophilia A, and relates to a sufficient amount of a composition having therapeutic cells or their progeny to provide a desired effect, e.g., treat a symptom of hemophilia A in a subject. Thus, the term "therapeutically effective amount" refers to an amount of therapeutic cells or a composition having therapeutic cells sufficient to promote a particular effect when administered to a subject in need of treatment, such as a subject with or at risk of hemophilia A. An effective amount also includes an amount sufficient to prevent or delay the onset of disease symptoms, alter the course of disease symptoms (e.g., but not limited to, delaying the progression of disease symptoms), or reverse disease symptoms. In the context of in vivo treatment of hemophilia A in a subject (e.g., a patient) or genome editing performed in cells cultured in vitro, an effective amount refers to the amount of components used for genome editing, such as gRNA, donor template, and / or site-specific polypeptide (e.g., DNA endonuclease), required to edit the genome of cells in the subject or cells cultured in vitro. It will be understood that an appropriate "effective amount" for any given case can be determined by one of ordinary skill in the art using routine experimentation.

[0150] As used herein, the term "pharmaceutically acceptable excipient" refers to any suitable substance that provides a pharmaceutically acceptable carrier, additive, or diluent for administering a compound(s) of interest to a subject. A "pharmaceutically acceptable excipient" can encompass substances referred to as pharmaceutically acceptable diluents, pharmaceutically acceptable additives, and pharmaceutically acceptable carriers.

[0151] Systems for genome editing In one aspect, provided herein are compositions, methods, and systems for expressing a gene of interest (GOI) in cells by genome editing. In some embodiments, the provided compositions, methods, and systems are for knocking in a GOI at a specific safe harbor location within a genome, particularly at a genomic location within or near the endogenous albumin locus. Generally, those skilled in the art will understand that a safe harbor locus is a location within a genome that can be used to integrate an exogenous nucleic acid, and the addition of an exogenous nucleic acid to the safe harbor locus does not significantly affect the growth of the host cell by the addition of the nucleic acid alone. In some embodiments, a GOI can be inserted into a specific safe harbor location within a genome, utilizing a promoter found in the safe harbor locus, or allowing for regulating the expression of the GOI by an exogenous promoter fused to the GOI coding sequence before insertion. In some embodiments, the GOI of interest is integrated in a targeted manner near or within the first intron of the albumin gene.

[0152] In principle, there are no particular limitations on the transgene delivered to the safe harbor locus. In some embodiments, the GOI encodes a polypeptide selected from the group consisting of therapeutic polypeptides and prophylactic polypeptides. In some embodiments, the GOI encodes a protein selected from the group consisting of FVIII protein, factor IX protein, alpha-1-antitrypsin, FXIII protein, FVII protein, FX protein, protein C, or any functional derivative thereof. Some specific embodiments relate to compositions and methods for regulating the expression, function, or activity of blood coagulation proteins such as FVIII in cells by genome editing. The present disclosure also provides, inter alia, compositions and methods for treating patients with or suspected of having a disorder or condition associated with one or more of the above proteins, both ex vivo and in vivo. In some embodiments, the patient has or is suspected of having a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE. In some embodiments, the patient has hemophilia A. In some embodiments, the patient has hemophilia B. In some embodiments, the patient has HAE.

[0153] Hemophilia A (HemA) and Factor VIII Hemophilia A (HemA) is caused by a genetic defect in the FVIII gene, resulting in low or undetectable levels of FVIII protein in the blood. This results in ineffective clot formation at sites of tissue injury, leading to uncontrolled bleeding that can be fatal if left untreated. Replacing the missing FVIII protein is an effective treatment for HemA patients and is the current standard of care. However, protein replacement therapy requires frequent intravenous injections of FVIII protein, which are inconvenient for adults, problematic for children, prohibitively expensive (>$200,000 / year), and can lead to breakthrough bleeding events if the treatment plan is not strictly adhered to.

[0154] FVIII gene is mainly expressed in the sinusoidal endothelial cells present in the liver and other parts of the body.Exogenous FVIII can be expressed in the hepatocytes of the liver that produce FVIII and secreted into the circulation, thus affecting the healing of disease.Gene delivery methods that target hepatocytes of the liver have been developed, and therefore have been used to deliver FVIII gene as a treatment for HemA in both animal models and patients in clinical trials.

[0155] A permanent cure for hemophilia A is highly desirable. While conventional viral-based gene therapy using AAVs has shown promise in preclinical animal models and patients, it has many drawbacks. AAV-based gene therapy uses a liver-specific promoter-driven FVIII gene encapsulated within an AAV viral capsid (commonly using serotypes AAV5, AAV8, or AAV9, or AAVrh10). All AAV viruses used in gene therapy deliver the packaged gene cassette to the nucleus of the transduced cell, where it remains almost exclusively episomal—an episomal copy of the therapeutic gene that produces the therapeutic protein. AAV does not have a mechanism for integrating its encapsulated DNA into the host cell genome; instead, it is maintained episomally and therefore not replicated when the host cell divides. Episomal DNA can be subject to degradation over time. It has been demonstrated that when hepatocytes containing AAV episomes are induced to divide, the AAV genome does not replicate but is instead diluted. As a result, AAV-based gene therapy is not expected to be effective when given to children whose livers have not yet reached adult size. Furthermore, it is currently unknown how long AAV-based gene therapy will last when given to adults, although animal data have shown only minor loss of therapeutic efficacy over periods as long as 10 years. Therefore, there is a critical need to develop new, effective, and systemic treatments for HemA.

[0156] Hemophilia B (HemB) and Factor IX Hemophilia B is an inherited bleeding disorder caused by a deficiency or dysfunction of blood clotting factor IX (FIX). Without sufficient factor IX, blood cannot clot properly to control bleeding. It was originally named "Christmas disease" after the first person diagnosed with the disorder. All racial and economic groups are affected by the disorder. Hemophilia B is inherited as an X-linked recessive disorder, usually affecting males and inherited by females who carry a causative mutation on the X chromosome. Hemophilia B results from various defects in the FIX gene. Hemophilia B is the second most common type of hemophilia, and FIX deficiency is four to six times less prevalent than FVIII deficiency (hemophilia A).

[0157] Hemophilia B is generally classified as severe, moderate, or mild based on the plasma levels of factor IX in affected individuals (<1%, 2–5%, and 6–30%, respectively). Multiple underlying mutations have been identified and are associated with different levels of clinical severity. Factor IX deficiency leads to an increased tendency to bleeding, which can occur spontaneously or in response to minor trauma. Factor IX deficiency can cause interference with the coagulation cascade, resulting in spontaneous bleeding following trauma. When activated, factor IX activates factor X, which promotes the conversion of fibrinogen to fibrin. Currently, diagnosis of hemophilia B can be performed by many known techniques and methods, including coagulation screening tests, bleeding scores, and coagulation factor assays.

[0158] Hereditary Angioedema (HAE) and SERPING1 Hereditary angioedema (HAE) is a genetic disorder primarily caused by mutations in the SERPING1 gene, which encodes C1 inhibitor (C1INH), a serine protease inhibitor (serpin) that causes plasma depletion and leads to recurrent attacks of severe swelling. There are three main types of HAE: types I and II are caused by mutations in the SERPING1 gene, which makes the C1 inhibitor protein, while type III is often due to mutations in the factor XII gene. This results in increased amounts of bradykinin, which promotes swelling. The condition can be inherited from an individual's parents in an autosomal dominant manner or can arise as a de novo mutation. Attack triggers can include minor trauma or stress, but attacks often occur without any apparent antecedent events.

[0159] Hereditary angioedema affects approximately 1 in 50,000 people. The disorder is typically first noticed during childhood. Types I and II affect women and men equally. Type III is more common in women than men. It involves the airways and, if untreated, is associated with approximately 25% mortality. Currently, diagnosis of types I and II can be performed by many known techniques and methods, including those based on measuring serum complement factor 4 (C4) and C1 inhibitor (C1-INH) levels. For example, blood tests can be used to diagnose the disorder by measuring one or more of serum complement factors 2 and 4 (C2 and C4), C1 inhibitor (C1-INH) antigen protein, and C1 inhibitor (C1-INH) functional levels.

[0160] In some embodiments, provided herein are systems for genome editing, particularly systems for inserting a nucleic acid sequence encoding a gene of interest (GOI) into the genome of a cell. These systems can be used in the methods described herein, such as editing the genome of a cell and treating a subject, e.g., a patient suffering from a condition or disorder associated with the GOI. In some embodiments, the GOI can encode the amino acid sequence of a polypeptide. Generally, there are no particular limitations on the size or biological activity or functionality of the encoded polypeptide. Thus, the encoded polypeptide can be any polypeptide, such as a therapeutic polypeptide, a preventive polypeptide, a diagnostic polypeptide, or a nutraceutical polypeptide. In some embodiments, the GOI encodes a protein selected from the group consisting of FVIII protein, factor IX protein, alpha-1-antitrypsin, FXIII protein, FVII protein, FX protein, protein C, or a functional derivative of any of them. In some embodiments, the systems disclosed herein can be used in the methods described herein, such as editing the genome of a cell and treating a patient suffering from or suspected of having a disorder or condition associated with one or more of the above proteins, both ex vivo and in vivo. In some embodiments, the patient has or is suspected of having a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE. In some embodiments, the patient has hemophilia A. In some embodiments, the patient has hemophilia B. In some embodiments, the patient has HAE.

[0161] In some embodiments, provided herein is a system comprising: (a) a nucleic acid encoding a deoxyribonucleic acid (DNA) endonuclease or a DNA endonuclease; (b) a guide RNA (gRNA) comprising a spacer sequence or a nucleic acid encoding a gRNA from any one of SEQ ID NOs: 18-44 and 104; and (c) a donor template comprising a nucleic acid sequence encoding a gene of interest (e.g., FVIII, FIX, or SERPING1). In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0162] In some embodiments, provided herein is a system comprising: (a) a nucleic acid encoding a deoxyribonucleic acid (DNA) endonuclease or a DNA endonuclease; (b) a guide RNA (gRNA) comprising a spacer sequence or a nucleic acid encoding a gRNA from any one of SEQ ID NOs: 18-44 and 104; and (c) a donor template comprising a nucleic acid sequence encoding a FVIII gene. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0163] In some embodiments, provided herein is a system comprising: (a) a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding a DNA endonuclease; (b) a guide RNA (gRNA) comprising a spacer sequence or a nucleic acid encoding a gRNA from any one of SEQ ID NOs: 18-44 and 104; and (c) a donor template comprising a nucleic acid sequence encoding a FIX gene. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0164] In some embodiments, provided herein is a system comprising: (a) a deoxyribonucleic acid (DNA) endonuclease or a nucleic acid encoding a DNA endonuclease; (b) a guide RNA (gRNA) comprising a spacer sequence or a nucleic acid encoding a gRNA from any one of SEQ ID NOs: 18-44 and 104; and (c) a donor template comprising a nucleic acid sequence encoding a SERPING1 gene. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0165] In some embodiments, according to any of the systems described herein comprising a DNA endonuclease or a nucleic acid encoding a DNA endonuclease, the DNA endonuclease is a Cas endonuclease. In some embodiments, the Cas endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide. In some embodiments, the Cas endonuclease is a type II Cas endonuclease. In some embodiments, the Cas endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease is derived from Streptococcus pyogenes (SpyCas9). For example, in some embodiments, the Cas9 comprises the amino acid sequence of SEQ ID NO: 110 or a variant thereof having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 110. In some embodiments, the Cas9 endonuclease is derived from Staphylococcus lugdunensis (SluCas9). For example, in some embodiments, the Cas9 comprises the amino acid sequence of SEQ ID NO:111 or a variant thereof having at least 75% sequence identity to the amino acid sequence of SEQ ID NO:111.

[0166] In some embodiments, according to any of the systems described herein comprising a DNA endonuclease or a nucleic acid encoding a DNA endonuclease, the DNA endonuclease is an engineered endonuclease comprising two or more portions derived from different Cas endonucleases. In some embodiments, the engineered endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide. In some embodiments, the different Cas endonuclease is a Type II Cas endonuclease. In some embodiments, the different Cas endonuclease is a Cas9 endonuclease. In some embodiments, the engineered endonuclease comprises a PAM-interacting domain (PID) derived from Streptococcus pyogenes Cas9 (SpyCas9). In some embodiments, the engineered endonuclease comprises a PID derived from Staphylococcus lugdunensis Cas9 (SluCas9).

[0167] In some embodiments, any of the systems described herein allows the DNA endonuclease to recognize a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or functional derivative thereof. In some embodiments, the DNA endonuclease is a type II Cas endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, Cas9 is derived from Streptococcus pyogenes (spCas9). In some embodiments, Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0168] In some embodiments, by any of the systems described herein, the nucleic acid sequence encoding the gene of interest is codon-optimized for expression in a host cell, hi some embodiments, the nucleic acid sequence encoding the gene of interest is codon-optimized for expression in a human cell.

[0169] In some embodiments, according to any of the systems described herein, the system includes a nucleic acid encoding a DNA endonuclease. In some embodiments, the nucleic acid encoding the DNA endonuclease is codon-optimized for expression in a host cell. In some embodiments, the nucleic acid encoding the DNA endonuclease is codon-optimized for expression in a human cell. In some embodiments, the nucleic acid encoding the DNA endonuclease is DNA, such as a DNA plasmid. In some embodiments, the nucleic acid encoding the DNA endonuclease is RNA, such as mRNA.

[0170] In some embodiments, in any of the systems described herein, the donor template is encoded by an AAV vector. In some embodiments, the donor template includes a donor cassette containing a nucleic acid sequence encoding a GOI, and the donor cassette is flanked on one or both sides by gRNA target sites. In some embodiments, the donor cassette is flanked on both sides by gRNA target sites. In some embodiments, the gRNA target sites are target sites for the gRNA in the system. In some embodiments, the gRNA target site of the donor template is the reverse complement of the cellular genome gRNA target site for the gRNA in the system.

[0171] In some embodiments, according to any of the systems described herein, the DNA endonuclease or a nucleic acid encoding the DNA endonuclease is formulated into a liposome or lipid nanoparticle. In some embodiments, the liposome or lipid nanoparticle also comprises a gRNA. In some embodiments, the liposome or lipid nanoparticle is a lipid nanoparticle. In some embodiments, the system comprises a lipid nanoparticle comprising a nucleic acid encoding the DNA endonuclease and a gRNA. In some embodiments, the nucleic acid encoding the DNA endonuclease is an mRNA encoding the DNA endonuclease.

[0172] In some embodiments, by any of the systems described herein, a DNA endonuclease is complexed with a gRNA to form an RNP complex.

[0173] nucleic acid Genome-targeting nucleic acids or guide RNAs The present disclosure provides genome-targeting nucleic acids that can direct the activity of an associated polypeptide (e.g., a site-specific polypeptide or DNA endonuclease) to a specific target sequence within a target nucleic acid. In some embodiments, the genome-targeting nucleic acid is RNA. The genome-targeting RNA is referred to herein as a "guide RNA" or "gRNA." The guide RNA has at least a spacer sequence that hybridizes to the target nucleic acid sequence of interest and a CRISPR repeat sequence. In Type II systems, the gRNA also contains a second RNA called a tracrRNA sequence. In Type II guide RNAs (gRNAs), the CRISPR repeat sequence and the tracrRNA sequence hybridize to each other to form a duplex. In Type V guide RNAs (gRNAs), the crRNA forms a duplex. In both systems, the duplex binds to a site-specific polypeptide, thereby forming a complex between the guide RNA and the site-specific polypeptide. The genome-targeting nucleic acid provides target specificity to the complex through its association with the site-specific polypeptide. Thus, the genome-targeting nucleic acid directs the activity of the site-specific polypeptide.

[0174] In some embodiments, the genome-targeting nucleic acid is a dual-molecule guide RNA. In some embodiments, the genome-targeting nucleic acid is a single-molecule guide RNA. A dual-molecule guide RNA has two RNA strands. The first strand has, from 5' to 3', an optional spacer extension sequence, a spacer sequence, and a minimal CRISPR repeat sequence. The second strand has, from 5' to 3', a minimal tracrRNA sequence (complementary to the minimal CRISPR repeat sequence), a 3' tracrRNA sequence, and an optional tracrRNA extension sequence. In a Type II system, a single-molecule guide RNA (sgRNA) has, from 5' to 3', an optional spacer extension sequence, a spacer sequence, a minimal CRISPR repeat sequence, a single-molecule guide linker, a minimal tracrRNA sequence, a 3' tracrRNA sequence, and an optional tracrRNA extension sequence. The optional tracrRNA extension may have an element that confers additional function (e.g., stability) to the guide RNA. The single-molecule guide linker connects the minimal CRISPR repeat and the minimal tracrRNA sequence to form a hairpin structure. Any tracrRNA extension has one or more hairpins. The single-molecule guide RNA (sgRNA) in the Type V system has, in the 5' to 3' direction, the minimal CRISPR repeat sequence and a spacer sequence.

[0175] As an illustration, guide RNAs used in the CRISPR / Cas / Cpf1 system, or other smaller RNAs, can be easily synthesized by chemical means, as shown below and described in the art. While chemical synthesis procedures are continually expanding, purification of such RNAs by procedures such as high-performance liquid chromatography (HPLC), which avoid the use of gels such as PAGE, tends to become more difficult as the length of polynucleotides increases significantly beyond about 100 nucleotides. One approach used to generate longer RNAs is to generate two or more molecules that are ligated together. Much longer RNAs, such as those encoding Cas9 or Cpf1 endonucleases, are more easily generated enzymatically. Various types of RNA modifications can be introduced during or after chemical synthesis and / or enzymatic production of the RNA; for example, modifications that increase stability, reduce the likelihood or severity of innate immune responses, and / or enhance other attributes, as described in the art.

[0176] Spacer extension sequence In some embodiments of genome-targeting nucleic acids, a spacer extension sequence can modify activity, provide stability, and / or provide a location for modification of the genome-targeting nucleic acid. The spacer extension sequence can modify on-target or off-target activity or specificity. In some embodiments, a spacer extension sequence can be provided. The spacer extension sequence can have a length of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 1000, 2000, 3000, 4000, 5000, 6000, or 7000 or more nucleotides. The spacer extension sequence can have a length of about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 1000, 2000, 3000, 4000, 5000, 6000, or 7000 or more nucleotides. The spacer extension sequence can have a length of less than 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 1000, 2000, 3000, 4000, 5000, 6000, 7000, or more nucleotides. In some embodiments, the spacer extension sequence is less than 10 nucleotides in length. In some embodiments, the spacer extension sequence is 10-30 nucleotides in length. In some embodiments, the spacer extension sequence is 30-70 nucleotides in length.

[0177] In some embodiments, the spacer extension sequence comprises another moiety (e.g., a stability control sequence, an endoribonuclease binding sequence, a ribozyme). In some embodiments, the moiety decreases or increases the stability of the nucleic acid targeting the nucleic acid. In some embodiments, the moiety is a transcription terminator segment (i.e., a transcription termination sequence). In some embodiments, the moiety functions in eukaryotic cells. In some embodiments, the moiety functions in prokaryotic cells. In some embodiments, the moiety functions in both eukaryotic and prokaryotic cells. Non-limiting examples of suitable moieties include a 5' cap (e.g., a 7-methylguanylate cap (m7 G)), a riboswitch sequence (e.g., to allow for regulated stability and / or regulated accessibility by proteins and protein complexes), a sequence that forms a dsRNA duplex (i.e., a hairpin), a sequence that targets the RNA to a subcellular location (e.g., the nucleus, mitochondria, chloroplasts, etc.), a modification or sequence that provides tracking (e.g., direct conjugation to a fluorescent molecule, conjugation to a moiety that facilitates fluorescent detection, a sequence that allows for fluorescent detection, etc.), and / or a modification or sequence that provides a binding site for a protein (e.g., a protein that acts on DNA, including a transcriptional activator, a transcriptional repressor, a DNA methyltransferase, a DNA demethylase, a histone acetyltransferase, a histone deacetylase, etc.).

[0178] Spacer sequence Spacer sequence hybridizes with the sequence of target nucleic acid of interest.The spacer of genome targeting nucleic acid interacts with target nucleic acid in a sequence-specific manner through hybridization (i.e., base pairing).Therefore, the nucleotide sequence of spacer varies according to the sequence of target nucleic acid of interest.

[0179] In the CRISPR / Cas system herein, the spacer sequence is designed to hybridize to the target nucleic acid located 5' of the PAM of the Cas9 enzyme used in the system. The spacer can perfectly match the target sequence or can have a mismatch. Each Cas9 enzyme has a specific PAM sequence that it recognizes in the target DNA. For example, S. pyogenes recognizes a PAM with the sequence 5'-NRG-3' in the target nucleic acid, where R is either A or G, and N is any nucleotide, and N is immediately 3' of the target nucleic acid sequence targeted by the spacer sequence.

[0180] In some embodiments, the target nucleic acid sequence has 20 nucleotides. In some embodiments, the target nucleic acid has fewer than 20 nucleotides. In some embodiments, the target nucleic acid has more than 20 nucleotides. In some embodiments, the target nucleic acid has at least 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or more nucleotides. In some embodiments, the target nucleic acid has up to 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or more nucleotides. In some embodiments, the target nucleic acid sequence has 20 bases immediately 5' to the first nucleotide of the PAM. For example, [ka] In a sequence having the formula: , the target nucleic acid can have a sequence corresponding to N, where N is any nucleotide, and the underlined sequence NRG (where R is G or A) is a Streptococcus pyogenes Cas9 PAM. In some embodiments, the PAM sequence used in the disclosed compositions and methods as a sequence recognized by SpCas9 is NGG.

[0181] In some embodiments, the spacer sequence that hybridizes to the target nucleic acid has a length of at least about 6 nucleotides (nt), such as at least about 6 nt, about 10 nt, about 15 nt, about 18 nt, about 19 nt, about 20 nt, about 25 nt, about 30 nt, about 35 nt, or about 40 nt, or from about 6 nt to about 80 nt, from about 6 nt to about 50 nt, from about 6 nt to about 45 nt, from about 6 nt to about 40 nt, from about 6 nt to about 35 nt, from about 6 nt to about 30 nt, from about 6 nt to about 25 nt, from about 6 nt to about 20 nt, from about 6 nt to about 19 nt, from about 10 nt to about 50 nt, from about 10 nt to about 45 nt, from about 10 nt to about 40 nt, from about 10 nt to about 35 nt, or from about The spacer sequence may be 10 nt to about 30 nt, about 10 nt to about 25 nt, about 10 nt to about 20 nt, about 10 nt to about 19 nt, about 19 nt to about 25 nt, about 19 nt to about 30 nt, about 19 nt to about 35 nt, about 19 nt to about 40 nt, about 19 nt to about 45 nt, about 19 nt to about 50 nt, about 19 nt to about 60 nt, about 20 nt to about 25 nt, about 20 nt to about 30 nt, about 20 nt to about 35 nt, about 20 nt to about 40 nt, about 20 nt to about 45 nt, about 20 nt to about 50 nt, or about 20 nt to about 60 nt. In some embodiments, the spacer sequence comprises 20 nucleotides. In some embodiments, the spacer comprises 19 nucleotides. In some embodiments, the spacer comprises 18 nucleotides. In some embodiments, the spacer comprises 17 nucleotides. In some embodiments, the spacer comprises 16 nucleotides. In some embodiments, the spacer comprises 15 nucleotides.

[0182] In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, at least about 99%, or 100%. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is up to about 30%, up to about 40%, up to about 50%, up to about 60%, up to about 65%, up to about 70%, up to about 75%, up to about 80%, up to about 85%, up to about 90%, up to about 95%, up to about 97%, up to about 98%, up to about 99%, or 100%. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is 100% over the six consecutive 5'-terminal nucleotides of the target sequence of the complementary strand of the target nucleic acid. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is at least 60% over approximately 20 consecutive nucleotides. In some embodiments, the lengths of the spacer sequence and the target nucleic acid can differ by 1 to 6 nucleotides, which can be considered one or more bulges.

[0183] In some embodiments, spacer sequences are designed or selected using a computer program, which may use variables such as predicted melting temperature, secondary structure formation, predicted annealing temperature, sequence identity, genomic context, chromatin accessibility, %GC, genomic frequency (e.g., of identical or similar sequences that differ in one or more spots as a result of mismatches, insertions, or deletions), methylation status, and the presence of SNPs.

[0184] Minimal CRISPR repeat sequence In some embodiments, a minimal CRISPR repeat sequence is a sequence that has at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% sequence identity to a reference CRISPR repeat sequence (e.g., crRNA from S. pyogenes).

[0185] In some embodiments, the minimum CRISPR repeat sequence has nucleotides that can hybridize to the minimum tracrRNA sequence in cells. The minimum CRISPR repeat sequence and the minimum tracrRNA sequence form a duplex, i.e., a double-stranded structure of base pairs. Together, the minimum CRISPR repeat sequence and the minimum tracrRNA sequence bind to the site-specific polypeptide. At least a portion of the minimum CRISPR repeat sequence hybridizes to the minimum tracrRNA sequence. In some embodiments, at least a portion of the minimum CRISPR repeat sequence has at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% complementarity to the minimum tracrRNA sequence. In some embodiments, at least a portion of the minimal CRISPR repeat sequence has at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% complementarity to the minimal tracrRNA sequence.

[0186] The minimal CRISPR repeat sequence can be about 7 nucleotides to about 100 nucleotides in length. For example, the length of the minimal CRISPR repeat sequence is about 7 nucleotides (nt) to about 50 nt, about 7 nt to about 40 nt, about 7 nt to about 30 nt, about 7 nt to about 25 nt, about 7 nt to about 20 nt, about 7 nt to about 15 nt, about 8 nt to about 40 nt, about 8 nt to about 30 nt, about 8 nt to about 25 nt, about 8 nt to about 20 nt, about 8 nt to about 15 nt, about 15 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt. In some embodiments, the minimal CRISPR repeat sequence is approximately 9 nucleotides in length. In some embodiments, the minimal CRISPR repeat sequence is approximately 12 nucleotides in length.

[0187] In some embodiments, the minimal CRISPR repeat sequence is at least about 60% identical to a reference minimal CRISPR repeat sequence (e.g., a wild-type crRNA from S. pyogenes) over a stretch of at least 6, 7, or 8 consecutive nucleotides. For example, the minimal CRISPR repeat sequence is at least about 65% identical, at least about 70% identical, at least about 75% identical, at least about 80% identical, at least about 85% identical, at least about 90%, at least about 95% identical, at least about 98% identical, at least about 99% identical, or 100% identical to the reference minimal CRISPR repeat sequence over a stretch of at least 6, 7, or 8 consecutive nucleotides.

[0188] Minimal tracrRNA sequence In some embodiments, the minimal tracrRNA sequence is a sequence that has at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% sequence identity to a reference tracrRNA sequence (e.g., a wild-type tracrRNA from S. pyogenes).

[0189] In some embodiments, the minimal tracrRNA sequence has nucleotides that hybridize to the minimal CRISPR repeat sequence in cells. The minimal tracrRNA sequence and the minimal CRISPR repeat sequence form a duplex, i.e., a double-stranded structure of base pairs. Together, the minimal tracrRNA sequence and the minimal CRISPR repeat sequence bind to the site-specific polypeptide. At least a portion of the minimal tracrRNA sequence can hybridize to the minimal CRISPR repeat sequence. In some embodiments, the minimal tracrRNA sequence is at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% complementary to the minimal CRISPR repeat sequence.

[0190] The minimal tracrRNA sequence can be about 7 nucleotides to about 100 nucleotides in length. For example, the minimal tracrRNA sequence can be about 7 nucleotides (nt) to about 50 nt, about 7 nt to about 40 nt, about 7 nt to about 30 nt, about 7 nt to about 25 nt, about 7 nt to about 20 nt, about 7 nt to about 15 nt, about 8 nt to about 40 nt, about 8 nt to about 30 nt, about 8 nt to about 25 nt, about 8 nt to about 20 nt, about 8 nt to about 15 nt, about 15 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt in length. In some embodiments, the minimal tracrRNA sequence is approximately 9 nucleotides in length. In some embodiments, the minimal tracrRNA sequence is approximately 12 nucleotides in length. In some embodiments, the minimal tracrRNA consists of tracrRNA nts 23-48 as described in Jinek et al. Science, 337(6096):816-821 (2012).

[0191] In some embodiments, the minimal tracrRNA sequence is at least about 60% identical to a reference minimal tracrRNA (e.g., a wild-type, S. pyogenes-derived tracrRNA) over a stretch of at least 6, 7, or 8 contiguous nucleotides. For example, the minimal tracrRNA sequence is at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to the reference minimal tracrRNA sequence over a stretch of at least 6, 7, or 8 contiguous nucleotides.

[0192] In some embodiments, the duplex between the minimal CRISPR RNA and the minimal tracrRNA comprises a double helix. In some embodiments, the duplex between the minimal CRISPR RNA and the minimal tracrRNA comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides. In some embodiments, the duplex between the minimal CRISPR RNA and the minimal tracrRNA comprises at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides.

[0193] In some embodiments, the duplex has mismatches (i.e., the two strands of the duplex are not 100% complementary). In some embodiments, the duplex has at least about 1, 2, 3, 4, or 5 mismatches. In some embodiments, the duplex has at most about 1, 2, 3, 4, or 5 mismatches. In some embodiments, the duplex has no more than 2 mismatches.

[0194] bulge In some embodiments, a "bulge" is present in the duplex between the minimal CRISPR RNA and the minimal tracrRNA. The bulge is an unpaired region of nucleotides within the duplex. In some embodiments, the bulge contributes to the binding of the duplex to the site-specific polypeptide. The bulge has an unpaired 5'-XXXY-3' (X is any purine, and Y has a nucleotide that can form a wobble pair with a nucleotide on the opposite strand) on one side of the duplex, and an unpaired nucleotide region on the other side of the duplex. The number of unpaired nucleotides on both sides of the duplex can be different.

[0195] In one example, the bulge has an unpaired purine (e.g., adenine) on the minimal CRISPR repeat strand of the bulge. In some embodiments, the bulge has an unpaired 5'-AAGY-3' on the minimal tracrRNA sequence strand of the bulge, where Y has a nucleotide that can form a wobble pair with a nucleotide on the minimal CRISPR repeat strand.

[0196] In some embodiments, the bulge on the minimal CRISPR repeat side of the duplex has at least 1, 2, 3, 4, or 5 or more unpaired nucleotides. In some embodiments, the bulge on the minimal CRISPR repeat side of the duplex has at most 1, 2, 3, 4, or 5 or more unpaired nucleotides. In some embodiments, the bulge on the minimal CRISPR repeat side of the duplex has 1 unpaired nucleotide.

[0197] In some embodiments, the bulge on the side of the duplex facing the minimal tracrRNA sequence has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more unpaired nucleotides. In some embodiments, the bulge on the side of the duplex facing the minimal tracrRNA sequence has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more unpaired nucleotides. In some embodiments, the bulge on the second side of the duplex (e.g., on the side of the duplex facing the minimal tracrRNA sequence) has four unpaired nucleotides.

[0198] In some embodiments, the bulge has at least one wobble pair. In some embodiments, the bulge has at most one wobble pair. In some embodiments, the bulge has at least one purine nucleotide. In some embodiments, the bulge has at least three purine nucleotides. In some embodiments, the bulge sequence has at least five purine nucleotides. In some embodiments, the bulge sequence has at least one guanine nucleotide. In some embodiments, the bulge sequence has at least one adenine nucleotide.

[0199] hairpin In various embodiments, one or more hairpins are positioned 3' of the minimal tracrRNA in the 3' tracrRNA sequence.

[0200] In some embodiments, the hairpin begins at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 or more nucleotides 3' from the last nucleotide pair in the minimal CRISPR repeat and minimal tracrRNA sequence duplex. In some embodiments, the hairpin can begin up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides 3' of the last nucleotide pair in the minimal CRISPR repeat and minimal tracrRNA sequence duplex.

[0201] In some embodiments, the hairpin has at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 or more contiguous nucleotides. In some embodiments, the hairpin has at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or more contiguous nucleotides.

[0202] In some embodiments, the hairpin has a CC dinucleotide (ie, two consecutive cytosine nucleotides).

[0203] In some embodiments, the hairpin has duplex nucleotides (e.g., nucleotides within the hairpin that are hybridized together). For example, the hairpin has a CC dinucleotide that hybridizes to a GG dinucleotide in the hairpin duplex of the 3' tracrRNA sequence.

[0204] One or more of the hairpins can interact with the guide RNA-interacting region of the site-directed polypeptide.

[0205] In some embodiments, there are two or more hairpins, and in other embodiments, there are three or more hairpins.

[0206] 3′tracrRNA sequence In some embodiments, the 3' tracrRNA sequence has a sequence that has at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% sequence identity to a reference tracrRNA sequence (e.g., a tracrRNA from S. pyogenes).

[0207] In some embodiments, the 3' tracrRNA sequence is about 6 nucleotides to about 100 nucleotides in length. For example, the 3' tracrRNA sequence can be about 6 nucleotides (nt) to about 50 nt, about 6 nt to about 40 nt, about 6 nt to about 30 nt, about 6 nt to about 25 nt, about 6 nt to about 20 nt, about 6 nt to about 15 nt, about 8 nt to about 40 nt, about 8 nt to about 30 nt, about 8 nt to about 25 nt, about 8 nt to about 20 nt, about 8 nt to about 15 nt, about 15 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt. In some embodiments, the 3' tracrRNA sequence is approximately 14 nucleotides in length.

[0208] In some embodiments, the 3' tracrRNA sequence is at least about 60% identical to a reference 3' tracrRNA sequence (e.g., a wild-type 3' tracrRNA sequence from S. pyogenes) over a stretch of at least 6, 7, or 8 contiguous nucleotides. For example, the 3' tracrRNA sequence can be at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to a reference 3' tracrRNA sequence (e.g., a wild-type 3' tracrRNA sequence from S. pyogenes) over a stretch of at least 6, 7, or 8 contiguous nucleotides.

[0209] In some embodiments, the 3' tracrRNA sequence has two or more duplex regions (e.g., hairpin, hybridization region). In some embodiments, the 3' tracrRNA sequence has two duplex regions.

[0210] In some embodiments, the 3' tracrRNA sequence has a stem-loop structure. In some embodiments, the stem-loop structure in the 3' tracrRNA has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 or more nucleotides. In some embodiments, the stem-loop structure in the 3' tracrRNA has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides. In some embodiments, the stem-loop structure has a functional moiety. For example, the stem-loop structure has an aptamer, a ribozyme, a protein-interacting hairpin, a CRISPR array, an intron, or an exon. In some embodiments, the stem-loop structure has at least about 1, 2, 3, 4, or 5 or more functional moieties. In some embodiments, the stem-loop structure has at most about 1, 2, 3, 4, or 5 or more functional moieties.

[0211] In some embodiments, the hairpin in the 3' tracrRNA sequence comprises a P domain. In some embodiments, the P domain comprises a double-stranded region in the hairpin.

[0212] tracrRNA extension sequence In some embodiments, tracrRNA extension sequences can be provided regardless of whether they are in the context of a single-molecule guide or a dual-molecule guide. In some embodiments, tracrRNA extension sequences have a length of about 1 nucleotide to about 400 nucleotides. In some embodiments, tracrRNA extension sequences have a length of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, or greater than 400 nucleotides. In some embodiments, tracrRNA extension sequences have a length of about 20 to about 5000 or more nucleotides. In some embodiments, tracrRNA extension sequences have a length of greater than 1000 nucleotides. In some embodiments, the tracrRNA extension sequence may be less than 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, or more nucleotides in length. In some embodiments, the tracrRNA extension sequence may be less than 1000 nucleotides in length. In some embodiments, the tracrRNA extension sequence is less than 10 nucleotides in length. In some embodiments, the tracrRNA extension sequence is 10-30 nucleotides in length. In some embodiments, the tracrRNA extension sequence is 30-70 nucleotides in length.

[0213] In some embodiments, the tracrRNA extension sequence comprises a functional moiety (e.g., a stability control sequence, a ribozyme, or an endoribonuclease binding sequence). In some embodiments, the functional moiety comprises a transcription terminator segment (i.e., a transcription termination sequence). In some embodiments, the functional moiety has a total length of about 10 nucleotides (nt) to about 100 nucleotides, about 10 nt to about 20 nt, about 20 nt to about 30 nt, about 30 nt to about 40 nt, about 40 nt to about 50 nt, about 50 nt to about 60 nt, about 60 nt to about 70 nt, about 70 nt to about 80 nt, about 80 nt to about 90 nt, or about 90 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt. In some embodiments, the functional moiety functions in eukaryotic cells. In some embodiments, the functional moiety functions in prokaryotic cells. In some embodiments, the functional moiety functions in both eukaryotic and prokaryotic cells.

[0214] Non-limiting examples of suitable tracrRNA extension functional portions include a 3' poly-adenylation tail, a riboswitch sequence (e.g., to allow for regulated stability and / or regulated accessibility by proteins and protein complexes), a sequence that forms a dsRNA duplex (i.e., a hairpin), a sequence that targets the RNA to a subcellular location (e.g., the nucleus, mitochondria, chloroplasts, etc.), a modification or sequence that provides tracking (e.g., direct conjugation to a fluorescent molecule, conjugation to a moiety that facilitates fluorescent detection, a sequence that allows fluorescent detection, etc.), and / or a modification or sequence that provides binding sites for proteins (e.g., proteins that act on DNA, including transcriptional activators, transcriptional repressors, DNA methyltransferases, DNA demethylases, histone acetyltransferases, histone deacetylases, etc.). In some embodiments, the tracrRNA extension sequence has a primer binding site or a molecular index (e.g., a barcode sequence). In some embodiments, the tracrRNA extension sequence has one or more affinity tags.

[0215] Single molecule guide linker sequence In some embodiments, the linker sequence of the single-molecule guide nucleic acid has a length of about 3 nucleotides to about 100 nucleotides. For example, a simple four-nucleotide "tetraloop" (-GAAA-) was used in Jinek et al., Science, 337(6096):816-821(2012), supra. Exemplary linkers have lengths of about 3 nucleotides (nt) to about 90 nt, about 3 nt to about 80 nt, about 3 nt to about 70 nt, about 3 nt to about 60 nt, about 3 nt to about 50 nt, about 3 nt to about 40 nt, about 3 nt to about 30 nt, about 3 nt to about 20 nt, or about 3 nt to about 10 nt. For example, the linker can have a length of about 3 nt to about 5 nt, about 5 nt to about 10 nt, about 10 nt to about 15 nt, about 15 nt to about 20 nt, about 20 nt to about 25 nt, about 25 nt to about 30 nt, about 30 nt to about 35 nt, about 35 nt to about 40 nt, about 40 nt to about 50 nt, about 50 nt to about 60 nt, about 60 nt to about 70 nt, about 70 nt to about 80 nt, about 80 nt to about 90 nt, or about 90 nt to about 100 nt. In some embodiments, the linker of the single-molecule guide nucleic acid is 4 to 40 nucleotides. In some embodiments, the linker is at least about 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, or 7000 or more nucleotides, In some embodiments, the linker is at most about 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, or 7000 or more nucleotides.

[0216] The linker can have any of a variety of sequences, but in some embodiments, the linker does not have a sequence with extensive homology to other parts of the guide RNA, which may cause intramolecular binding that may interfere with other functional regions of the guide. In Jinek et al., Science, 337(6096):816-821(2012) above, a simple four-nucleotide sequence -GAAA- was used, but many other sequences, including longer sequences, can be used as well.

[0217] In some embodiments, the linker sequence has functional moieties. For example, the linker sequence can have one or more features, including aptamers, ribozymes, protein interaction hairpins, protein binding sites, CRISPR arrays, introns, or exons. In some embodiments, the linker sequence has at least about 1, 2, 3, 4, or 5 or more functional moieties. In some embodiments, the linker sequence has at most about 1, 2, 3, 4, or 5 or more functional moieties.

[0218] In some embodiments, the genomic location targeted by a gRNA according to a given disclosure can be at, within, or near the endogenous albumin locus in a genome, for example, the human genome. Exemplary guide RNAs targeting such locations include the spacer sequences and associated Cas9 or Cpf1 cleavage sites listed in Tables 3 or 4. As will be understood by those skilled in the art, each guide RNA is designed to include a spacer sequence complementary to its genomic target sequence. For example, each of the spacer sequences listed in Tables 3 or 4 can be included in a single RNA chimera or crRNA (along with the corresponding tracrRNA). See Jinek et al., Science, 337, 816-821 (2012) and Deltcheva et al., Nature, 471, 602-607 (2011).

[0219] Donor DNA or donor template Site-specific polypeptides, such as DNA endonucleases, can introduce double-strand or single-strand breaks into nucleic acids, such as genomic DNA. The double-strand break can stimulate the cell's endogenous DNA repair pathways (e.g., homology-dependent repair (HDR), non-homologous end joining (NHEJ), alternative non-homologous end joining (A-NHEJ), or microhomology-mediated end joining (MMEJ)). NHEJ can repair the cleaved target nucleic acid without the need for a homologous template. This can result in small deletions or insertions (indels) in the target nucleic acid at the cleavage site, which can disrupt or alter gene expression. HDR, also known as homologous recombination (HR), can occur if a homologous repair template or donor is available.

[0220] A homologous donor template has a sequence homologous to the sequence adjacent to the target nucleic acid cleavage site. Sister chromatids are commonly used by cells as repair templates. However, for genome editing purposes, repair templates are often provided as exogenous nucleic acids, such as plasmids, double-stranded oligonucleotides, single-stranded oligonucleotides, double-stranded oligonucleotides, or viral nucleic acids. It is common to use an exogenous donor template to introduce additional nucleic acid sequences (such as transgenes) or modifications (such as single or multiple base changes or deletions) between the adjacent homologous regions so that the added or modified nucleic acid sequence is also integrated into the target locus. MMEJ produces genetic outcomes similar to NHEJ in that small deletions and insertions can occur at the cleavage site. MMEJ uses a few base pairs of homologous sequences adjacent to the cleavage site to promote favorable end-joining DNA repair outcomes. In some cases, potential repair outcomes can be predicted based on analysis of potential microhomologies in the nuclease target region.

[0221] Therefore, in some examples, homologous recombination is used to insert exogenous polynucleotide sequences into target nucleic acid cleavage sites.Exogenous polynucleotide sequences are herein referred to as donor polynucleotides (alternatively, donor or donor sequence or polynucleotide donor template).In some embodiments, donor polynucleotides, parts of donor polynucleotides, copies of donor polynucleotides, or parts of copies of donor polynucleotides are inserted into target nucleic acid cleavage sites.In some embodiments, donor polynucleotides are exogenous polynucleotide sequences, i.e., sequences that do not naturally occur at target nucleic acid cleavage sites.

[0222] When exogenous DNA molecules are provided in sufficient concentration in the nucleus of the cell where double-strand break occurs, the exogenous DNA can be inserted into double-strand break during the NHEJ repair process, and thus become a permanent addition to genome.In some embodiments, these exogenous DNA molecules are called donor templates.When donor templates include the coding sequence of a gene of interest, such as the FVIII gene, and optionally together with related regulatory sequences, such as promoter, enhancer, polyA sequence, and / or splice acceptor sequence (also referred to herein as "donor cassette"), the gene of interest can be expressed from the copy integrated into genome, resulting in permanent expression during the life of cell.Furthermore, the integrated copy of donor DNA template can be transmitted to daughter cells when cell divides.

[0223] In the presence of a sufficient concentration of donor DNA template (called homology arms) containing flanking DNA sequences homologous to the DNA sequences on either side of the double-strand break, the donor DNA template can be integrated via the HDR pathway. The homology arms serve as substrates for homologous recombination between the donor template and the sequences on either side of the double-strand break. This can result in error-free insertion of the donor template, whose sequences on either side of the double-strand break are unchanged from those of the unmodified genome.

[0224] Donors supplied for HDR editing vary significantly, but generally contain the intended sequence with small or large flanking homology arms to allow annealing to genomic DNA. The homology regions flanking the introduced genetic alteration can be as small as 30 bp or smaller, or as large as multi-kilobase cassettes that can include promoters, cDNA, etc. Both single-stranded and double-stranded oligonucleotide donors can be used. These oligonucleotides range in size from less than 100 nt to over several kb, although longer ssDNA can also be generated and used. Double-stranded donors such as PCR amplicons, plasmids, and minicircles are often used. While the packaging limit for individual donors is generally less than 5 kb, AAV vectors have proven to be highly effective means of delivering donor templates. Active transcription of the donor increases HDR by 3-fold, indicating that including a promoter can increase conversion. Conversely, CpG methylation of the donor can decrease gene expression and HDR.

[0225] In some embodiments, donor DNA can be supplied independently with nuclease or by various different methods, for example, by transfection, nanoparticle, microinjection or viral transduction.In some embodiments, to increase the availability of donor for HDR, various linking options can be used.Examples include binding donor to nuclease, binding to nearby DNA binding protein, or binding to the protein involved in DNA end joining or repair.

[0226] In addition to genome editing by NHEJ or HDR, site-specific gene insertion can be performed using both NHEJ pathway and HR.A combined approach can be applied in certain settings, possibly including intron / exon boundaries.NHEJ can prove to be effective in intron ligation, while error-free HDR may be more suitable in coding regions.

[0227] In some embodiments, the exogenous sequence intended to be inserted into the genome is a gene of interest (GOI) or a functional derivative thereof. The exogenous gene may comprise a nucleotide sequence encoding a GOI product, e.g., a GOI protein, or a functional derivative thereof. A functional derivative of a GOI may comprise a nucleic acid sequence encoding a functional derivative of a GOI protein having substantial activity of a wild-type GOI protein, such as a wild-type human GOI protein, e.g., at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% of the activity exhibited by the wild-type GOI. In some embodiments, a functional derivative of a GOI protein may have at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with the GOI protein, e.g., the wild-type GOI protein. In some embodiments, one skilled in the art can use many methods known in the art to test the functionality or activity of a compound, e.g., a peptide or protein. A functional derivative of a GOI protein can also include any fragment of a wild-type GOI protein, or a fragment of a modified GOI protein having conservative modifications to one or more amino acid residues of the full-length wild-type GOI protein. Thus, in some embodiments, a functional derivative of a nucleic acid sequence of a GOI can have at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% nucleic acid sequence identity to the GOI, e.g., the wild-type GOI.

[0228] In some embodiments involving the insertion of a GOI or a functional derivative thereof, a cDNA of the GOI or a functional derivative thereof can be inserted into the genome of a patient with a defective GOI or its regulatory sequence. In such cases, the donor DNA or donor template can be an expression cassette or vector construct having a sequence, e.g., a cDNA sequence, encoding the GOI or its functional derivative. In some embodiments, an expression vector can be used that contains a sequence encoding a modified GOI protein, such as FVIII-BDD, as described elsewhere in this disclosure.

[0229] In some embodiments, according to any of the donor templates described herein that include a donor cassette, the donor cassette is flanked on one or both sides by gRNA target sites. For example, such a donor template may include a donor cassette having a gRNA target site 5' of the donor cassette and / or a gRNA target site 3' of the donor cassette. In some embodiments, the donor template includes a donor cassette having a gRNA target site 5' of the donor cassette. In some embodiments, the donor template includes a donor cassette having a gRNA target site 3' of the donor cassette. In some embodiments, the donor template includes a donor cassette having a gRNA target site 5' of the donor cassette and a gRNA target site 3' of the donor cassette. In some embodiments, the donor template includes a donor cassette having a gRNA target site 5' of the donor cassette and a gRNA target site 3' of the donor cassette. In some embodiments, the donor template includes a donor cassette having a gRNA target site 5' of the donor cassette and a gRNA target site 3' of the donor cassette, wherein the two gRNA target sites comprise the same sequence. In some embodiments, the donor template comprises at least one gRNA target site, wherein the at least one gRNA target site in the donor template comprises the same sequence as a gRNA target site in the target locus into which the donor cassette of the donor template will be integrated. In some embodiments, the donor template comprises at least one gRNA target site, wherein the at least one gRNA target site in the donor template comprises the reverse complement of a gRNA target site in the target locus into which the donor cassette of the donor template will be integrated. In some embodiments, the donor template comprises a donor cassette having a gRNA target site 5' of the donor cassette and a gRNA target site 3' of the donor cassette, wherein the two gRNA target sites in the donor template comprise the same sequence as a gRNA target site in the target locus into which the donor cassette of the donor template will be integrated.In some embodiments, the donor template comprises a donor cassette having a gRNA target site 5' of the donor cassette and a gRNA target site 3' of the donor cassette, wherein the two gRNA target sites in the donor template comprise the reverse complements of gRNA target sites at the target locus into which the donor cassette of the donor template will integrate.

[0230] Nucleic acids encoding site-specific polypeptides or DNA endonucleases In some embodiments, the genome editing and composition methods can therefore use a nucleic acid sequence (or oligonucleotide) encoding a site-specific polypeptide or DNA endonuclease. The nucleic acid sequence encoding the site-specific polypeptide can be DNA or RNA. If the nucleic acid sequence encoding the site-specific polypeptide is RNA, it can be covalently linked to the gRNA sequence or exist as a separate sequence. In some embodiments, the peptide sequence of the site-specific polypeptide or DNA endonuclease can be used instead of the nucleic acid sequence.

[0231] vector In another aspect, the present disclosure provides a nucleic acid having a nucleotide sequence encoding a genome-targeting nucleic acid of the present disclosure, a site-specific polypeptide of the present disclosure, and / or any nucleic acid or protein molecule necessary to carry out an embodiment of a method of the present disclosure. In some embodiments, such a nucleic acid is a vector (e.g., a recombinant expression vector).

[0232] Contemplated expression vectors include, but are not limited to, vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, human immunodeficiency virus, retroviruses (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), and other recombinant vectors. Other contemplated vectors for eukaryotic target cells include, but are not limited to, the vectors pXT1, pSG5, pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). Additional contemplated vectors for eukaryotic target cells include, but are not limited to, the vectors pCTx-1, pCTx-2, and pCTx-3. Other vectors can be used as long as they are compatible with the host cell.

[0233] In some embodiments, the vector can include one or more transcriptional and / or translational control elements. Depending on the host / vector system used, any of a number of suitable transcriptional and translational control elements can be used in the expression vector, including constitutive and inducible promoters, transcriptional enhancer elements, transcriptional terminators, etc. In some embodiments, the vector is a self-inactivating vector that inactivates either viral sequences or components of the CRISPR machinery or other elements.

[0234] Non-limiting examples of suitable eukaryotic promoters (i.e., promoters that function in eukaryotic cells) include those derived from cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retroviruses, human elongation factor-1 promoter (EF1), a hybrid construct having the cytomegalovirus (CMV) enhancer fused to the chicken β-actin promoter (CAG), murine stem cell virus promoter (MSCV), phosphoglycerate kinase-1 locus promoter (PGK), and mouse metallothionein-I.

[0235] For the expression of small RNA, including the guide RNA used in conjunction with Cas endonuclease, various promoters can be advantageous, such as the RNA polymerase III promoter, including U6 and H1.The explanation and parameters for enhancing the use of such promoters are known in the art, and additional information and approaches are regularly described.For example, see Ma, H. et al., Molecular Therapy-Nucleic Acids 3, e161 (2014) doi:10.1038 / mtna.2014.12.

[0236] The expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator. The expression vector may also contain an appropriate sequence for amplifying expression. The expression vector may also contain a nucleotide sequence encoding a non-natural tag (e.g., a histidine tag, a hemagglutinin tag, a green fluorescent protein, etc.) that is fused to the site-specific polypeptide, thus resulting in a fusion protein.

[0237] In some embodiments, the promoter is an inducible promoter (e.g., a heat shock promoter, a tetracycline-regulated promoter, a steroid-regulated promoter, a metal-regulated promoter, an estrogen receptor-regulated promoter, etc.). In some embodiments, the promoter is a constitutive promoter (e.g., a CMV promoter, a UBC promoter). In some embodiments, the promoter is a spatially and / or temporally restricted promoter (e.g., a tissue-specific promoter, a cell-type-specific promoter, etc.). In some embodiments, the vector does not have a promoter for at least one gene to be expressed in a host cell when, after it is inserted into the genome, it is expressed under an endogenous promoter present in the genome.

[0238] Site-specific polypeptides or DNA endonucleases Modification of target DNA by NHEJ and / or HDR can lead to, for example, mutation, deletion, alteration, integration, gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, translocation, and / or gene mutation. The process of incorporating non-natural nucleic acids into genomic DNA is an example of genome editing.

[0239] Site-specific polypeptides are nucleases used to cleave DNA in genome editing. Site-specific polypeptides can be administered to cells or patients either as one or more polypeptides or as one or more mRNAs encoding the polypeptides.

[0240] In the context of a CRISPR / Cas or CRISPR / Cpf1 system, the site-directed polypeptide can in turn bind to a guide RNA, specifying a site in the target DNA to which the polypeptide is directed. In some embodiments of the CRISPR / Cas or CRISPR / Cpf1 system herein, the site-directed polypeptide is an endonuclease, such as a DNA endonuclease.

[0241] In some embodiments, the site-directed polypeptide has multiple nucleic acid cleavage (i.e., nuclease) domains. Two or more nucleic acid cleavage domains can be linked together via a linker. In some embodiments, the linker has a flexible linker. The linker can have a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 or more amino acids.

[0242] Naturally occurring wild-type Cas9 enzyme has two nuclease domains: an HNH nuclease domain and a RuvC domain. As used herein, "Cas9" refers to both naturally occurring Cas9 and recombinant Cas9. The Cas9 enzyme contemplated herein has an HNH or HNH-like nuclease domain, and / or a RuvC or RuvC-like nuclease domain.

[0243] The HNH or HNH-like domain has an McrA-like fold. The HNH or HNH-like domain has two antiparallel β-strands and an α-helix. The HNH or HNH-like domain has a metal binding site (e.g., a divalent cation binding site). The HNH or HNH-like domain can cleave one strand of the target nucleic acid (e.g., the complementary strand of the crRNA target strand).

[0244] The RuvC or RuvC-like domain has an RNaseH or RNaseH-like fold. The RuvC / RNaseH domain is involved in various nucleic acid-based functions, including acting on both RNA and DNA. The RNaseH domain has five β strands surrounded by multiple α helices. The RuvC / RNaseH or RuvC / RNaseH-like domain has a metal-binding site (e.g., a divalent cation-binding site). The RuvC / RNaseH or RuvC / RNaseH-like domain can cleave one strand of a target nucleic acid (e.g., the non-complementary strand of a double-stranded target DNA).

[0245] In some embodiments, the site-directed polypeptide has an amino acid sequence that has at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% amino acid sequence identity to a wild-type exemplary site-directed polypeptide [e.g., Cas9 from S. pyogenes, US2014 / 0068797, SEQ ID NO:8 or Sapranauskas et al., Nucleic Acids Res, 39(21):9275-9282(2011)] and various other site-directed polypeptides.

[0246] In some embodiments, the site-directed polypeptide has an amino acid sequence with at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% amino acid sequence identity to the nuclease domain of a wild-type exemplary site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra).

[0247] In some embodiments, the site-directed polypeptide has at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids. In some embodiments, the site-directed polypeptide has at most 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids. In some embodiments, the site-directed polypeptide has at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids within the HNH nuclease domain of the site-directed polypeptide. In some embodiments, the site-directed polypeptide has at most 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids within the HNH nuclease domain of the site-directed polypeptide. In some embodiments, the site-directed polypeptide has at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids within the RuvC nuclease domain of the site-directed polypeptide. In some embodiments, the site-directed polypeptide has at most 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids within the RuvC nuclease domain of the site-directed polypeptide.

[0248] In some embodiments, the site-directed polypeptide comprises a modified form of a wild-type exemplary site-directed polypeptide. The modified form of the wild-type exemplary site-directed polypeptide comprises a mutation that reduces the nucleic acid cleavage activity of the site-directed polypeptide. In some embodiments, the modified form of the wild-type exemplary site-directed polypeptide has less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nucleic acid cleavage activity of the wild-type exemplary site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra). The modified form of the site-directed polypeptide may not have substantial nucleic acid cleavage activity. When the site-directed polypeptide is a modified form that does not have substantial nucleic acid cleavage activity, it is referred to herein as "enzymatically inactive."

[0249] In some embodiments, the modified form of the site-directed polypeptide has a mutation such that it can induce a single-strand break (SSB) on the target nucleic acid (e.g., by cleaving only one of the sugar phosphate backbones of a double-stranded target nucleic acid). In some embodiments, the mutation results in less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or 1% of the nucleic acid cleavage activity of one or more of the multiple nucleic acid cleavage domains of a wild-type site-directed polypeptide (e.g., Cas9 from S. pyogenes, supra). In some embodiments, the mutation results in one or more of the multiple nucleic acid cleavage domains retaining the ability to cleave a complementary strand of the target nucleic acid but reducing their ability to cleave a non-complementary strand of the target nucleic acid. In some embodiments, the mutation results in one or more of the multiple nucleic acid cleavage domains retaining the ability to cleave a non-complementary strand of the target nucleic acid but reducing their ability to cleave a complementary strand of the target nucleic acid. For example, residues of a wild-type exemplary S. pyogenes Cas9 polypeptide, such as AsplO, His840, Asn854, and Asn856, are mutated to inactivate one or more of the nucleic acid cleavage domains (e.g., nuclease domains). In some embodiments, the mutated residues correspond to residues AsplO, His840, Asn854, and Asn856 of a wild-type exemplary S. pyogenes Cas9 polypeptide (e.g., as determined by sequence and / or structural alignment). Non-limiting examples of mutations include D10A, H840A, N854A, or N856A. One of skill in the art will recognize that mutations other than alanine substitutions may be appropriate.

[0250] In some embodiments, the D10A mutation is combined with one or more of the H840A, N854A, or N856A mutations to generate a site-directed polypeptide that substantially lacks DNA cleavage activity. In some embodiments, the H840A mutation is combined with one or more of the D10A, N854A, or N856A mutations to generate a site-directed polypeptide that substantially lacks DNA cleavage activity. In some embodiments, the N854A mutation is combined with one or more of the H840A, D10A, or N856A mutations to generate a site-directed polypeptide that substantially lacks DNA cleavage activity. In some embodiments, the N856A mutation is combined with one or more of the H840A, N854A, or D10A mutations to generate a site-directed polypeptide that substantially lacks DNA cleavage activity. Site-directed polypeptides with one substantially inactive nuclease domain are referred to as "nickases."

[0251] In some embodiments, variants of RNA-guided endonucleases, such as Cas9, can be used to enhance the specificity of CRISPR-mediated genome editing. Wild-type Cas9 is generally guided by a single guide RNA designed to hybridize with a specific approximately 20-nucleotide sequence of the target sequence (such as an endogenous genomic locus). However, some mismatches are tolerated between the guide RNA and the target locus, which can effectively reduce the required homology length at the target site to, for example, only 13nt of homology, thereby increasing the likelihood of CRISPR / Cas9 complex binding and double-stranded nucleic acid cleavage elsewhere in the target genome, also known as off-target cleavage. Because Cas9 nickase variants only cleave one strand each, to create a double-stranded break, a pair of nickases must bind to opposite strands in close proximity to the target nucleic acid, thereby creating a pair of nicks, which is equivalent to a double-stranded break. This requires two separate guide RNAs (one for each nickase) to bind to opposite strands in close proximity to the target nucleic acid. This requirement essentially doubles the minimum length of homology required for double-strand breaks, thereby reducing the likelihood that double-strand breaks will occur elsewhere in the genome; the two guide RNA sites (if present) are unlikely to be close enough to each other to allow the formation of double-strand breaks.As described in the art, nickases can also be used to promote HDR versus NHEJ.HDR can be used to introduce selected changes into target sites in the genome by using specific donor sequences that effectively mediate the desired changes.Descriptions of various CRISPR / Cas systems for use in gene editing can be found, for example, in International Patent Application Publication No. WO2013 / 176772 and Nature Biotechnology 32, 347-355 (2014), and the references cited therein.

[0252] In some embodiments, the site-directed polypeptides (e.g., variant, mutated, enzymatically inactive, and / or conditionally enzymatically inactive site-directed polypeptides) target nucleic acids. In some embodiments, the site-directed polypeptides (e.g., variant, mutated, enzymatically inactive, and / or conditionally enzymatically inactive site-directed polypeptides) target DNA. In some embodiments, the site-directed polypeptides (e.g., variant, mutated, enzymatically inactive, and / or conditionally enzymatically inactive site-directed polypeptides) target RNA.

[0253] In some embodiments, the site-directed polypeptide has one or more non-native sequences (eg, the site-directed polypeptide is a fusion protein).

[0254] In some embodiments, the site-directed polypeptide has an amino acid sequence with at least 15% amino acid identity to Cas9 from a bacterium (e.g., S. pyogenes), a nucleic acid binding domain, and two nucleic acid cleavage domains (i.e., an HNH domain and a RuvC domain).

[0255] In some embodiments, the site-directed polypeptide has an amino acid sequence with at least 15% amino acid identity to Cas9 from a bacterium (e.g., S. pyogenes) and two nucleic acid cleavage domains (i.e., an HNH domain and a RuvC domain).

[0256] In some embodiments, the site-directed polypeptide has an amino acid sequence that comprises at least 15% amino acid identity to a Cas9 derived from a bacterium (e.g., S. pyogenes), and two nucleic acid cleavage domains, one or both of which have at least 50% amino acid identity to a nuclease domain derived from a bacterial Cas9 (e.g., S. pyogenes).

[0257] In some embodiments, the site-directed polypeptide has an amino acid sequence with at least 15% amino acid identity to Cas9 from a bacterium (e.g., S. pyogenes), two nucleic acid cleavage domains (i.e., an HNH domain and a RuvC domain), and a non-native sequence (e.g., a nuclear localization signal) or a linker connecting the site-directed polypeptide to the non-native sequence.

[0258] In some embodiments, the site-directed polypeptide has an amino acid sequence that comprises at least 15% amino acid identity to Cas9 from a bacterium (e.g., S. pyogenes), two nucleic acid cleavage domains (i.e., an HNH domain and a RuvC domain), and the site-directed polypeptide has a mutation in one or both of the nucleic acid cleavage domains that reduces the cleavage activity of the nuclease domain by at least 50%.

[0259] In some embodiments, the site-directed polypeptide has an amino acid sequence comprising at least 15% amino acid identity to Cas9 from a bacterium (e.g., S. pyogenes) and two nucleic acid cleavage domains (i.e., an HNH domain and a RuvC domain), wherein one of the nuclease domains comprises a mutation at aspartic acid position 10 and / or one of the nuclease domains comprises a mutation at histidine position 840, which mutation reduces the cleavage activity of the nuclease domain(s) by at least 50%.

[0260] In some embodiments, one or more site-specific polypeptides, e.g., DNA endonucleases, comprise two nickases that together create a double-stranded break at a specific locus in the genome, or four nickases that create two double-stranded breaks at a specific locus in the genome, or one site-specific polypeptide, e.g., DNA endonuclease, creates a double-stranded break at a specific locus in the genome.

[0261] In some embodiments, a polynucleotide encoding a site-directed polypeptide can be used to edit a genome. In some embodiments, the polynucleotide encoding the site-directed polypeptide is codon-optimized according to standard methods in the art for expression in cells containing the target DNA of interest. For example, when the intended target nucleic acid is in a human cell, a human codon-optimized polynucleotide encoding Cas9 is contemplated for use in producing Cas9 polypeptide.

[0262] The following provide some examples of site-directed polypeptides that can be used in various embodiments of the present disclosure.

[0263] CRISPR endonuclease system CRISPR (clustered regularly interspaced short palindromic repeats) genomic loci can be found in the genomes of many prokaryotes (e.g., bacteria and archaea). In prokaryotes, CRISPR loci encode products that function as a type of immune system that helps defend prokaryotes from foreign invaders such as viruses and phages. CRISPR locus function involves three stages: integration of new sequences into the CRISPR locus, expression of CRISPR RNA (crRNA), and silencing of foreign invading nucleic acids. Five types of CRISPR systems (e.g., type I, type II, type III, type U, and type V) have been identified.

[0264] CRISPR loci contain numerous short repetitive sequences called "repeats." When expressed, the repeats form secondary hairpin structures (e.g., hairpins) and / or have unstructured single-stranded sequences. The repeats usually occur in clusters and frequently diverge between species. The repeats are regularly spaced with unique intervening sequences called "spacers," resulting in a repeat-spacer-repeat locus architecture. The spacers are identical to or highly homologous to known foreign invader sequences. The spacer-repeat units encode crisprRNAs (crRNAs), which are processed into the mature form of the spacer-repeat units. The crRNAs have "seed" or spacer sequences responsible for targeting the target nucleic acid (in naturally occurring forms in prokaryotes, the spacer sequences target the foreign invader nucleic acid). The spacer sequences are located at the 5' or 3' end of the crRNA.

[0265] CRISPR loci also contain polynucleotide sequences encoding CRISPR-associated (Cas) genes. Cas genes encode endonucleases involved in the biosynthesis and interference stages of prokaryotic crRNA function. Some Cas genes have homologous secondary and / or tertiary structures.

[0266] Type II CRISPR system In natural Type II CRISPR systems, crRNA biogenesis requires a trans-activating CRISPR RNA (tracrRNA). The tracrRNA is modified by endogenous RNase III and then hybridizes to the crRNA repeats of the pre-crRNA array. Endogenous RNase III is recruited to cleave the pre-crRNA. The cleaved crRNA is subjected to exoribonuclease trimming to generate the mature crRNA form (e.g., 5' trimming). The tracrRNA remains hybridized to the crRNA, and the tracrRNA and crRNA associate with a site-specific polypeptide (e.g., Cas9). The crRNA in the crRNA-tracrRNA-Cas9 complex guides the complex to a target nucleic acid to which the crRNA can hybridize. Hybridization of the crRNA to the target nucleic acid activates Cas9 for targeted nucleic acid cleavage. The target nucleic acid in Type II CRISPR systems is called a protospacer adjacent motif (PAM). In nature, PAM is essential for promoting the binding of site-specific polypeptides (e.g., Cas9) to target nucleic acids. Type II systems (also known as Nmeni or CASS4) are further subdivided into type II-A (CASS4) and type II-B (CASS4a). Jinek et al., Science, 337(6096):816-821(2012) demonstrated that the CRISPR / Cas9 system is useful for RNA-programmable genome editing, and International Patent Application Publication No. WO2013 / 176772 provides many examples and applications of the CRISPR / Cas endonuclease system for site-specific gene editing.

[0267] Type V CRISPR system Type V CRISPR systems have several key differences from type II systems. For example, Cpf1 is a single RNA-guided endonuclease that lacks a tracrRNA, in contrast to type II systems. Indeed, Cpf1-associated CRISPR arrays are processed into mature crRNAs without the need for an additional transactivating tracrRNA. Type V CRISPR arrays are processed into short mature crRNAs, 42–44 nucleotides in length, each of which begins with a 19-nucleotide direct repeat followed by a 23–25-nucleotide spacer sequence. In contrast, mature crRNAs in type II systems begin with a 20–24-nucleotide spacer sequence followed by approximately 22-nucleotide direct repeats. Furthermore, Cpf1 utilizes a T-rich protospacer adjacent motif, allowing the Cpf1-crRNA complex to efficiently cleave target DNA preceded by a short T-rich PAM, in contrast to the G-rich PAM that follows target DNA in type II systems. Thus, type V systems cleave at a point distal to the PAM, whereas type II systems cleave at a point adjacent to the PAM. Furthermore, in contrast to type II systems, Cpf1 cleaves DNA through staggered double-strand breaks in 4- or 5-nucleotide 5' overhangs. Type II systems cleave through blunt double-strand breaks. Like type II systems, Cpf1 contains a predicted RuvC-like endonuclease domain, but in contrast to type II systems, it lacks the second HNH endonuclease domain.

[0268] Cas gene / polypeptide and protospacer adjacent motifs Exemplary CRISPR / Cas polypeptides include the Cas9 polypeptide in Figure 1 of Fonfara et al., Nucleic Acids Research, 42:2577-2590 (2014). The CRISPR / Cas gene nomenclature system has been significantly rewritten since the discovery of Cas genes. Figure 5 of Fonfara, supra, provides PAM sequences for Cas9 polypeptides from various species.

[0269] Complex of genome-targeting nucleic acid and site-specific polypeptide The genome-targeting nucleic acid interacts with a site-specific polypeptide (e.g., a nucleic acid-guided nuclease such as Cas9), thereby forming a complex. The genome-targeting nucleic acid (e.g., a gRNA) guides the site-specific polypeptide to the target nucleic acid.

[0270] As mentioned above, in some embodiments, the site-specific polypeptide and the genome-targeting nucleic acid can be administered separately to a cell or a patient. On the other hand, in some other embodiments, the site-specific polypeptide can be pre-complexed with one or more guide RNAs or one or more crRNAs together with a tracrRNA. The pre-complexed material can then be administered to a cell or a patient. Such pre-complexed material is known as a ribonucleoprotein particle (RNP).

[0271] Genome editing methods In one aspect, the present disclosure provides a method for genome editing, particularly a method for inserting a gene of interest into the genome of a cell.Some embodiments relate to a method for editing a protein in a cell by genome editing to regulate its expression, function, or activity, wherein the protein is selected from the group consisting of FVIII protein, FIX protein, alpha-1-antitrypsin, FXIII protein, FVII protein, FX protein, protein C, and serpin G1.Some specific embodiments relate to a method for editing a blood coagulation protein such as FVIII in a cell by genome editing to regulate its expression, function, or activity.This method can be used to treat a subject, for example, a patient with hemophilia A, and in such cases, cells can be isolated from the patient or another donor.The chromosomal DNA of the cell is then edited using the materials and methods described herein.Some other specific embodiments relate to a method for editing a blood coagulation protein FIX in a cell by genome editing to regulate its expression, function, or activity.This method can be used to treat a subject, for example, a patient with hemophilia B, and in such cases, cells can be isolated from the patient or another donor. Yet some other specific embodiments relate to methods for editing to regulate the expression, function, or activity of serine protease inhibitor G1 in cells by genome editing. The methods can be used to treat a subject, such as a patient with hereditary angioedema, in which case cells can be isolated from the patient or another donor.

[0272] In some embodiments, the knock-in strategy involves knocking in a gene of interest (GOI). There are no particular limitations regarding the size or biological activity or function of the encoded polypeptide. In some embodiments, the GOI encodes a protein selected from the group consisting of FVIII protein, FIX protein, alpha-1-antitrypsin, FXIII protein, FVII protein, FX protein, protein C, and serpin G1, or any functional derivative thereof. In some embodiments, the genomic sequence into which the GOI is inserted is located in, within, or near the albumin locus. In some embodiments, the GOI encodes a blood coagulation protein such as FVIII. In some embodiments, the knock-in strategy involves knocking in a FVIII coding sequence, such as a wild-type FVIII gene (e.g., a wild-type human FVIII gene), a FVIII cDNA, a minigene (having a natural or synthetic enhancer and promoter, one or more exons, a natural or synthetic intron, a natural or synthetic 3' UTR, and a polyadenylation signal), or a modified FVIII gene, into the genomic sequence. In some embodiments, the knock-in strategy involves knocking in a FIX coding sequence, such as a wild-type FIX gene (e.g., a wild-type human FIX gene), a FIX cDNA, a minigene (with a natural or synthetic enhancer and promoter, one or more exons, and a natural or synthetic intron, and a natural or synthetic 3' UTR, and a polyadenylation signal), or a modified FIX gene, into a genomic sequence. In some embodiments, the knock-in strategy involves knocking in a SERPING1 coding sequence, such as a wild-type SERPING1 gene (e.g., a wild-type human SERPING1 gene), a SERPING1 cDNA, a minigene (with a natural or synthetic enhancer and promoter, one or more exons, and a natural or synthetic intron, and a natural or synthetic 3' UTR and a polyadenylation signal), or a modified SERPING1 gene, into a genomic sequence.

[0273] In some embodiments, provided herein is a method for knocking in a gene of interest (GOI), e.g., a gene encoding a FVIII gene or a functional derivative thereof, into a genome. In one aspect, the present disclosure provides for inserting a nucleic acid sequence of a GOI, e.g., a FVIII gene, e.g., a nucleic acid sequence encoding a FVIII protein or a functional derivative thereof, into the genome of a cell. The nucleic acid sequence of the GOI can encode a wild-type protein of the GOI or a derivative thereof. Thus, in some embodiments, the GOI can encode a wild-type protein. A functional derivative of a wild-type protein can include a peptide having substantial activity of the wild-type protein, e.g., at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% of the activity exhibited by the wild-type protein. In some embodiments, one skilled in the art can test the functionality or activity of a compound, e.g., a peptide or protein, using many methods known in the art. In some embodiments, a functional derivative of an encoded wild-type protein can also include any fragment of the wild-type protein or a fragment of a modified protein having conservative modifications at one or more amino acid residues in the corresponding full-length wild-type protein. In some embodiments, a functional derivative of an encoded wild-type protein can also include any modification(s) that do not substantially negatively affect the functionality of the wild-type protein, e.g., deletion, insertion, and / or mutation of one or more amino acids. Thus, in some embodiments, a functional derivative of a nucleic acid sequence of a wild-type GOI can have at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% nucleic acid sequence identity to the wild-type GOI.

[0274] In some embodiments, the GOI or a functional derivative thereof is inserted into a genomic sequence in a cell. In some embodiments, the insertion site is at or within the albumin locus in the genome of the cell. The insertion method uses one or more gRNAs targeting the first intron (or intron 1) of the albumin gene. In some embodiments, the donor DNA is single-stranded or double-stranded DNA comprising the coding sequence of the GOI or a functional derivative thereof. In some embodiments, the donor DNA is single-stranded or double-stranded DNA comprising the coding sequence of a protein selected from the group consisting of FVIII protein, FIX protein, alpha-1-antitrypsin, FXIII protein, FVII protein, FX protein, protein C, serpin G1, or a functional derivative thereof.

[0275] In some embodiments, genome editing methods utilize DNA endonucleases, such as the CRISPR / Cas system, to engineer the introduction (knock-in) of a gene of interest or its functional derivative. In some embodiments, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide, a homolog thereof, a recombinant naturally occurring molecule, a codon-optimized or modified version thereof, or a combination of any of the above. In some embodiments, the DNA endonuclease is a type II Cas endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, Cas9 is derived from Streptococcus pyogenes (spCas9). In some embodiments, Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0276] In some embodiments, the cells subjected to genome editing have one or more mutations in the genome, which result in reduced expression of the endogenous gene of interest compared to expression in normal cells without such mutation(s). The normal cell can be a healthy cell or a control cell derived from (or isolated from) another subject without a defect in the GOI. In some embodiments, the cells subjected to genome editing can be derived from (or isolated from) a subject in need of treatment for a condition or disorder associated with the GOI. In some specific embodiments, the cells subjected to genome editing can be derived from (or isolated from) a patient in need of treatment for a condition or disorder associated with the GOI. In some embodiments, the patient has or is suspected of having a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE. In some embodiments, the patient has hemophilia A. In some embodiments, the patient has hemophilia B. In some embodiments, the patient is a patient with HAE. Thus, in some embodiments, expression of the endogenous GOI gene in such cells is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to expression of the endogenous gene of interest in normal cells.

[0277] In some embodiments, the genome editing method performs targeted integration in the non-coding region of the genome of a functional GOI, such as a FVIII gene, for example, a FVIII coding sequence operably linked to a provided promoter so as to stably produce FVIII protein in vivo. In some embodiments, the targeted integration of the GOI coding sequence occurs in an intron of an albumin gene, which is highly expressed in a cell type of interest, such as hepatocytes or sinusoidal endothelial cells. In some embodiments, the inserted GOI coding sequence can be a wild-type GOI coding sequence, for example, a wild-type human GOI coding sequence. In some embodiments, the GOI coding sequence can be a functional derivative of a wild-type GOI coding sequence, such as a wild-type human GOI coding sequence.

[0278] In one aspect, the present disclosure provides for the insertion of a nucleic acid sequence of a gene of interest (GOI), such as, for example, a FVIII gene or a functional derivative thereof, into the genome of a cell. In some embodiments, the inserted GOI coding sequence is a modified GOI coding sequence. In some embodiments, the modified GOI coding sequence is specifically integrated into intron 1 of the albumin gene in target cells. In some embodiments, the modified GOI coding sequence is specifically integrated into intron 1 of the albumin gene in mammalian hepatocytes, including humans. In some embodiments, the inserted GOI coding sequence is a modified FVIII coding sequence. In some embodiments, in the modified FVIII coding sequence, the B domain of the wild-type FVIII coding sequence is deleted and replaced with a linker peptide called "SQ link" (amino acid sequence SFSQNPPVLKRHQR-SEQ ID NO: 1). This B domain-deleted FVIII (FVIII-BDD) is well known in the art and has biological activity equivalent to that of full-length FVIII. For example, in some embodiments, B-domain deleted FVIII exceeds full-length FVIII due to its smaller size (4371 bp vs. 7053 bp). Thus, in some embodiments, a FVIII-BDD coding sequence lacking the FVIII signal peptide and containing a splice acceptor sequence at its 5' end (the N-terminus of the FVIII coding sequence) is specifically integrated into intron 1 of the albumin gene in mammalian, including human, hepatocytes. In some embodiments, transcription of this modified GOI coding sequence from the albumin promoter can result in a pre-mRNA containing exon 1, a portion of intron 1, and the integrated GOI sequence of albumin. For example, transcription of the above modified FVIII coding sequence from the albumin promoter can result in a pre-mRNA containing exon 1, a portion of intron 1, and the integrated FVIII-BDD gene sequence of albumin.When this pre-mRNA undergoes natural splicing processes to remove introns, the splicing machinery can ligate the splice donor at the 3' end of albumin exon 1 to the next available splice acceptor at the 5' end of the FVIII-BDD coding sequence of the inserted DNA donor. This can result in a mature mRNA containing albumin exon 1 fused to the mature coding sequence of FVIII-BDD. Albumin exon 1 encodes a signal peptide plus two additional amino acids and one-third of a codon encoding the protein sequence DAH, which is normally located at the N-terminus of albumin in humans. Thus, in some embodiments, after cleavage of the predicted albumin signal peptide upon secretion from cells, a FVIII-BDD protein can be produced, and the N-terminus of the FVIII-BDD protein contains the amino acid sequence -. [ka] -. Because the third of these three amino acids (underlined) is encoded partly by the end of exon 1 and partly by the FVIII-BDD DNA donor template, it is possible to select the identity of the third additional amino acid residue to be either Leu, Pro, His, Gln, or Arg. Of these options, Leu is selected in some embodiments because it is molecularly the least complex and therefore least likely to form new T-cell epitopes, and because it has the amino acid sequence - [ka] - at the N-terminus of the FVIII-BDD protein. Alternatively, the DNA donor template can be designed to delete the third residue, resulting in the amino acid sequence [ka] to the N-terminus of the FVIII-BDD protein. In some instances, adding additional amino acids to the native protein sequence can increase the immunogenicity risk. Thus, in some embodiments, a computational analysis predicting the immunogenic potential of two potential options for the N-terminus of FVIII-BDD revealed that the deletion of one residue ( [ka] ) has a lower immunogenicity score, which may, at least in some embodiments, be the design selected.

[0279] In some embodiments, DNA sequences encoding modified GOIs, such as FVIII-BDD, that have been optimized for codon usage can be used to improve expression in mammalian cells (so-called codon optimization). Different computer algorithms are also available in the field for performing codon optimization, which generate distinct DNA sequences. Examples of commercially available codon optimization algorithms are those employed by the companies ATUM and GeneArt (part of Thermo Fisher Scientific). A codon-optimized FVIII coding sequence has been demonstrated to significantly improve FVIII expression after gene-based delivery in mice (Nathwani AC, Gray JT, Ng CY, et al. Blood. 2006; 107(7):2653-2661, Ward NJ, Buckley SM, Waddington SN, et al. Blood. 2011; 117(3):798-807, Radcliffe PA, Sion CJ, Wilkes FJ, et al. Gene Ther. 2008; 15(4):289-297).

[0280] In some embodiments, the sequence homology or identity between a modified GOI coding sequence codon-optimized by different algorithms and the native GOI sequence (present in the human genome) can be in the range of about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100%. In some embodiments, the codon-optimized coding sequence of the modified GOI has about 75% to about 79% sequence homology or identity to the native GOI sequence. In some embodiments, the codon-optimized coding sequence of the modified GOI has about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% sequence homology or identity to the native GOI sequence.

[0281] In some embodiments, a donor template or donor construct is prepared to contain a DNA sequence encoding a modified GOI. In some embodiments, a DNA donor template is designed to contain a codon-optimized human coding sequence of the modified GOI. In some embodiments, the codon optimization is performed in such a way that the sequence encoding the signal peptide of the GOI, e.g., FVIII, at the 5' end is deleted and replaced with a splice acceptor sequence, and a polyadenylation signal is added to the 3' end after the FVIII stop codon (MAB8A-SEQ ID NO: 87). The splice acceptor sequence can be selected from known splice acceptor sequences from known genes, or a consensus splice acceptor sequence derived from an alignment of many splice acceptor sequences known in the art can be used. In some embodiments, a splice acceptor sequence from a highly expressed gene is used, as such a sequence is believed to provide optimal splicing efficiency. In some embodiments, the consensus splice acceptor sequence is composed of a branch site with the consensus sequence T / CNC / TT / CA / GAC / T (SEQ ID NO: 99), followed by a 10-12 base polypyrimidine tract (C or T) followed within 20 bp by AG>G / A (where > is the position of the intron / exon boundary). In some embodiments, the synthetic splice acceptor sequence [ka] In another embodiment, the natural splice acceptor sequence from the human albumin gene intron 1 / exon 2 boundary is used. [ka] or mouse [ka] is used.

[0282] The polyadenylation sequence provides a signal for the cell to add a poly(A) tail, which is essential for intracellular mRNA stability. In some embodiments in which a DNA donor template is packaged into AAV particles, the size of the packaged DNA is generally maintained within the packaging limits of AAV, e.g., less than about 5 Kb, e.g., about 4.7 Kb or less. Therefore, in some embodiments, it is desirable to use the shortest possible poly(A) sequence, e.g., about 10-mer, about 20-mer, about 30-mer, about 40-mer, about 50-mer, or about 60-mer, or any number of nucleotides between the aforementioned. A consensus synthetic poly(A) signal sequence has been reported in the literature (Levitt N, Briggs D, Gil A, Proudfoot NJ. Genes Dev. 1989;3(7):1019-1025) and has the sequence AATAAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTG (SEQ ID NO: 5), and is commonly used in many expression vectors.

[0283] In some embodiments, additional sequence elements can be added to the DNA donor template to improve integration frequency. One such element is a homology arm, which is the same sequence as the DNA sequence on either side of the double-strand break in the genome where integration is targeted to enable HDR integration. The sequence from the left side of the double-strand break (LHA) is added to the 5' end (N-terminus of the FVIII coding sequence) of the DNA donor template, and the sequence from the right side of the double-strand break (RHA) is added to the 3' end (C-terminus of the FVIII coding sequence) of the DNA donor template, for example, MAB8B (SEQ ID NO: 88).

[0284] An alternative DNA donor template design provided in some embodiments has a sequence complementary to the recognition sequence of the sgRNA used to cleave the genomic site. MAB8C (SEQ ID NO: 89) represents an example of this type of DNA donor template. By including the sgRNA recognition site, the DNA donor template is cleaved by the sgRNA / Cas9 complex in the nucleus of the cell to which the DNA donor template and sgRNA / Cas9 are delivered. Cleavage of the donor DNA template into linear fragments can increase the frequency of integration at double-stranded breaks by the non-homologous end joining or HDR mechanism. This may be particularly beneficial in the case of delivery of AAV-packaged donor DNA templates, because it is known that after delivery to the nucleus, the AAV genome concatenates to form larger circular double-stranded DNA molecules (Nakai et al. J. Viology 2001, vol. 75, pp. 6969-6976). Therefore, in some instances, circular concatemers may be less efficient donors for integration at double-stranded breaks, especially by the NHEJ mechanism. It has previously been reported that the efficiency of targeted integration using circular plasmid DNA donor templates can be increased by including zinc finger nuclease cleavage sites in the plasmid (Cristea et al. Biotechnol. Bioeng. 2013;110:871-880). Recently, this approach has been applied using CRISPR / Cas9 nuclease (Suzuki et al. 2017, Nature 540,144-149). Although sgRNA recognition sequences are active when present on either strand of a double-stranded DNA donor template, the use of the reverse complement of the sgRNA recognition sequence present in the genome is predicted to favor stable integration, as integration in the reverse orientation regenerates the sgRNA recognition sequence, which can be re-cleaved to release the inserted donor DNA template. Integration of such a donor DNA template in the genome in the forward orientation by NHEJ is predicted not to regenerate the sgRNA recognition sequence, so that the integrated donor DNA template is not excised from the genome.The benefit of including sgRNA recognition sequences in the donor, with or without homology arms, on the efficiency of integration of the GOI donor DNA template can be determined, for example, by testing in mice using AAV for donor delivery and LNP for CRISPR-Cas9 component delivery.

[0285] In some embodiments, the donor DNA template comprises a GOI or a functional derivative thereof within a donor cassette according to any of the embodiments described herein, flanked on one or both sides by gRNA target sites. In some embodiments, the donor template comprises a gRNA target site 5' of the donor cassette and / or a gRNA target site 3' of the donor cassette. In some embodiments, the donor template comprises two adjacent gRNA target sites, wherein the two gRNA target sites comprise the same sequence. In some embodiments, the donor template comprises at least one gRNA target site, wherein the at least one gRNA target site in the donor template is the target site of at least one of one or more gRNAs targeting the first intron of the albumin gene. In some embodiments, the donor template comprises at least one gRNA target site, wherein the at least one gRNA target site in the donor template is the reverse complement of the target site of at least one of one or more gRNAs in the first intron of the albumin gene. In some embodiments, the donor template comprises a 5' gRNA target site of the donor cassette and a 3' gRNA target site of the donor cassette, wherein the two gRNA target sites in the donor template are targeted by one or more gRNAs that target the first intron of the albumin gene. In some embodiments, the donor template comprises a 5' gRNA target site of the donor cassette and a 3' gRNA target site of the donor cassette, wherein the two gRNA target sites in the donor template are reverse complements of the target site of at least one of the one or more gRNAs in the first intron of the albumin gene.

[0286] The insertion of the gene encoding the GOI into the target site, i.e., the genomic location where the gene encoding the GOI is inserted, can be in the endogenous albumin locus or its adjacent sequence. In some embodiments, the GOI-encoding gene is inserted in such a way that expression of the inserted gene is controlled by the endogenous promoter of the albumin gene. In some embodiments, the gene encoding the GOI is inserted into one of the introns of the albumin gene. In some embodiments, the gene encoding the GOI is inserted into one of the exons of the albumin gene. In some embodiments, the gene encoding the GOI is inserted at an intron:exon junction (or vice versa). In some embodiments, the insertion of the gene encoding the GOI is in the first intron (or intron 1) of the albumin locus. In some embodiments, the insertion of the gene encoding the GOI does not significantly affect, e.g., up-regulate or down-regulate, the expression of the albumin gene.

[0287] In some embodiments, the target site for insertion of the gene encoding the GOI is in, within, or near the endogenous albumin gene. In some embodiments, the target site is in an intergenic region upstream of the promoter of the albumin locus in the genome. In some embodiments, the target site is within the albumin locus. In some embodiments, the target site is in one of the introns of the albumin locus. In some embodiments, the target site is in one of the exons of the albumin locus. In some embodiments, the target site is at one of the junctions between an intron and an exon (or vice versa) of the albumin locus. In some embodiments, the target site is in the first intron (or intron 1) of the albumin locus. In certain embodiments, the target site is at least about or almost 0, 1, 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, or 650 bp downstream (i.e., from the last nucleic acid of the first exon) of the albumin gene. In some embodiments, the target site is at least about or almost 0.1 kb, about 0.2 kb, about 0.3 kb, about 0.4 kb, about 0.5 kb, about 1 kb, about 1.5 kb, about 2 kb, about 2.5 kb, about 3 kb, about 3.5 kb, about 4 kb, about 4.5 kb, or about 5 kb upstream of the first intron of the albumin gene.In some embodiments, the target site is located between about 0 bp and about 100 bp upstream, between about 101 bp and about 200 bp upstream, between about 201 bp and about 300 bp upstream, between about 301 bp and about 400 bp upstream, between about 401 bp and about 500 bp upstream, between about 501 bp and about 600 bp upstream, between about 601 bp and about 700 bp upstream, between about 701 bp and about 800 bp upstream, or between about 801 bp and about 900 bp upstream of the second exon of the albumin gene. The target site is any of the following positions: downstream, about 901 bp to about 1000 bp upstream, about 1001 bp to about 1500 bp upstream, about 1501 bp to about 2000 bp upstream, about 2001 bp to about 2500 bp upstream, about 2501 bp to about 3000 bp upstream, about 3001 bp to about 3500 bp upstream, about 3501 bp to about 4000 bp upstream, about 4001 bp to about 4500 bp upstream, or about 4501 bp to about 5000 bp upstream. In some embodiments, the target site is at least 37 bp downstream of the end (i.e., 3' end) of the first exon of the human albumin gene in the genome. In some embodiments, the target site is at least 330 bp upstream of the start (i.e., 5' start) of the second exon of the human albumin gene in the genome.

[0288] In some embodiments, provided herein are methods for editing a genome in a cell, the method comprising providing to the cell: (a) a gRNA, or a nucleic acid encoding a gRNA, comprising a spacer sequence from any one of SEQ ID NOS: 18-44 and 104; (b) a DNA endonuclease or a nucleic acid encoding a DNA endonuclease; and (c) a donor template comprising a nucleic acid sequence encoding a GOI or a functional derivative. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 30. In some embodiments, the cell is a human cell, e.g., a human hepatocyte.

[0289] In some embodiments, by any of the methods of genome editing in a cell described herein, the DNA endonuclease recognizes a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or functional derivative thereof. In some embodiments, the DNA endonuclease is a type II Cas endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, Cas9 is derived from Streptococcus pyogenes (spCas9). In some embodiments, Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0290] In some embodiments, the nucleic acid sequence encoding the GOI or a functional derivative thereof is codon-optimized for expression in the cell by any of the methods of genome editing in a cell described herein. In some embodiments, the cell is a human cell.

[0291] In some embodiments, any of the methods for editing a genome in a cell described herein uses a nucleic acid encoding a DNA endonuclease. In some embodiments, the nucleic acid encoding the DNA endonuclease is codon-optimized for expression in the cell. In some embodiments, the cell is a human cell, such as a human hepatocyte. In some embodiments, the nucleic acid encoding the DNA endonuclease is DNA, such as a DNA plasmid. In some embodiments, the nucleic acid encoding the DNA endonuclease is RNA, such as mRNA.

[0292] In some embodiments, by any of the methods for editing genomes in cells described herein, the donor template is encoded by an AAV vector. In some embodiments, the donor template comprises a donor cassette comprising a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof, and the donor cassette is flanked by gRNA target sites on one or both sides. In some embodiments, the donor cassette is flanked by gRNA target sites on both sides. In some embodiments, the gRNA target sites are the target sites for the gRNA (a). In some embodiments, the gRNA target sites of the donor template are the reverse complement of the cell genome gRNA target sites for the gRNA (a).

[0293] In some embodiments, in any of the methods for genome editing in cells described herein, the DNA endonuclease or a nucleic acid encoding the DNA endonuclease is formulated into a liposome or lipid nanoparticle. In some embodiments, the liposome or lipid nanoparticle also comprises a gRNA. In some embodiments, the liposome or lipid nanoparticle is a lipid nanoparticle. In some embodiments, the method uses a lipid nanoparticle comprising a nucleic acid encoding the DNA endonuclease and the gRNA. In some embodiments, the nucleic acid encoding the DNA endonuclease is an mRNA encoding the DNA endonuclease.

[0294] In some embodiments, by any of the methods of editing a genome in a cell described herein, the DNA endonuclease is pre-complexed with the gRNA to form an RNP complex.

[0295] In some embodiments, by any of the methods for editing a genome in a cell described herein, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell more than four days after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell at least 14 days after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell at least 17 days after the donor template of (c) is provided to the cell. In some embodiments, (a) and (b) are provided to cells as lipid nanoparticles comprising a nucleic acid encoding a DNA endonuclease and gRNA.In some embodiments, the nucleic acid encoding a DNA endonuclease is an mRNA encoding a DNA endonuclease.In some embodiments, (c) is provided to cells as an AAV vector encoding a donor template.

[0296] In some embodiments, by any of the methods for editing a genome in a cell described herein, one or more additional doses of the (a) gRNA and (b) DNA endonuclease or nucleic acid encoding the DNA endonuclease are provided to the cell subsequent to the first dose of the (a) gRNA and (b) DNA endonuclease or nucleic acid encoding the DNA endonuclease. In some embodiments, one or more additional doses of the (a) gRNA and (b) DNA endonuclease or nucleic acid encoding the DNA endonuclease are provided to the cell subsequent to the first dose of the (a) gRNA and (b) DNA endonuclease or nucleic acid encoding the DNA endonuclease until a target level of targeted integration of a nucleic acid sequence encoding a gene of interest (GOI) or a functional derivative thereof and / or a target level of expression of a nucleic acid sequence encoding a GOI or a functional derivative thereof is achieved.

[0297] In some embodiments, by any of the methods of editing a genome in a cell described herein, the nucleic acid sequence encoding the GOI or a functional derivative is expressed under the control of the endogenous albumin promoter.

[0298] In some embodiments, provided herein are methods for inserting a GOI or a functional derivative thereof into the albumin locus of a cell's genome, the method comprising introducing into the cell (a) a Cas DNA endonuclease (e.g., Cas9) or a nucleic acid encoding the Cas DNA endonuclease, (b) a gRNA or a nucleic acid encoding the gRNA capable of directing the Cas DNA endonuclease to cleave a target polynucleotide sequence in the albumin locus, and (c) a donor template according to any of the embodiments described herein, comprising the GOI or a functional derivative thereof. In some embodiments, the method comprises introducing into the cell mRNA encoding the Cas DNA endonuclease. In some embodiments, the method comprises introducing into the cell an LNP according to any of the embodiments described herein, comprising i) an mRNA encoding the Cas DNA endonuclease, and ii) a gRNA. In some embodiments, the donor template is an AAV donor template. In some embodiments, the donor template comprises a donor cassette containing a GOI or a functional derivative thereof, wherein the donor cassette is flanked on one or both sides by gRNA target sites. In some embodiments, the gRNA target sites flanking the donor cassette are reverse complements of gRNA target sites in the albumin locus. In some embodiments, the Cas DNA endonuclease or a nucleic acid encoding the Cas DNA endonuclease and the gRNA or a nucleic acid encoding the gRNA are introduced into the cell following introduction of the donor template into the cell. In some embodiments, the Cas DNA endonuclease or a nucleic acid encoding the Cas DNA endonuclease and the gRNA or a nucleic acid encoding the gRNA are introduced into the cell following introduction of the donor template into the cell for a period of time sufficient to allow the donor template to enter the cell nucleus.In some embodiments, the Cas DNA endonuclease or a nucleic acid encoding the Cas DNA endonuclease and the gRNA or a nucleic acid encoding the gRNA are introduced into the cell for a time sufficient following introduction of the donor template into the cell to allow the donor template to be converted from a single-stranded AAV genome into a double-stranded DNA molecule in the cell nucleus. In some embodiments, the Cas DNA endonuclease is Cas9.

[0299] In some embodiments, by any of the methods for inserting a GOI or a functional derivative thereof into the albumin locus of a cell's genome described herein, the target polynucleotide sequence is in intron 1 of the albumin gene. In some embodiments, the gRNA comprises a spacer sequence listed in Table 3 or 4. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 18-44 and 104, or a nucleic acid encoding the gRNA. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 30.

[0300] In some embodiments, provided herein are methods for inserting a GOI or a functional derivative thereof into the albumin locus of a cell's genome, the method comprising introducing into the cell (a) an LNP according to any of the embodiments described herein, comprising i) an mRNA encoding Cas9 DNA endonuclease and ii) a gRNA capable of directing the Cas9 DNA endonuclease to cleave a target polynucleotide sequence in the albumin locus, and (b) an AAV donor template according to any of the embodiments described herein, comprising a GOI or a functional derivative thereof. In some embodiments, the donor template comprises a donor cassette comprising the GOI or a functional derivative thereof, the donor cassette being flanked on one or both sides by gRNA target sites. In some embodiments, the gRNA target sites flanking the donor cassette are the reverse complements of the gRNA target sites in the albumin locus. In some embodiments, the LNP is introduced into the cell following introduction of the AAV donor template into the cell. In some embodiments, the LNPs are introduced into the cell for a sufficient time following introduction of the AAV donor template into the cell to allow the donor template to enter the cell nucleus. In some embodiments, the LNPs are introduced into the cell for a sufficient time following introduction of the AAV donor template into the cell to allow the donor template to be converted from a single-stranded AAV genome to a double-stranded DNA molecule in the cell nucleus. In some embodiments, additional introduction of one or more (e.g., 2, 3, 4, 5, or more) LNPs into the cell is performed following the initial introduction of the LNPs into the cell. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 18-44 and 104, or a nucleic acid encoding the gRNA. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22.In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NO: 30.

[0301] Selection of target sequence In some embodiments, as further described and exemplified herein, shifting the position of the 5' and / or 3' boundaries relative to a particular reference locus, depending in part on the endonuclease system selected for editing, is used to facilitate or enhance particular applications of gene editing.

[0302] In a first non-limiting embodiment of such target sequence selection, many endonuclease systems have rules or criteria that guide the initial selection of potential target sites for cleavage, such as, in the case of CRISPR Type II or Type V endonucleases, the requirement for a PAM sequence motif at a specific position adjacent to the DNA cleavage site.

[0303] In another non-limiting aspect of target sequence selection or optimization, the frequency of "off-target" activity (i.e., the frequency of DSBs occurring at sites other than the selected target sequence) of a particular combination of target sequence and gene editing endonuclease is evaluated relative to the frequency of on-target activity. In some examples, cells that are correctly edited at a desired locus may have a selective advantage compared to other cells. Illustrative, but non-limiting, examples of selective advantages include improved replication rate, persistence, resistance to certain conditions, improved engraftment success or persistence in vivo after introduction into a patient, and other attributes associated with maintaining or increasing the number or viability of such cells. In other examples, cells that are correctly edited at a desired locus can be appropriately selected by one or more screening methods used to identify, sort, or otherwise select correctly edited cells. Both selective advantage and directed selection methods can utilize phenotypes associated with the correction. In some embodiments, cells can be edited more than once to create a second modification that creates a new phenotype used to select or purify the intended cell population. Such a second modification can be created by adding a second gRNA to a selectable or screenable marker. In some instances, a DNA fragment containing the cDNA and a selectable marker can be used to correctly edit a cell at the desired locus.

[0304] In some embodiments, regardless of whether any selective advantage is applicable or which directed selection is applied in a particular case, the selection of target sequence is also guided by consideration of off-target frequency, to increase the effectiveness of application and / or reduce the possibility of undesired changes at sites other than the desired target.As further described and exemplified herein and in the art, the occurrence of off-target activity is influenced by many factors, including the similarity and dissimilarity between the target site and various off-target sites, and the specific endonuclease used.Bioinformatics tools can be utilized to help predict off-target activity, and often such tools can also be used to identify the most likely sites of off-target activity, which can then be assessed in an experimental setting to evaluate the relative frequency of off-target activity relative to on-target activity, thereby enabling the selection of sequences with high relative on-target activity.Illustrative examples of such techniques are provided herein, and others are known in the art.

[0305] Another aspect of target sequence selection relates to homologous recombination events. Sequences sharing homologous regions can serve as a focus for homologous recombination events, resulting in the deletion of intervening sequences. Such recombination events occur regularly during the normal replication of chromosomes and other DNA sequences, as well as at other times when DNA sequences are synthesized, for example, during the normal cell replication cycle, but can be enhanced by the occurrence of various events (such as UV light and other DNA break inducers) or the presence of certain agents (such as various chemical inducers), such as in the case of double-strand break (DSB) repair. Many of these inducers indiscriminately generate DSBs within the genome, and DSBs are regularly induced and repaired in normal cells. During repair, the original sequence can be completely and faithfully reconstructed, but in some cases, small insertions or deletions (called "indels") are introduced at the DSB site.

[0306] As in the case of the endonuclease system described herein, DSBs can also be specifically induced at specific locations, which can be used to cause directed or preferential gene modification events at selected chromosomal locations.The tendency of homologous sequences to be the target of recombination in the context of DNA repair (and replication) can be advantageous in many situations, and is the basis for one application of gene editing systems such as CRISPR, which uses homology-directed repair to insert the sequence of interest provided by the use of a "donor" polynucleotide into a desired chromosomal location.

[0307] The desired deletion can also be achieved by using a homologous region between specific sequences, which can be a small region of "microhomology" with only 10 base pairs or less. For example, a single DSB is introduced at a site that shows microhomology with a nearby sequence. During normal repair of such DSBs, the most frequent result is the deletion of the intervening sequence as a result of recombination promoted by the DSB and the accompanying cellular repair process.

[0308] However, in some circumstances, selecting a target sequence within the region of homology may result in much larger deletions, including gene fusions (if the deletion is in a coding region), which may or may not be desirable in certain circumstances.

[0309] The examples provided herein further illustrate the selection of various target regions for the creation of DSBs designed to insert a GOI, e.g., a FVIII-encoding gene, as well as the selection of specific target sequences within such regions designed to minimize off-target events relative to on-target events.

[0310] Targeted integration In some embodiments, the method provided herein is to integrate a gene of interest (GOI) or a functional GOI into a specific location in the genome of a hepatocyte, referred to as "targeted integration." In some embodiments, targeted integration can be achieved by generating a double-strand break in genomic DNA using a sequence-specific nuclease.

[0311] The CRISPR-Cas system used in some embodiments has the advantage of being able to rapidly screen a large number of genomic targets to identify optimal CRISPR-Cas designs. The CRISPR-Cas system uses an RNA molecule called a single guide RNA (sgRNA) to target a related Cas nuclease (e.g., Cas9 nuclease) to a specific sequence in DNA. This targeting occurs through Watson-Crick base pairing between the sgRNA and a genomic sequence within the sgRNA's approximately 20-bp targeting sequence. Upon binding to the target site, the Cas nuclease cleaves both strands of the genomic DNA, creating a double-stranded break. The only requirement for designing an sgRNA to target a specific DNA sequence is that the target sequence must contain a protospacer adjacent motif (PAM) sequence at the 3' end of the sgRNA sequence that is complementary to the genomic sequence. In the case of Cas9 nuclease, the PAM sequence is NRG (where R is A or G and N is any base) or the more restricted PAM sequence NGG. Therefore, sgRNA molecules targeting any region of the genome can be designed computationally by placing a 20-bp sequence adjacent to all PAM motifs. PAM motifs occur on average at exactly 15 bp in eukaryotic genomes. However, computationally designed sgRNAs generate double-strand breaks in cells with varying efficiencies, and the cleavage efficiency of a set of sgRNA molecules cannot be predicted using computational methods. Because sgRNAs can be rapidly synthesized in vitro, this allows for the rapid screening of all potential sgRNA sequences within a given genomic region to identify the sgRNA that results in the most efficient cleavage. Generally, when a set of sgRNAs within a given genomic region is tested in cells, cleavage efficiencies ranging from 0 to 90% are observed. Computer algorithms as well as laboratory tests can also be used to determine the off-target potential of any given sgRNA. While perfect matches with the 20-bp recognition sequence of an sgRNA primarily occur only once in most eukaryotic genomes, numerous additional sites with one or more base pair mismatches with the sgRNA exist within the genome.These sites may cleave with variable frequencies that are often unpredictable based on the number or location of mismatches. Cleavage at additional off-target sites not identified by computational analysis may also occur. Therefore, screening multiple sgRNAs in relevant cell types to identify sgRNAs with the most favorable off-target profile is a key factor in selecting optimal sgRNAs for therapeutic use. A favorable off-target profile considers not only the number of actual off-target sites and the frequency of cleavage at these sites, but also the location of these sites within the genome. For example, off-target sites near or within functionally important genes, particularly oncogenes or anti-cancer genes, are considered less favorable than sites in intergenic regions with no known function. Therefore, identifying optimal sgRNAs cannot be predicted solely by computational analysis of an organism's genome sequence and requires experimental testing. While computational analysis can help narrow the number of guides to test, it cannot predict guides with high on-target cleavage or low desirable off-target cleavage. Experimental data show that the cleavage efficiency of sgRNAs, each with a perfect match to the genome of a region of interest (e.g., albumin intron 1), varies from no cleavage to >90% cleavage and is not predictable by any known algorithm. The ability of a given sgRNA to promote cleavage by a Cas enzyme may be related to the accessibility of its specific site within the genomic DNA, which may be determined by the chromatin structure of that region. While the majority of genomic DNA in quiescent differentiated cells, such as hepatocytes, exists in highly condensed heterochromatin, actively transcribed regions exist in a more open chromatin state, known to be more accessible to large molecules, such as proteins like Cas proteins. Even within actively transcribed genes, some specific regions of DNA are more accessible than others, depending on the presence or absence of bound transcription factors or other regulatory proteins. It is not possible to predict sites within a genome or at a specific genomic locus, or regions of a genomic locus, such as introns like albumin intron 1, and therefore must be determined experimentally in the relevant cell type.Once several sites have been selected as potential sites for insertion, it may be possible to add several mutations to such sites, for example, by moving several nucleotides upstream or downstream from the selected site, with or without experimental testing.

[0312] In some embodiments, the gRNAs that can be used in the methods disclosed herein are one or more of those listed in Table 3, or any derivatives thereof having at least about 85% nucleotide sequence identity to those from Table 3.

[0313] Nucleic acid modification In some embodiments, the polynucleotide introduced into the cell can have one or more modifications that can be used individually or in combination to, for example, increase activity, stability, or specificity, alter delivery, reduce innate immune responses in the host cell, or otherwise enhance, as further described herein and known in the art.

[0314] In certain embodiments, modified polynucleotides are used in the CRISPR / Cas9 / Cpf1 system, where the guide RNA (either a single-molecule guide or a dual-molecule guide) and / or the DNA or RNA encoding the Cas or Cpf1 endonuclease introduced into a cell can be modified as described and illustrated below. Such modified polynucleotides can be used in the CRISPR / Cas9 / Cpf1 system to edit any one or more genomic loci.

[0315] Using the CRISPR / Cas9 / Cpf1 system as a non-limiting example of such an application, guide RNA modifications can be used to enhance the formation or stability of a CRISPR / Cas9 / Cpf1 genome editing complex comprising a guide RNA, which may be a single-molecule guide or a dual-molecule guide, and a Cas or Cpf1 endonuclease. Guide RNA modifications can also, or alternatively, be used to enhance the initiation, stability, or kinetics of the interaction between the genome editing complex and the target sequence within the genome, which can be used, for example, to enhance intra-target activity. Guide RNA modifications can also, or alternatively, be used to enhance specificity, e.g., the relative rate of genome editing at intra-target sites, compared to the effect at other (non-target) sites.

[0316] Modifications can also, or alternatively, be used to increase the stability of the guide RNA, thereby increasing its half-life within the cell, for example, by increasing its resistance to degradation by ribonucleases (RNases) present in the cell. Modifications that increase the half-life of the guide RNA can be particularly useful in embodiments in which the Cas or Cpfl endonuclease is introduced into the cell to be edited via RNA that needs to be translated to produce the endonuclease, as increasing the half-life of the guide RNA introduced simultaneously with an endonuclease-encoding RNA can be used to increase the time that the guide RNA and the encoded Cas or Cpfl endonuclease coexist within the cell.

[0317] Modifications can also, or alternatively, be used to reduce the likelihood or extent to which RNA introduced into a cell will induce an innate immune response. As described below and in the art, such responses, which have been well characterized in the context of RNA interference (RNAi), including small interfering RNA (siRNA), tend to be associated with reduced RNA half-life and / or induction of cytokines or other factors associated with the immune response.

[0318] One or more modifications can also be made to the RNA encoding the endonuclease that is introduced into a cell, including, but not limited to, modifications that increase the stability of the RNA (e.g., by increasing degradation by RNases present in the cell), modifications that enhance translation of the resulting product (i.e., the endonuclease), and / or modifications that reduce the likelihood or extent to which the RNA introduced into a cell will elicit an innate immune response.

[0319] Combinations of modifications, such as those described above and others, can be used as well. For example, in the case of CRISPR / Cas9 / Cpfl, one or more modifications can be made to the guide RNA (including those exemplified above) and / or one or more modifications can be made to the RNA encoding the Cas endonuclease (including those exemplified above).

[0320] As an illustration, guide RNAs used in the CRISPR / Cas9 / Cpf1 system, or other smaller RNAs, can be readily synthesized by chemical means, as shown below and described in the art, allowing many modifications to be readily incorporated. While chemical synthesis procedures are continually expanding, purification of such RNAs by procedures such as high-performance liquid chromatography (HPLC, which avoids the use of gels such as PAGE), tends to become more difficult as polynucleotide lengths increase significantly beyond approximately 100 nucleotides. One approach used to generate longer chemically modified RNAs is to generate two or more molecules that are linked together. Much longer RNAs, such as those encoding the Cas9 endonuclease, are more easily generated enzymatically. While the types of modifications generally available for use in enzymatically generated RNAs are limited, additional modifications exist that can be used to, for example, increase stability, reduce the likelihood or severity of innate immune responses, and / or enhance other attributes, as described below and further in the art, and new types of modifications are regularly developed.

[0321] Examples of various types of modifications, particularly those frequently used in smaller chemically synthesized RNAs, include one or more nucleotides modified at the 2' position of the sugar, in some embodiments, 2'-O-alkyl, 2'-O-alkyl-O-alkyl, or 2'-fluoro modified nucleotides. In some embodiments, RNA modifications include 2'-fluoro, 2'-amino, or 2'-O-methyl modifications to pyrimidines, abasic residues, or the ribose of the reverse base at the 3' end of RNA. Such modifications are routinely incorporated into oligonucleotides, and these oligonucleotides have been shown to have higher Tm (i.e., higher target binding affinity) for a given target than 2'-deoxyoligonucleotides.

[0322] Many nucleotide and nucleoside modifications have been shown to make the oligonucleotides they incorporate more resistant to nuclease digestion than natural oligonucleotides. These modified oligonucleotides remain intact for a longer period of time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those with modified backbones, such as phosphorothioates, phosphotriesters, methylphosphonates, short alkyl or cycloalkyl intersugar linkages, or short heteroatom or heterocyclic intersugar linkages. Some oligonucleotides have phosphorothioate and heteroatom backbones, particularly CH2-NH-O-CH2, CH, ~N(CH3)~O~CH2 (known as the methylene(methylimino) or MMI backbone), CH2--O--N(CH3)-CH2, CH2-N(CH3)-N(CH3)-CH2, and ON(CH3)-CH2-CH2 backbones. The natural phosphodiester backbone is represented by the backbone O-P--O-CH, the amide backbone [De Mesmaeker et al., Ace. Chem. Res., 28:366-374 (1995)], the morpholino backbone structure (see Summerton and Weller, U.S. Pat. No. 5,034,506), and the peptide nucleic acid (PNA) backbone (in which the phosphodiester backbone of the oligonucleotide is replaced by a polyamide backbone and the nucleotides are attached directly or indirectly to the aza-nitrogen atoms of the polyamide backbone; Nielsen et al., Science 1991, 254, 1497).Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates with 3' alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates with 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates with normal 3'-5' linkages, their 2'-5' linked analogs, and those with inverted polarity (adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'). U.S. Patent Nos. 3,687,808, 4,469,863, 4,476,301, 5,023,243, 5,177,196, 5,188,897, 5,264,423, 5,276,019, 5,278,302, 5,286,717, 5,321,131, 5,399,676, 5,405,9 See Nos. 39, 5,453,496, 5,455,233, 5,466,677, 5,476,925, 5,519,126, 5,536,821, 5,541,306, 5,550,111, 5,563,253, 5,571,799, 5,587,361, and 5,625,050.

[0323] Morpholino-based oligomeric compounds are described in Braasch and David Corey, Biochemistry, 41(14):4503-4510 (2002), Genesis, Volume 30, Issue 3, (2001), Heasman, Dev. Biol., 243:209-214 (2002), Nasevicius et al., Nat. Genet., 26:216-220 (2000), Lacerra et al., Proc. Natl. Acad. Sci., 97:9591-9596 (2000), and U.S. Patent No. 5,034,506, issued July 23, 1991.

[0324] Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 122:8595-8602 (2000).

[0325] Modified oligonucleotide backbones that do not contain an internal phosphorus atom include backbones formed by short-chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short-chain heteroatom or heterocyclic internucleoside linkages, including those with morpholino linkages (formed in part from the sugar portion of the nucleoside), siloxane backbones, sulfide, sulfoxide, and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonic acid and sulfonamide backbones, amide backbones, and those containing a mixture of N, O, S, and CH2 moieties. U.S. Patent Nos. 5,034,506, 5,166,315, 5,185,444, 5,214,134, 5,216,141, 5,235,033, 5,264,562, 5,264,564, 5,405,938, 5,434,257, 5,466,677, 5,470,967, 5,489,677, 5,541,307, 5,56 Nos. 1,225, 5,596,086, 5,602,240, 5,610,289, 5,602,240, 5,608,046, 5,610,289, 5,618,704, 5,623,070, 5,663,312, 5,633,360, 5,677,437, and 5,677,439, each of which is incorporated herein by reference.

[0326] One or more substituted sugar moieties, such as one of the following, may also be included at the 2' position: OH, SH, SCH, F, OCN, OCH, OCHO(CH). n CH3, O(CH2) n NH2, or O(CH2) nCH3 (wherein n is 1 to about 10); C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl, or aralkyl; Cl; Br; CN; CF3; OCF3; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; RNA cleaving group; reporter group; intercalating agent; group for improving the pharmacokinetic properties of oligonucleotides; or group for improving the pharmacodynamic properties of oligonucleotides and other substituents with similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-CH2CHOCH3), also known as 2'-O-(2-methoxyethyl) (Martin et al., HeIv. Chim. Acta, 1995, 78, 486). Other modifications include 2'-methoxy (2'-O-CH3), 2'-propoxy (2'-OCH2CH2CH3), and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of the 5' terminal nucleotide. Oligonucleotides can also have sugar mimetics such as cyclobutyls in place of pentofuranosyl groups.

[0327] In some embodiments, both the sugar and internucleoside linkages, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with appropriate nucleic acid target compounds. One such oligomeric compound, an oligonucleotide mimic that has been shown to have excellent hybridization properties, is called a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an oligonucleotide is replaced with an amide-containing backbone, such as an aminoethylglycine backbone. The nucleobases are retained and are directly or indirectly bound to the aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082, 5,714,331, and 5,719,262. Further teachings on PNA compounds can be found in Nielsen et al., Science, 254:1497-1500 (1991).

[0328] In some embodiments, a guide RNA can additionally or alternatively include a nucleobase (often referred to in the art simply as a "base") modification or substitution. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C), and uracil (U). Modified nucleobases include nucleobases that are found rarely or only occasionally in natural nucleic acids, such as hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also called 5-methyl-2'deoxycytosine, and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC, and gentobiosyl HMC, as well as synthetic nucleobases such as 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine, or other heterosubstituted alkyl adenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N6(6-aminohexyl)adenine, and 2,6-diaminopurine. Kornberg, A., DNA Replication, W.H. Freeman & Co., San Francisco, pp. 75-77 (1980); Gebeyehu et al., Nucl. Acids Res. 15:4513 (1997). "Universal" bases known in the art, such as inosine, may also be included. 5-Me-C substitution has been shown to improve nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., in Crooke, S.T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278), and is an example of a base substitution.

[0329] In some embodiments, modified nucleobases are selected from the group consisting of 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, These include cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, and 3-deazaguanine and 3-deazaadenine.

[0330] Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in 'The Concise Encyclopedia of Polymer Science and Engineering', pages 858-859, Kroschwitz, JI, ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandle Chemie, International Edition', 1991, 30, page 613, and those disclosed by Sanghvi, YS, Chapter 15, 'Antisense Research and Applications', pages 289-302, Crooke, ST and Lebleu, B. ea., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the present disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, such as 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-Methylcytosine substitutions have been shown to improve nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T., and Lebleu, B., eds., "Antisense Research and Applications," CRC Press, Boca Raton, 1993, pp. 276-278), and even more specifically, base substitutions in combination with 2'-O-methoxyethyl sugar modifications.Modified nucleobases are disclosed in U.S. Patent Nos. 3,687,808, 4,845,205, 5,130,302, 5,134,066, 5,175,273, 5,367,066, 5,432,272, 5,457,187, 5,459,255, 5,484,908, 5,502,177, 5,502,178, 5,502,179, 5,502,180, 5,502,181, 5,502,182, 5,502,183, 5,502,184, 5,502,185, 5,502,186, 5,502,187, 5,502,188, 5,502,189 ... Nos. 5,525,711, 5,552,540, 5,587,469, 5,596,091, 5,614,617, 5,681,941, 5,750,692, 5,763,588, 5,830,653, and 6,005,096, as well as U.S. Patent Application Publication No. 2003 / 0158403.

[0331] In some embodiments, the guide RNA and / or mRNA (or DNA) encoding the endonuclease is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. Such moieties include lipid moieties such as cholesterol moieties [Letsinger et al., Proc. Natl. Acad. Sci. USA, 86:6553-6556 (1989)], cholic acid [Manoharan et al., Bioorg. Med. Chem. Let., 4:1053-1060 (1994)], thioethers such as hexyl-S-tritylthiol [Manoharan et al., Ann. NY Acad. Sci., 660:306-309 (1992) and Manoharan et al., Bioorg. Med. Chem. Let., 3:2765-2770 (1993)], thiocholesterol [Oberhauser et al., Nucl. Acids Res., 20:533-538 (1992)], aliphatic chains such as dodecanediol or undecyl residues [Kabanov ... al., FEBS Lett., 259:327-330 (1990) and Svinarchuk et al., Biochimie, 75:49-54 (1993)], phospholipids, such as dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate [Manoharan et al., Tetrahedron Lett., 36:3651-3654 (1995) and Shea et al., Nucl. Acids Res., 18:3777-3783 (1990)], polyamines or polyethylene glycol chains [Mancharan et al., Nucleosides & Nucleotides, 14:969-973 (1995)], adamantane acetic acid [Manoharan et al., Tetrahedron Lett., 36:3651-3654(1995)], palmityl moiety [(Mishra et al., Biochim. Biophys.Acta, 1264:229-237 (1995)], or octadecylamine or hexylamino-carbonyl-t-oxycholesterol moieties [Crooke et al., J. Pharmacol. Exp. Ther., 277:923-937 (1996)]. No. 109,124, No. 5,118,802, No. 5,138,045, No. 5,414,077, No. 5,486,603, No. 5,512,439, No. 5,578,718, No. 5,608,046, No. 4, No. 587,044, No. 4,605,735, No. 4,667,025, No. 4,762,779, No. 4,789,737, No. 4,824,941, No. 4,835,263, No. 4,876,335, No. 4, No. 904,582, No. 4,958,013, No. 5,082,830, No. 5,112,963, No. 5,214,136, No. 5,082,830, No. 5,112,963, No. 5,214,136, No. 5, No. 245,022, No. 5,254,469, No. 5,258,506, No. 5,262,536, No. 5,272,250, No. 5,292,873, No. 5,317,098, No. 5,371,241, 5,391 See also Nos. 5,723, 5,416,203, 5,451,463, 5,510,475, 5,512,667, 5,514,785, 5,565,552, 5,567,810, 5,574,142, 5,585,481, 5,587,371, 5,595,726, 5,597,696, 5,599,923, 5,599,928, and 5,688,941.

[0332] In some embodiments, sugars and other moieties can be used to target proteins and complexes with nucleotides, such as cationic polysomes and liposomes, to specific sites.For example, delivery to hepatocytes can be mediated through asialoglycoprotein receptor (ASGPR).See, for example, Hu, et al., Protein Pept Lett.21(10):1025-30(2014).Other systems known in the art and being developed regularly can be used to target the biomolecules and / or their complexes used in this case to specific target cells of interest.

[0333] In some embodiments, these targeting moieties or conjugates may contain a conjugate group covalently attached to a functional group such as a primary or secondary hydroxyl group. Conjugate groups of the present disclosure include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folic acid, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, and dyes. In the context of the present disclosure, groups that enhance pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and / or enhance sequence-specific hybridization with target nucleic acids. In the context of the present disclosure, groups that enhance pharmacokinetic properties include groups that improve uptake, distribution, metabolism, or excretion of the compounds of the present disclosure. Representative conjugate groups are disclosed in International Patent Application No. PCT / US92 / 09196, filed October 23, 1992, and U.S. Patent No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties, such as cholesterol moieties, cholic acid, thioethers such as hexyl-5-tritylthiol, thiocholesterol, aliphatic chains such as dodecanediol or undecyl residues, phospholipids such as di-hexadecyl-rac-glycerol or triethylammonium, 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, polyamines, or polyethylene glycol chains, or adamantane acetic acid, palmityl moieties, or octadecylamine or hexylamino-carbonyl-oxycholesterol moieties.For example, U.S. Patent Nos. 4,828,979, 4,948,882, 5,218,105, 5,525,465, 5,541,313, 5,545,730, 5,552,538, 5,578,717, 5,580,731, 5,580,731, 5,591,584, 5,109,124, 5,118,802, 5,138,045, 5,414 ,077, No. 5,486,603, No. 5,512,439, No. 5,578,718, No. 5,608,046, No. 4,587,044, No. 4,605,735, No. 4,667,025, No. 4,762,779, No. 4,789,737, No. 4,824,941, No. 4,835,263, No. 4,876,335, No. 4,904,582, No. 4,958,013, No. 5,08 No. 2,830, No. 5,112,963, No. 5,214,136, No. 5,082,830, No. 5,112,963, No. 5,214,136, No. 5,245,022, No. 5,254,469 , No. 5,258,506, No. 5,262,536, No. 5,272,250, No. 5,292,873, No. 5,317,098, No. 5,371,241, No. 5,391,723, No. 5,416, 203, 5,451,463, 5,510,475, 5,512,667, 5,514,785, 5,565,552, 5,567,810, 5,574,142, 5,585,481, 5,587,371, 5,595,726, 5,597,696, 5,599,923, 5,599,928, and 5,688,941.

[0334] Longer polynucleotides that are not amenable to chemical synthesis and are generally produced by enzymatic synthesis can also be modified by various means. Such modifications can include, for example, the introduction of certain nucleotide analogs, the incorporation of specific sequences or other moieties at the 5' or 3' end of the molecule, and other modifications. For example, mRNA encoding Cas9 is approximately 4 kb in length and can be synthesized by in vitro transcription. Modification of mRNA can be applied, for example, to enhance its translation or stability (e.g., by increasing resistance to degradation in cells), or to reduce the tendency of RNA to induce the innate immune response often observed in cells, followed by the introduction of exogenous RNA, particularly a longer RNA encoding Cas9.

[0335] Many such modifications have been described in the art, such as polyA tails, 5' cap analogs (e.g., anti-reverse cap analog (ARCA) or m7G(5')ppp(5')G (mCAP)), modified 5' or 3' untranslated regions (UTRs), the use of modified bases (e.g., pseudo-UTP, 2-thio-UTP, 5-methylcytidine-5'-triphosphate (5-methyl-CTP) or N6-methyl-ATP, or treatment with phosphatases to remove the 5' terminal phosphate. These and other modifications are known in the art, and new modifications of RNA are regularly developed.

[0336] There are numerous commercial suppliers of modified RNAs, including, for example, TriLink Biotech, AxoLabs, Bio-Synthesis Inc., Dharmacon, and many others. As described in TriLink, for example, 5-methyl-CTP can be used to confer desirable properties such as increased nuclease stability, increased translation, or reduced interaction of innate immune receptors with in vitro transcribed RNA. 5-Methylcytidine-5'-triphosphate (5-methyl-CTP), N6-methyl-ATP, pseudo-UTP, and 2-thio-UTP have also been shown to enhance translation while reducing innate immune stimulation in culture and in vivo, as described in the publications by Kormann et al. and Warren et al., referenced below.

[0337] It has been shown that improved therapeutic effects can be achieved using chemically modified mRNA delivered in vivo. See, for example, Kormann et al., Nature Biotechnology 29, 154-157 (2011). Such modifications can be used, for example, to increase the stability of RNA molecules and / or reduce their immunogenicity. It has been found that using chemical modifications such as pseudo-U, N6-methyl-A, 2-thio-U, and 5-methyl-C to replace only one-quarter of uridine and cytidine residues with 2-thio-U and 5-methyl-C, respectively, significantly reduced toll-like receptor (TLR)-mediated recognition of mRNA in mice. By reducing activation of the innate immune system, these modifications can be used to effectively increase the stability and longevity of mRNA in vivo. See, for example, Kormann et al., supra.

[0338] Additionally, repeated administration of synthetic messenger RNA incorporating modifications designed to bypass the innate antiviral response has been shown to reprogram differentiated human cells to pluripotency. See, e.g., Warren, et al., Cell Stem Cell, 7(5):618-30 (2010). Such modified mRNAs, acting as primary reprogramming proteins, may be an efficient means of reprogramming multiple human cell types. Such cells, called induced pluripotent stem cells (iPSCs), have been shown to effectively evade cellular antiviral responses using enzymatically synthesized RNA incorporating 5-methyl-CTP, pseudo-UTP, and anti-reverse cap analog (ARCA). See, e.g., Warren et al., supra.

[0339] Other modifications of polynucleotides described in the art include, for example, the use of a polyA tail, the addition of a 5' cap analog (such as m7G(5')ppp(5')G (mCAP)), modification of the 5' or 3' untranslated region (UTR), or treatment with phosphatase to remove the 5' terminal phosphate, and new approaches are regularly developed.

[0340] Many compositions and technologies applicable to the generation of modified RNA for use herein have been developed in the context of RNA interference (RNAi) modifications, including small interfering RNA (siRNA). siRNA presents particular challenges in vivo because its effects on gene silencing via mRNA interference are generally transient and may require repeated administration. Furthermore, siRNA is double-stranded RNA (dsRNA), and mammalian cells have evolved immune responses to detect and neutralize dsRNA, which is often a by-product of viral infection. Accordingly, there are mammalian enzymes such as PKR (dsRNA-responsive kinase) and retinoic acid-inducible gene I (RIG-I) that can potentially mediate cellular responses to dsRNA, as well as Toll-like receptors (TLR3, TLR7, and TLR8) that can trigger cytokine induction in response to such molecules. See, for example, the reviews by Angart et al., Pharmaceuticals (Basel) 6(4):440-468 (2013), Kanasty et al., Molecular Therapy 20(3):513-524 (2012), Burnett et al., Biotechnol J. 6(9):1130-46 (2011), Judge and MacLachlan, Hum Gene Ther 19(2):111-24 (2008), and the references cited therein.

[0341] As described herein, a wide variety of modifications have been developed and applied to increase RNA stability, reduce innate immune responses, and / or achieve other advantages that may be useful in connection with the introduction of polynucleotides into human cells. See, for example, the reviews by Whitehead KA et al., Annual Review of Chemical and Biomolecular Engineering, 2:77-96 (2011); Gaglione and Messere, Mini Rev Med Chem, 10(7):578-95 (2010); Chernolovskaya et al., Curr Opin Mol Ther., 12(2):158-67 (2010); Deleavy et al., Curr Protoc Nucleic Acid Chem Chapter 16:Unit 16.3 (2009); Behlke, Oligonucleotides 18(4):305-19 (2008); Fucini et al., Nucleic Acid Ther 22(3):205-210 (2012); Bremsen et al., Front Genet 3:154 (2012).

[0342] As mentioned above, there are many commercial suppliers of modified RNAs, many of which specialize in modifications designed to improve the efficacy of siRNAs. Various approaches are offered based on various findings reported in the literature. For example, Dharmacon notes that the substitution of non-bridging oxygens with sulfur (phosphorothioate, PS) has been widely used to improve the nuclease resistance of siRNAs, as reported by Kole, Nature Reviews Drug Discovery 11:125-140 (2012). Modifications at the 2' position of ribose have been reported to improve the nuclease resistance of internucleotide phosphate bonds while also increasing duplex stability (Tm), which has also been shown to provide protection from immune activation. The combination of moderate PS backbone modifications with small, well-tolerated 2'-substitutions (2'-O-methyl, 2'-fluoro, and 2'-hydro) has been associated with highly stable siRNAs for in vivo applications (Soutschek et al. Nature 432:173-178 (2004)). 2'-O-methyl modifications have also been reported to be effective in improving stability (Volkov, Oligonucleotides 19:191-202 (2009)). Regarding the reduced induction of innate immune responses, modifications of specific sequences with 2'-O-methyl, 2'-fluoro, and 2'-hydro have been reported to generally reduce TLR7 / TLR8 interactions while maintaining silencing activity. See, for example, Judge et al., Mol. Ther. 13:494-505 (2006) and Cekaite et al., J. Mol. Biol. 365:90-108 (2007). Additional modifications such as 2-thiouracil, pseudouracil, 5-methylcytosine, 5-methyluracil, and N6-methyladenosine have also been shown to minimize the immune effects mediated by TLR3, TLR7, and TLR8. See, for example, Kariko, K. et al., Immunity 23:165-175 (2005).

[0343] As known in the art and commercially available, many conjugates can be applied to polynucleotides such as RNA that can enhance delivery and / or uptake by cells, including, for example, cholesterol, tocopherol and folic acid, lipids, peptides, polymers, linkers, and aptamers for use herein.See, for example, the review by Winkler, Ther. Deliv. 4:791-809 (2013) and the references cited therein.

[0344] delivery In some embodiments, any nucleic acid molecule used in the methods provided herein, such as the genome-targeting nucleic acid and / or the nucleic acid encoding the site-specific polypeptide of the present disclosure, can be packaged on or in a delivery vehicle for delivery to cells.Contemplated delivery vehicles include, but are not limited to, nanospheres, liposomes, quantum dots, nanoparticles, polyethylene glycol particles, hydrogels, and micelles.As described in the art, various targeting moieties can be used to enhance the preferential interaction of such vehicles with desired cell types or locations.

[0345] Introduction of the complexes, polypeptides, and nucleic acids of the present disclosure into cells can occur by viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, nucleofection, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, and similar techniques.

[0346] In some embodiments, the guide RNA polynucleotide (RNA or DNA) and / or endonuclease polynucleotide(s) (RNA or DNA) can be delivered by viral or non-viral delivery vehicles known in the art. Alternatively, the endonuclease polypeptide(s) can be delivered by viral or non-viral delivery vehicles known in the art, such as electroporation or lipid nanoparticles. In some embodiments, the DNA endonuclease can be delivered as one or more polypeptides, either alone or pre-complexed with one or more guide RNAs or one or more crRNAs and tracrRNAs.

[0347] In some embodiments, polynucleotide can be delivered by non-viral delivery vehicle, including but not limited to nanoparticles, liposomes, ribonucleoproteins, positively charged peptides, small RNA conjugates, aptamer-RNA chimeras, RNA fusion protein complexes.Some exemplary non-viral delivery vehicles are described in Peer and Lieberman, Gene Therapy, 18:1127-1133 (2011) (focusing on the non-viral delivery vehicle of siRNA, which is also useful for the delivery of other polynucleotides).

[0348] In some embodiments, polynucleotides such as guide RNAs, sgRNAs, and mRNAs encoding endonucleases can be delivered to cells or patients by lipid nanoparticles (LNPs).

[0349] While several nonviral delivery methods for nucleic acids have been tested in both animal models and humans, the most well-developed system is lipid nanoparticles. Lipid nanoparticles (LNPs) generally consist of ionizable cationic lipids and three or more additional components, usually cholesterol, DOPE, and polyethylene glycol (PEG) containing lipids (see, for example, Example 2). The cationic lipids can bind to positively charged nucleic acids to form dense complexes that protect the nucleic acids from degradation. During passage through a microfluidic system, the components self-assemble to form particles in the 50-150 nM size range, in which the nucleic acid is encapsulated in a core complexed with the cationic lipid and surrounded by a lipid bilayer-like structure. After injection into a subject's circulation, these particles can bind apolipoprotein E (apoE). ApoE is a ligand for the LDL receptor and mediates uptake into hepatocytes in the liver via receptor-mediated endocytosis. This type of LNP has been shown to efficiently deliver mRNA and siRNA to hepatocytes in the liver of rodents, primates, and humans. After endocytosis, the LNP resides in endosomes. The encapsulated nucleic acid undergoes endosomal escape, a process mediated by the ionizable nature of the cationic lipid. This delivers the nucleic acid to the cytoplasm, where the mRNA can be translated into the encoded protein. Thus, in some embodiments, encapsulation of gRNA and mRNA encoding Cas9 in LNPs is used to efficiently deliver both components to hepatocytes after IV injection. After endosomal escape, the Cas9 mRNA can be translated into the Cas9 protein and form a complex with the gRNA. In some embodiments, the inclusion of a nuclear localization signal in the Cas9 protein sequence facilitates the translocation of the Cas9 protein / gRNA complex to the nucleus. Alternatively, the small gRNA passes through the nuclear pore complex and forms a complex with the Cas9 protein in the nucleus. Once in the nucleus, the gRNA / Cas9 complex probes the genome for homologous target sites and preferentially generates double-strand breaks at the desired target site in the genome. The half-life of RNA molecules in vivo is short, on the order of hours to days.Similarly, the half-life of proteins tends to be short, on the order of a few hours to a few days. Therefore, in some embodiments, delivery of gRNA and Cas9 mRNA using LNPs can result in only transient expression and activity of the gRNA / Cas9 complex. This offers the advantage of reducing the frequency of off-target cleavage, and therefore, in some embodiments, can minimize the risk of genotoxicity. LNPs are generally less immunogenic than viral particles. Many humans have pre-existing immunity to AAV, but not to LNPs. Furthermore, supplemental and adaptive immune responses to LNPs are unlikely to occur, allowing for repeated administration of LNPs.

[0350] Several different ionizable cationic lipids have been developed for use in LNPs. These include, among others, C12-200 (Love et al. (2010), Proc Natl Acad Sci USA vol. 107, 1864-1869), MC3, LN16, and MD1. In one type of LNP, a GalNac moiety is attached to the outside of the LNP and acts as a ligand for liver uptake via the asialyloglycoprotein receptor. Any of these cationic lipids can be used to formulate LNPs for delivery of gRNA and Cas9 mRNA to the liver.

[0351] In some embodiments, LNP refers to any particle having a diameter of less than 1000 nm, 500 nm, 250 nm, 200 nm, 150 nm, 100 nm, 75 nm, 50 nm, or 25 nm. Alternatively, nanoparticles can range in size from 1 to 1000 nm, 1 to 500 nm, 1 to 250 nm, 25 to 200 nm, 25 to 100 nm, 35 to 75 nm, or 25 to 60 nm.

[0352] LNPs can be made from cationic, anionic, or neutral lipids. Neutral lipids, such as the fusogenic phospholipid DOPE or the membrane component cholesterol, can be included in LNPs as "helper lipids" to enhance transfection activity and nanoparticle stability. Limitations of cationic lipids include reduced efficacy due to their low stability and rapid clearance, as well as the generation of inflammatory or anti-inflammatory responses. LNPs can also contain hydrophobic, hydrophilic, or both hydrophobic and hydrophilic lipids.

[0353] Any lipid or lipid combination known in the art can be used to produce LNPs. Examples of lipids used to produce LNPs are DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG). Examples of cationic lipids are 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1. Examples of neutral lipids are DPSC, DPPC, POPC, DOPE, and SM. Examples of PEG-modified lipids are PEG-DMG, PEG-CerC14, and PEG-CerC20.

[0354] In some embodiments, lipids can be combined in any molar ratio to produce LNPs. Additionally, polynucleotide(s) can be combined with lipid(s) in a wide range of molar ratios to produce LNPs.

[0355] In some embodiments, the site-specific polypeptide and the genome-targeting nucleic acid can be administered separately to cells or patients. Alternatively, the site-specific polypeptide can be pre-complexed with one or more guide RNAs or one or more crRNAs together with tracrRNA. The pre-complexed material can then be administered to cells or patients. Such pre-complexed material is known as a ribonucleoprotein particle (RNP).

[0356] RNA can form specific interactions with either RNA or DNA. This property is exploited in many biological processes, but it also carries the risk of promiscuous interactions in the nucleic acid-rich cellular environment. One solution to this problem is the formation of ribonucleoprotein particles (RNPs), in which RNA is pre-complexed with endonucleases. Another advantage of RNPs is the protection of RNA from degradation.

[0357] In some embodiments, the endonuclease of RNP can be modified or unmodified.Similarly, gRNA, crRNA, tracrRNA or sgRNA can be modified or unmodified.Many modifications are known in the art and can be used.

[0358] The endonuclease and sgRNA can be combined in a molar ratio of typically 1:1. Alternatively, the endonuclease, crRNA, and tracrRNA can be combined in a molar ratio of typically 1:1:1. However, a wide range of molar ratios can be used to generate RNPs.

[0359] In some embodiments, recombinant adeno-associated virus (AAV) vectors can be used for delivery.The technology of producing rAAV particles, which contain the polynucleotide to be delivered, the packaged AAV genome, rep and cap genes, and helper virus functions are provided in cells, is standard in the art.The production of rAAV requires the following components to be present in a single cell (referred to herein as packaging cell): the rAAV genome, the AAV rep and cap genes separated from the rAAV genome (i.e., not present in the rAAV genome), and helper virus functions. The AAV rep and cap genes can be derived from any AAV serotype from which a recombinant virus can be derived, and can be derived from an AAV serotype different from the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAVrh.74. The generation of pseudotyped rAAVs is disclosed, for example, in International Patent Application Publication No. WO 01 / 83692. See Table 1. [Table 2]

[0360] In some embodiments, a method for producing packaging cells involves creating a cell line that stably expresses all components necessary for AAV particle production. For example, a plasmid (or multiple plasmids) carrying a rAAV genome lacking the AAV rep and cap genes, a separate AAV rep and cap gene from the rAAV genome, and a selectable marker such as a neomycin resistance gene is integrated into the cell's genome. The AAV genome is introduced into a bacterial plasmid by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing a restriction endonuclease cleavage site (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Another example of a suitable method uses adenovirus or baculovirus, rather than plasmids, to introduce the rAAV genome and / or the rep and cap genes into packaging cells.

[0361] General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches include Ratschin et al., Mol. Cell. Biol. 4:2072 (1984), Hermonat et al., Proc. Natl. Acad. Sci. USA, 81: 6466 (1984), Tratschin et al., Mo 1. Cell. Biol. al., J. Virol., 62:1963 (1988), and Lebkowski et al., 1988 Mol. Cell. Biol., 7: 349 (1988), Samulski et al. al. (1989, J. Virol., 63:3822-3828), U.S. Pat. No. 5,173,414, WO95 / 13365 and corresponding U.S. Pat. No. 5,658,776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO99 / 11764, Perrin et al. (1995) Vaccine 13:1244-1250, Paul et al. al. (1993) Human Gene Therapy 4:609-615, Clark et al. (1996) Gene Therapy 3:1124-1132, U.S. Pat. No. 5,786,211, U.S. Pat. No. 5,871,982, and U.S. Pat. No. 6,258,595.

[0362] The serotype of AAV vector can be matched with target cell type.For example, the following exemplary cell types can be transduced by the AAV serotypes shown in the table.For example, the serotypes of AAV vector suitable for liver tissue / cell type include, but are not limited to, AAV3, AAV5, AAV8 and AAV9.

[0363] In addition to adeno-associated viral vectors, other viral vectors can be used, including, but not limited to, lentiviruses, alphaviruses, enteroviruses, pestiviruses, baculoviruses, herpesviruses, Epstein-Barr viruses, papovaviruses, poxviruses, vaccinia viruses, and herpes simplex viruses.

[0364] In some embodiments, the Cas9 mRNA, the sgRNA targeting one or two loci of the albumin gene, and the donor DNA are each formulated separately into lipid nanoparticles, or are all co-formulated into one lipid nanoparticle, or are co-formulated into two or more lipid nanoparticles.

[0365] In some embodiments, the Cas9 mRNA is formulated in a lipid nanoparticle, while the sgRNA and donor DNA are delivered in an AAV vector. In some embodiments, the Cas9 mRNA and sgRNA are co-formulated in a lipid nanoparticle, and the donor DNA is delivered in an AAV vector.

[0366] Options are available for delivering Cas9 nuclease as a DNA plasmid, mRNA, or protein. Guide RNA can be expressed from the same DNA or delivered as RNA. RNA can be chemically modified to alter or improve its half-life or to reduce the likelihood or severity of an immune response. The endonuclease protein can be complexed with the gRNA before delivery. Viral vectors allow for efficient delivery, and split versions of Cas9 and small orthologs of Cas9, as well as donors for HDR, can be packaged into AAVs. A range of non-viral delivery methods exist that can deliver each of these components, or non-viral and viral methods can be used in combination. For example, nanoparticles can be used to deliver proteins and guide RNA, while AAV can be used to deliver donor DNA.

[0367] In some embodiments relating to the delivery of genome editing components for therapeutic treatment, at least two components, a sequence-specific nuclease and a DNA donor template, are delivered to the nucleus of transformed cells, such as hepatocytes.In some embodiments, the donor DNA template is packaged in an AAV with tropism for the liver.In some embodiments, the AAV is selected from serotypes AAV8, AAV9, AAVrhlO, AAV5, AAV6, or AAV-DJ.In some embodiments, the AAV-packaged DNA donor template is first administered to a subject, such as a patient, via peripheral IV injection, followed by the sequence-specific nuclease.The advantage of first delivering the AAV-packaged donor DNA template is that the delivered donor DNA template is stably maintained in the nucleus of transduced hepatocytes, allowing the subsequent administration of a sequence-specific nuclease to create double-strand breaks in the genome, followed by the subsequent integration of the DNA donor by HDR or NHEJ. In some embodiments, it is desirable that sequence-specific nuclease maintains activity in target cells for the time required to promote the targeted integration of transgene at a sufficient level for desired therapeutic effect.If sequence-specific nuclease maintains activity in cells for a long period of time, this will result in an increase in the frequency of double-stranded cleavage at off-target sites.Specifically, the frequency of off-target cleavage is a function of the off-target cleavage efficiency multiplied by the time that nuclease is active.When sequence-specific nuclease is delivered in the form of mRNA, it will result in nuclease activity for a short period of time ranging from a few hours to a few days, because mRNA and translated protein are short-lived in cells.Therefore, it is expected that the delivery of sequence-specific nuclease to cells that already contain donor template will result in the highest possible rate of targeted integration compared to off-target integration. Furthermore, AAV-mediated delivery of donor DNA templates to the nuclei of hepatocytes after peripheral IV injection is time-consuming, generally on the order of 1–14 days, due to the need for the virus to infect the cell, escape endosomes, and transit the nucleus, as well as the conversion of single-stranded AAV genomes into double-stranded DNA molecules by host components.Thus, in some embodiments, the process of delivery of the donor DNA template to the nucleus can be completed before providing the CRISPR-Cas9 components, as these nuclease components are only active for approximately 1-3 days.

[0368] In some embodiments, the sequence-specific nuclease is CRISPR-Cas9, which is composed of a Cas9 nuclease and an sgRNA directed to a DNA sequence within intron 1 of the albumin gene. In some embodiments, the Cas9 nuclease is delivered as an mRNA encoding the Cas9 protein operably fused to one or more nuclear localization signals (NLS). In some embodiments, the sgRNA and Cas9 mRNA are delivered to hepatocytes by packaging into lipid nanoparticles. In some embodiments, the lipid nanoparticles comprise the lipid C12-200 (Love et al. 2010, Proc Natl Acad Sci USA vol 107 1864-1869). In some embodiments, the ratio of sgRNA to Cas9 mRNA packaged into LNPs is 1:1 (by mass), resulting in maximal DNA cleavage in vivo in mice. In alternative embodiments, different mass ratios of sgRNA to Cas9 mRNA packaged in the LNPs can be used, e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, or 2:1, or vice versa. In some embodiments, the Cas9 mRNA and sgRNA are packaged in separate LNP formulations, and the Cas9 mRNA-containing LNPs are delivered to the patient about 1 to about 8 hours before the sgRNA-containing LNPs, allowing optimal time for the Cas9 mRNA to be translated prior to delivery of the sgRNA.

[0369] In some embodiments, an LNP formulation encapsulating a gRNA and Cas9 mRNA ("LNP-nuclease formulation") is administered to a subject, e.g., a patient, to whom an AAV-packaged DNA donor template has already been administered. In some embodiments, the LNP-nuclease formulation is administered to the subject within 1 to 28 days, or within 7 to 28 days, or within 7 to 14 days after administration of the AAV-donor DNA template. The optimal timing of delivery of the LNP-nuclease formulation relative to the AAV-donor DNA template can be determined using techniques known in the art, e.g., studies conducted in animal models, including mice and monkeys.

[0370] In some embodiments, DNA donor template is delivered to the hepatocytes of a subject, for example, a patient, using non-viral delivery methods.Some patients (generally 30%) have pre-existing neutralizing antibodies directed against the most commonly used AAV serotype, which prevents the effective gene delivery by AAV, but all patients can be treated with non-viral delivery methods.Some non-viral delivery methodologies are known in the art.In particular, lipid nanoparticles (LNPs) are known to efficiently deliver their encapsulated cargo into the cytoplasm of hepatocytes after intravenous injection in animals and humans.These LNPs are actively taken up by the liver through the process of receptor-mediated endocytosis, resulting in preferential uptake into the liver.

[0371] In some embodiments, to promote nuclear localization of the donor template, DNA sequences that can promote nuclear localization of the plasmid, such as the 366-bp region of the Simian Virus 40 (SV40) replication origin and early promoter, can be added to the donor template. Other DNA sequences that bind to cellular proteins can also be used to improve nuclear entry of DNA.

[0372] In some embodiments, the level of expression or activity of the introduced GOI is measured in the blood of a subject, e.g., a patient, following a first administration of an LNP-nuclease formulation containing, for example, a gRNA and a Cas9 nuclease or an mRNA encoding a Cas9 nuclease, following an AAV-donor DNA template. If the GOI level is not sufficient to cure the disease, e.g., as defined as a GOI level of at least 5-50%, particularly 5-20% of normal levels, a second or third administration of the LNP-nuclease formulation is given to promote additional targeted integration into the albumin intron 1 site. The feasibility of using multiple administrations of the LNP-nuclease formulation to obtain the desired therapeutic level of the GOI can be tested and optimized using techniques known in the art, e.g., using animal models, including mice and monkeys.

[0373] In some embodiments, according to any of the methods described herein, comprising administering to a subject i) an AAV-donor DNA template comprising a donor cassette, and ii) an LNP-nuclease formulation, an initial dose of the LNP-nuclease formulation is administered to the subject within 1 day to 28 days after administration of the AAV donor DNA template to the subject. In some embodiments, the initial dose of the LNP-nuclease formulation is administered to the subject after a sufficient time to allow delivery of the donor DNA template to the nucleus of the target cell. In some embodiments, the initial dose of the LNP-nuclease formulation is administered to the subject after a sufficient time to allow conversion of the single-stranded AAV genome into a double-stranded DNA molecule in the nucleus of the target cell. In some embodiments, one or more (e.g., 2, 3, 4, 5, or more) additional doses of the LNP-nuclease formulation are administered to the subject following administration of the initial dose. In some embodiments, one or more doses of the LNP-nuclease formulation are administered to the subject until a target level of targeted integration of the donor cassette and / or a target level of expression of the donor cassette is achieved. In some embodiments, the method further includes measuring the level of targeted integration of the donor cassette and / or the level of expression of the donor cassette after each administration of the LNP-nuclease formulation, and administering an additional dose of the LNP-nuclease formulation if the target level of targeted integration of the donor cassette and / or the target level of expression of the donor cassette is not achieved. In some embodiments, the amount of at least one of the one or more additional doses of the LNP-nuclease formulation is the same as the initial dose. In some embodiments, the amount of at least one of the one or more additional doses of the LNP-nuclease formulation is less than the initial dose. In some embodiments, the amount of at least one of the one or more additional doses of the LNP-nuclease formulation is greater than the initial dose.

[0374] Genetically modified cells and cell populations In one aspect, the present disclosure provides a method for editing a genome in a cell, thereby creating a genetically modified cell. In some embodiments, a population of genetically modified cells is provided. Thus, a genetically modified cell refers to a cell having at least one genetic modification introduced by genome editing (e.g., using the CRISPR / Cas9 / Cpf1 system). In some embodiments, the genetically modified cell is a genetically modified hepatocyte. Genetically modified cells having an exogenous genome-targeting nucleic acid and / or an exogenous nucleic acid encoding the genome-targeting nucleic acid are contemplated herein. The term "genetically modified cell" refers not only to the specific subject cell, but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in subsequent generations due to either mutation or environmental influences, such progeny may not actually be identical to the parent cell, but still fall within the scope of the term as used herein.

[0375] In some embodiments, the genome of a cell can be edited by inserting a nucleic acid sequence of a gene of interest or a functional derivative thereof into the genomic sequence of the cell. In some embodiments, the cell subjected to genome editing has one or more mutations in its genome, resulting in reduced expression of the endogenous GOI compared to normal expression without such mutation(s). The normal cell can be a healthy cell or a control cell derived from (or isolated from) another subject without a GOI-related defect. In some embodiments, the cell subjected to genome editing can be derived from (or isolated from) a subject in need of treatment for a GOI-related condition or disorder. Thus, in some embodiments, the expression of the endogenous GOI in such cells is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to the expression of endogenous GOI expression in normal cells.

[0376] Upon successful insertion of a transgene, e.g., a nucleic acid encoding a GOI or a functional fragment thereof, expression of the introduced GOI or a functional derivative thereof in the cell can be at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900%, about 1,000%, about 2,000%, about 3,000%, about 5,000%, about 10,000% or more compared to expression of the endogenous GOI in the cell. In some embodiments, the activity of an introduced GOI product comprising a functional fragment of the GOI in a genome-edited cell may be at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900%, about 1,000%, about 2,000%, about 3,000%, about 5,000%, about 10,000% or more compared to the expression of the endogenous GOI in the cell. In some embodiments, expression of the introduced GOI or a functional derivative thereof in the cell is at least about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 15-fold, about 20-fold, about 30-fold, about 50-fold, about 100-fold, about 1000-fold or more, or more, than the expression of the endogenous GOI in the cell. Also, in some embodiments, the activity of the introduced GOI product comprising a functional fragment of the GOI in the genome-edited cell may be comparable to or greater than the activity of the GOI product in a normal, healthy cell.

[0377] In some embodiments, such as treating or improving disorders or health conditions, such as hemophilia A, the primary target of gene editing is human cells. For example, in ex vivo and in vivo methods, the human cells are hepatocytes. In some embodiments, gene editing is performed on autologous cells derived from a patient in need, and therefore already fully matched, thereby generating cells that can be safely reintroduced into the patient, effectively generating a cell population that is effective in improving one or more clinical conditions associated with the patient's disease. In some embodiments for such treatment, hepatocyte cells can be isolated according to any method known in the art and used to generate genetically modified, therapeutically effective cells. In some embodiments, liver stem cells are genetically modified ex vivo and then reintroduced into the patient, generating genetically modified hepatocytes or sinusoidal endothelial cells that express the inserted GOI (e.g., the inserted FVIII gene).

[0378] The present disclosure further provides progeny of the genetically modified cells, which can contain the same exogenous nucleic acid or polypeptide as the genetically modified cell from which it is derived.

[0379] Therapeutic approaches In one aspect, provided herein is a gene therapy approach for treating a disorder or condition in a patient by editing the patient's genome.In some embodiments, the gene therapy approach integrates a functional GOI, such as FVIII, FIX, and SERPING1, into the genome of the relevant cell type in the patient, which can provide a permanent cure for the GOI-related disorder or condition, such as hemophilia A.In an embodiment involving the use of the FVIII gene for the treatment of hemophilia A, the cell type that is subjected to the gene therapy approach for incorporating the FVIII gene is hepatocytes, because these cells efficiently express and secrete many proteins into the blood.In addition, this integration approach using hepatocytes can be considered for pediatric patients whose livers are not fully developed, because the integrated gene is transmitted to daughter cells when hepatocytes divide.

[0380] In another aspect, the present disclosure provides a method for the ex vivo and in vivo use of cellular genome engineering tools to knock-in GOI or its functional derivatives into a locus in the genome, thereby causing permanent changes in the genome by restoring the activity of the GOI product.Such a method uses endonucleases, such as CRISPR-related (CRISPR / Cas9, Cpf1 and similar endonucleases) nucleases, to permanently delete, insert, edit, modify or replace any sequence from the genome, or to insert exogenous sequences, such as GOI, into a genomic locus.In this way, the example described in the present disclosure restores the activity of GOI with a single treatment (rather than delivering a potential therapy for the patient's lifetime).

[0381] In some embodiments, provided herein is one or more components of a system for genome editing according to any of the embodiments described herein for use in treating a disorder or condition associated with a target protein, such as for use in the manufacture of a medicament for treating the disorder or condition.

[0382] In some embodiments, ex vivo cell-based therapy is performed using hepatocytes isolated from a patient. The chromosomal DNA of these cells is then edited using the materials and methods described herein. Finally, the edited cells are transplanted into the patient.

[0383] One advantage of the ex vivo cell therapy approach is that comprehensive analysis of therapeutic agents can be performed before administration. All nuclease-based therapeutic agents have some level of off-target effects. Performing gene correction ex vivo allows for complete characterization of the corrected cell population before transplantation. An embodiment of the present disclosure includes sequencing the entire genome of the corrected cells to ensure that off-target cleavage, if any, is located in a genomic location associated with minimal risk to the patient. Furthermore, specific cell populations, including clonal populations, can be isolated before transplantation.

[0384] Another embodiment of such a method is an in vivo-based therapy, in which the chromosomal DNA of cells in a patient is modified using the materials and methods described herein. In some embodiments, the cells are hepatocytes.

[0385] The advantage of in vivo gene therapy is the ease of therapeutic production and administration. The same therapeutic approach and therapy can be used to treat more than one patient, for example, multiple patients who share the same or similar genotypes or alleles. In contrast, ex vivo cell therapy generally uses the patient's own cells, which are isolated, manipulated, and then returned to the same patient.

[0386] In some embodiments, the subject in need of a treatment method according to the present disclosure is a patient with symptoms of a disorder or condition selected from the group consisting of hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, and HAE. In some embodiments, the subject can be a human suspected of having a disorder or condition. In some embodiments, the subject can be a human suspected of having hemophilia A. Alternatively, the subject can be a human diagnosed as being at risk for a disorder or condition, e.g., hemophilia A. In some embodiments, the subject can be a human suspected of having hemophilia B. Alternatively, the subject can be a human diagnosed as being at risk for hemophilia B. In some embodiments, the subject can be a human suspected of having HAE. Alternatively, the subject can be a human diagnosed as being at risk for HAE. In some embodiments, the subject in need of treatment may have one or more genetic defects (e.g., deletions, insertions, and / or mutations) in the endogenous GOI or its regulatory sequences, such that the expression level or activity, including functionality, of the GOI product is significantly reduced compared to a normal, healthy subject.

[0387] In some embodiments, provided herein are methods of treating hemophilia A in a subject, the method comprising providing to a cell in the subject: (a) a gRNA, or a nucleic acid encoding a gRNA, comprising a spacer sequence from any one of SEQ ID NOS: 18-44 and 104; (b) a DNA endonuclease or a nucleic acid encoding a DNA endonuclease; and (c) a donor template comprising a nucleic acid sequence encoding a GOI or a functional derivative. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 30. In some embodiments, the cell is a human cell, e.g., a human hepatocyte. In some embodiments, the subject is a patient with or suspected of having hemophilia A, hemophilia B, MPS II, MPS1H, alpha-1-antitrypsin deficiency, FXIII deficiency, FVII deficiency, FX deficiency, protein C deficiency, or HAE. In some embodiments, the subject has been diagnosed as being at risk for hemophilia A.

[0388] In some embodiments, provided herein are methods of treating hemophilia B in a subject, the method comprising providing to a cell in the subject: (a) a gRNA, or a nucleic acid encoding a gRNA, comprising a spacer sequence from any one of SEQ ID NOS: 18-44 and 104; (b) a DNA endonuclease or a nucleic acid encoding a DNA endonuclease; and (c) a donor template comprising a nucleic acid sequence encoding a GOI or a functional derivative. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 30. In some embodiments, the cell is a human cell, e.g., a human hepatocyte. In some embodiments, the subject is a patient with or suspected of having hemophilia B. In some embodiments, the subject is diagnosed as being at risk for hemophilia B.

[0389] In some embodiments, provided herein are methods for treating HAE in a subject, the method comprising providing to a cell in the subject: (a) a gRNA or a nucleic acid encoding the gRNA, comprising a spacer sequence from any one of SEQ ID NOS: 18-44 and 104; (b) a DNA endonuclease or a nucleic acid encoding the DNA endonuclease; and (c) a donor template comprising a nucleic acid sequence encoding a GOI or a functional derivative. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOS: 21, 22, 28, and 30. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 21. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 22. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 28. In some embodiments, the gRNA comprises a spacer sequence from SEQ ID NOS: 30. In some embodiments, the cell is a human cell, e.g., a human hepatocyte. In some embodiments, the subject is a patient with or suspected of having hereditary angioedema. In some embodiments, the subject has been diagnosed as being at risk for hereditary angioedema.

[0390] In some embodiments, any of the methods of treating a disorder or condition described herein causes the DNA endonuclease to recognize a protospacer adjacent motif (PAM) having the sequence NGG or NNGG, where N is any nucleotide or functional derivative thereof. In some embodiments, the DNA endonuclease is a type II Cas endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 is derived from Streptococcus pyogenes (spCas9). In some embodiments, the Cas9 is derived from Staphylococcus lugdunensis (SluCas9).

[0391] In some embodiments, the nucleic acid sequence encoding the GOI or a functional derivative thereof is codon-optimized for expression in a cell, in some embodiments, the cell is a human cell, in accordance with any of the methods of treating a disorder or condition described herein.

[0392] In some embodiments, any of the methods for treating disorders or conditions described herein employ a nucleic acid encoding a DNA endonuclease. In some embodiments, the nucleic acid encoding the DNA endonuclease is codon-optimized for expression in a cell. In some embodiments, the cell is a human cell, such as a human hepatocyte. In some embodiments, the nucleic acid encoding the DNA endonuclease is DNA, such as a DNA plasmid. In some embodiments, the nucleic acid encoding the DNA endonuclease is RNA, such as mRNA.

[0393] In some embodiments, in any of the methods for treating a disorder or condition described herein, the donor template is encoded by an AAV vector. In some embodiments, the donor template comprises a donor cassette comprising a nucleic acid sequence encoding a GOI or a functional derivative, wherein the donor cassette is flanked on one or both sides by gRNA target sites. In some embodiments, the donor cassette is flanked on both sides by gRNA target sites. In some embodiments, the gRNA target sites are target sites for the gRNA in (a). In some embodiments, the gRNA target site in the donor template is the reverse complement of the cellular genomic gRNA target site for the gRNA in (a). In some embodiments, providing the donor template to the cell comprises administering the donor template to the subject. In some embodiments, the administration is via an intravenous route.

[0394] In some embodiments, in any of the methods for treating a disorder or condition described herein, the DNA endonuclease or a nucleic acid encoding the DNA endonuclease is formulated in a liposome or lipid nanoparticle. In some embodiments, the liposome or lipid nanoparticle also comprises a gRNA. In some embodiments, providing a cell with a gRNA and a DNA endonuclease or a nucleic acid encoding the DNA endonuclease comprises administering the liposome or lipid nanoparticle to a subject. In some embodiments, the administration is via an intravenous route. In some embodiments, the liposome or lipid nanoparticle is a lipid nanoparticle. In some embodiments, the method uses a lipid nanoparticle comprising a nucleic acid encoding the DNA endonuclease and the gRNA. In some embodiments, the nucleic acid encoding the DNA endonuclease is an mRNA encoding the DNA endonuclease.

[0395] In some embodiments, according to any of the methods of treating a disorder or condition described herein, the DNA endonuclease is pre-complexed with the gRNA to form an RNP complex.

[0396] In some embodiments, in any of the methods for treating a disorder or condition described herein, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell more than four days after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell at least 14 days after the donor template of (c) is provided to the cell. In some embodiments, the gRNA of (a) and the DNA endonuclease or nucleic acid encoding the DNA endonuclease of (b) are provided to the cell at least 17 days after the donor template of (c) is provided to the cell. In some embodiments, providing the cells with (a) and (b) comprises administering (e.g., intravenously) lipid nanoparticles containing a nucleic acid encoding a DNA endonuclease and a gRNA to a subject. In some embodiments, the nucleic acid encoding the DNA endonuclease is an mRNA encoding a DNA endonuclease. In some embodiments, providing the cells with (c) comprises administering (e.g., intravenously) a donor template encoded by an AAV vector to a subject.

[0397] In some embodiments, according to any of the methods for treating a disorder or condition described herein, one or more additional doses of (a) the gRNA and (b) the DNA endonuclease or nucleic acid encoding the DNA endonuclease are provided to the cell following the first dose of (a) the gRNA and (b) the DNA endonuclease or nucleic acid encoding the DNA endonuclease. In some embodiments, one or more additional doses of (a) the gRNA and (b) the DNA endonuclease or nucleic acid encoding the DNA endonuclease are provided to the cell following the first dose of (a) the gRNA and (b) the DNA endonuclease or nucleic acid encoding the DNA endonuclease until a target level of targeted integration of the nucleic acid sequence encoding the GOI or functional derivative and / or a target level of expression of the nucleic acid sequence encoding the GOI or functional derivative is achieved. In some embodiments, providing (a) and (b) to the cell comprises administering (e.g., by intravenous route) lipid nanoparticles comprising the DNA endonuclease and the nucleic acid encoding the gRNA to the subject. In some embodiments, the nucleic acid encoding the DNA endonuclease is an mRNA encoding the DNA endonuclease.

[0398] In some embodiments, according to any of the methods of treating a disorder or condition described herein, the nucleic acid sequence encoding the GOI or a functional derivative is expressed under the control of the endogenous albumin promoter.

[0399] In some embodiments, any of the methods of treating a disorder or condition described herein causes the nucleic acid sequence encoding the GOI or a functional derivative to be expressed in the liver of the subject.

[0400] Transplanting the cells into a subject In some embodiments, the ex vivo methods of the present disclosure include transplanting genome-edited cells into a subject in need of such a method. This transplantation step can be accomplished using any transplantation method known in the art. For example, the genetically modified cells can be injected directly into the subject's blood or administered to the subject by other means.

[0401] In some embodiments, the methods disclosed herein involve administering genetically modified therapeutic cells to a subject by a method or route that results in at least partial localization of the introduced cells at a desired site to produce the desired effect(s), which can be used interchangeably with "introducing" and "implanting." The therapeutic cells, or their differentiated progeny, can be administered by any suitable route that results in delivery to a desired location in a subject, where at least a portion of the transplanted cells or components of the cells remain viable. The survival period of the cells after administration to a subject can be as short as a few hours, e.g., 24 hours, days, as long as several years, or even the lifespan of the patient, i.e., long-term engraftment.

[0402] When provided prophylactically, the therapeutic cells described herein can be administered to a subject prior to any symptoms of a GOI-related disorder or condition, e.g., hemophilia A. Thus, in some embodiments using the FVIII gene for the treatment of hemophilia A, prophylactic administration of a cell population of genetically modified hepatocytes serves to prevent the onset of hemophilia A symptoms.

[0403] When provided therapeutically in some embodiments, cells of genetically modified hepatocytes are provided, for example, at the onset of disease, at (or after) the onset of symptoms or signs of a GOI-associated disorder or condition.

[0404] In some embodiments, the therapeutic hepatocyte cell population administered according to the methods described herein comprises allogeneic hepatocyte cells obtained from one or more donors. "Allogeneic" refers to hepatocyte cells or a biological sample containing hepatocyte cells obtained from one or more different donors of the same species, where the genes at one or more genetic loci are not identical. For example, the hepatocyte cell population administered to a subject can be derived from one or more unrelated donor subjects, or from one or more non-identical siblings. In some embodiments, syngeneic hepatocyte cell populations can be used, such as those obtained from genetically identical animals or identical twins. In other embodiments, the hepatocyte cells are autologous, i.e., the hepatocyte cells are obtained or isolated from a subject and administered to the same subject, i.e., the donor and recipient are the same.

[0405] In some embodiments, an effective amount refers to the amount of a population of therapeutic cells necessary to prevent or alleviate at least one sign or symptom of a GOI-associated disorder or condition, and relates to a sufficient amount of a composition to provide the desired effect, e.g., treat a subject with a GOI-associated disorder or condition. In some embodiments, a therapeutically effective amount therefore refers to the amount of therapeutic cells or a composition comprising therapeutic cells sufficient to promote a particular effect when administered to a typical subject, such as one with or at risk for a GOI-associated disorder or condition. An effective amount also includes an amount sufficient to prevent or delay the onset of disease symptoms, alter the course of disease symptoms (e.g., without limitation, slow the progression of disease symptoms), or reverse disease symptoms. It is understood that the appropriate effective amount for any given case can be determined by one of ordinary skill in the art using routine experimentation.

[0406] For use in the various embodiments described herein, an effective amount of therapeutic cells, e.g., genome-edited hepatocytes, is at least 10 cells. 2 Cells, at least 5 x 10 2 cells, at least 10 3 Cells, at least 5 x 10 3 cells, at least 104 Cells, at least 5 x 10 4 cells, at least 10 5 Cells, at least 2 x 10 5 Cells, at least 3 x 10 5 Cells, at least 4 x 10 5 Cells, at least 5 x 10 5 Cells, at least 6 x 10 5 Cells, at least 7 x 10 5 Cells, at least 8 x 10 5 cells, at least 9 x 10 5 cells, at least 1 x 10 6 Cells, at least 2 x 10 6 Cells, at least 3 x 10 6 Cells, at least 4 x 10 6 Cells, at least 5 x 10 6 Cells, at least 6 x 10 6 Cells, at least 7 x 10 6 Cells, at least 8 x 10 6 cells, at least 9 x 10 6 The therapeutic cells can be derived from one or more donors or from an autologous source. In some embodiments described herein, the therapeutic cells are expanded in culture prior to administration to a subject in need thereof.

[0407] In some embodiments, a small, gradual increase in the level of a functional GOI product expressed in cells of a patient with a GOI-associated disorder or condition can be beneficial in ameliorating one or more symptoms of the disease, increasing long-term survival, and / or reducing side effects associated with other treatments. The presence of therapeutic cells that increase the level of a functional GOI product when administered to a human patient is beneficial. In some embodiments, effective treatment of a subject results in an increase in functional GOI product of at least about 1%, 3%, 5%, or 7% compared to the total GOI product in the treated subject. In some embodiments, the functional GOI product is at least about 10% of the total GOI product. In some embodiments, the functional GOI product is at least, about, or at most 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the total GOI product. Similarly, the introduction of even a relatively limited subpopulation of cells with significantly increased levels of a functional GOI product can be beneficial for various patients, as in some situations, normalized cells have a selective advantage over diseased cells. However, even moderate levels of therapeutic cells having elevated levels of functional GOI product may be beneficial in ameliorating one or more aspects of a GOI-associated disorder or condition in a patient. In some embodiments, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more of the treatments in patients to whom such cells are administered result in increased levels of functional GOI product.

[0408] In some embodiments, delivery of a therapeutic cell composition to a subject by a method or route results in at least partial localization of the cell composition at a desired site. The cell composition can be administered by any suitable route that results in effective treatment in the subject, i.e., administration results in delivery to the desired location in the subject, and at least a portion of the delivered composition, i.e., at least 1×10 4The cells are delivered to the desired location over a period of time. Administration methods include injection, infusion, drip, or ingestion. "Injection" includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intravesical, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebrospinal, and intrasternal injection and infusion. In some embodiments, the route is intravenous. For delivery of cells, administration can be performed by injection or infusion.

[0409] In some embodiments, the cells are administered systemically, in other words, a population of therapeutic cells is administered not directly to a target site, tissue, or organ, but instead enters the subject's circulatory system and is therefore subject to metabolic and other similar processes.

[0410] The effectiveness of treatment with a composition for the treatment of a GOI disorder or condition can be determined by a skilled clinician. However, a treatment is considered "effective" if one or all signs or symptoms of the level of a functional GOI product are beneficially altered (e.g., increased by at least 10%) or other clinically recognized symptoms or markers of the disease are improved or ameliorated. Efficacy can also be measured by the lack of deterioration of the individual, as assessed by the need for hospitalization or medical intervention (e.g., the progression of the disease is halted or at least slowed). Methods for measuring these indicators are known to those skilled in the art and / or described herein. Treatment includes any treatment of disease in an individual or animal (some non-limiting examples include humans or mammals), including (1) inhibiting the disease, e.g., halting or slowing the progression of symptoms, or (2) palliating the disease, e.g., causing regression of symptoms, and (3) preventing or reducing the likelihood of the onset of symptoms.

[0411] In some embodiments, provided herein is a genetically modified cell according to any of the embodiments described herein for use in treating a disorder or condition associated with a functional target protein deficiency, such as for use in the manufacture of a medicament for treating the disorder or condition.

[0412] composition In one aspect, the present disclosure provides compositions for carrying out the methods disclosed herein, which include one or more of the following: a genome-targeting nucleic acid (e.g., gRNA), a site-specific polypeptide (e.g., DNA endonuclease) or a nucleotide sequence encoding the site-specific polypeptide, and a polynucleotide (e.g., donor template) to be inserted to effect the desired genetic modification of the methods disclosed herein.

[0413] In some embodiments, the composition comprises a nucleotide sequence encoding a genome-targeting nucleic acid (e.g., a gRNA).

[0414] In some embodiments, the composition comprises a site-directed polypeptide (e.g., a DNA endonuclease). In some embodiments, the composition comprises a nucleotide sequence encoding the site-directed polypeptide.

[0415] In some embodiments, the composition comprises a polynucleotide (eg, a donor template) to be inserted into a genome.

[0416] In some embodiments, the composition has (i) a nucleotide sequence encoding a genome-targeting nucleic acid (e.g., a gRNA), and (ii) a site-directed polypeptide (e.g., a DNA endonuclease) or a nucleotide sequence encoding a site-directed polypeptide.

[0417] In some embodiments, the composition has (i) a nucleotide sequence encoding a genome-targeting nucleic acid (e.g., a gRNA), and (ii) a polynucleotide to be inserted into the genome (e.g., a donor template).

[0418] In some embodiments, the composition has (i) a site-directed polypeptide (e.g., a DNA endonuclease) or a nucleotide sequence encoding the site-directed polypeptide, and (ii) a polynucleotide to be inserted into the genome (e.g., a donor template).

[0419] In some embodiments, the composition has (i) a nucleotide sequence encoding a genome-targeting nucleic acid (e.g., a gRNA), (ii) a site-directed polypeptide (e.g., a DNA endonuclease) or a nucleotide sequence encoding a site-directed polypeptide, and (iii) a polynucleotide to be inserted into the genome (e.g., a donor template).

[0420] In some embodiments of any of the above compositions, the composition comprises a single-molecule guide genome-targeting nucleic acid. In some embodiments of any of the above compositions, the composition comprises a dual-molecule genome-targeting nucleic acid. In some embodiments of any of the above compositions, the composition comprises two or more dual-molecule guides or single-molecule guides. In some embodiments, the composition comprises a vector encoding the nucleic acid-targeting nucleic acid. In some embodiments, the genome-targeting nucleic acid is a DNA endonuclease, particularly Cas9.

[0421] In some embodiments, the composition can comprise one or more gRNAs that can be used for genome editing, particularly for inserting a GOI or its derivatives into the genome of a cell. The gRNA for the composition can target a genomic site in, within, or near the endogenous albumin gene. Thus, in some embodiments, the gRNA can have a spacer sequence that is complementary to the genomic sequence in, within, or near the albumin gene.

[0422] In some embodiments, the gRNA for the composition is a sequence selected from those listed in Table 3 and variants thereof having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% identity or homology to any of those listed in Table 3. In some embodiments, a variant of the gRNA for the kit has at least about 85% homology to any of those listed in Table 3.

[0423] In some embodiments, the gRNA for the composition has a spacer sequence that is complementary to a target site in the genome. In some embodiments, the spacer sequence is 15 to 20 bases in length. In some embodiments, the complementarity between the spacer sequence and the genome sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100%.

[0424] In some embodiments, the composition can have a donor template having a DNA endonuclease or a nucleic acid encoding a DNA endonuclease and / or the nucleic acid sequence of GOI or its functional derivative.In some embodiments, the DNA endonuclease is Cas9.In some embodiments, the nucleic acid encoding a DNA endonuclease is DNA or RNA.

[0425] In some embodiments, one or more of any oligonucleotide or nucleic acid sequences for the kit can be encoded by an AAV vector.Thus, in some embodiments, the gRNA can be encoded by an AAV vector.In some embodiments, the nucleic acid encoding the DNA endonuclease can be encoded by an AAV vector.In some embodiments, the donor template can be encoded by an AAV vector.In some embodiments, two or more oligonucleotide or nucleic acid sequences can be encoded by a single AAV vector.Thus, in some embodiments, the gRNA sequence and the nucleic acid encoding the DNA endonuclease can be encoded by a single AAV vector.

[0426] In some embodiments, the composition can comprise liposomes or lipid nanoparticles. Thus, in some embodiments, any of the components of the composition (e.g., the DNA endonuclease or the nucleic acid encoding it, the gRNA, and the donor template) can be formulated into liposomes or lipid nanoparticles. In some embodiments, one or more such compounds are associated with the liposomes or lipid nanoparticles via covalent or non-covalent bonds. In some embodiments, any of the components can be contained separately or together in the liposomes or lipid nanoparticles. Thus, in some embodiments, the DNA endonuclease or the nucleic acid encoding it, the gRNA, and the donor template are each formulated separately in the liposomes or lipid nanoparticles. In some embodiments, the DNA endonuclease is formulated together with the gRNA in the liposomes or lipid nanoparticles. In some embodiments, the DNA endonuclease or the nucleic acid encoding it, the gRNA, and the donor template are formulated together in the liposomes or lipid nanoparticles.

[0427] In some embodiments, the above-described compositions further comprise one or more additional reagents, such as selected from buffers, buffers for introducing polypeptides or polynucleotides into cells, wash buffers, control reagents, control vectors, control RNA polynucleotides, reagents for in vitro production of polypeptides from DNA, adapters for sequencing, etc. The buffer may be a stabilization buffer, a reconstitution buffer, a dilution buffer, etc. In some embodiments, the compositions may also include one or more components that can be used to facilitate or enhance intra-target binding or DNA cleavage by the endonuclease, or to improve targeting specificity.

[0428] In some embodiments, any component of the composition can be formulated with pharmaceutically acceptable excipients, such as carriers, solvents, stabilizers, adjuvants, and diluents, depending on the particular mode of administration and dosage form. In some embodiments, guide RNA compositions are formulated to achieve a physiologically compatible pH, typically ranging from about pH 3 to about pH 11, or from about pH 3 to about pH 7, depending on the formulation and route of administration. In some embodiments, the pH is adjusted to a range of about pH 5.0 to about pH 8. In some embodiments, the composition comprises a therapeutically effective amount of at least one compound described herein together with one or more pharmaceutically acceptable excipients. Optionally, the composition can comprise a combination of compounds described herein, or can contain a second active ingredient useful for treating or preventing bacterial growth (e.g., without limitation, an antibacterial or antimicrobial agent), or can include a combination of reagents of the present disclosure. In some embodiments, the gRNA is formulated with one or more other oligonucleotides, such as a nucleic acid encoding a DNA endonuclease and / or a donor template. Alternatively, the nucleic acid encoding the DNA endonuclease and the donor template are formulated separately or in combination with other oligonucleotides using the methods described above for gRNA formulation.

[0429] Suitable excipients may include carrier molecules comprising large, slowly metabolized macromolecules, such as, for example, proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Other exemplary excipients include antioxidants (e.g., but not limited to, ascorbic acid), chelating agents (e.g., but not limited to, EDTA), carbohydrates (e.g., but not limited to, dextrin, hydroxyalkylcellulose, and hydroxyalkylmethylcellulose), stearic acid, liquids (e.g., but not limited to, oils, water, saline, glycerol, and ethanol), wetting or emulsifying agents, pH buffering substances, and the like.

[0430] In some embodiments, any component of the composition (e.g., DNA endonuclease or the nucleic acid encoding it, gRNA, and donor template) can be delivered via transfection, such as electroporation. In some exemplary embodiments, the DNA endonuclease can be pre-complexed with gRNA to form an RNP complex before being delivered to cells, and the RNP complex can be electroporated. In such embodiments, the donor template can be delivered via electroporation.

[0431] In some embodiments, the composition refers to a therapeutic composition having therapeutic cells for use in ex vivo therapy.

[0432] In some embodiments, a therapeutic composition can include a cell composition together with a physiologically acceptable carrier, and optionally at least one additional bioactive agent described herein dissolved or dispersed therein as an active ingredient. In some embodiments, a therapeutic composition is not substantially immunogenic when administered to a mammalian or human patient for therapeutic purposes, unless desired.

[0433] Generally, the genetically modified therapeutic cells described herein are administered as an emulsion in a pharmaceutically acceptable carrier. Those skilled in the art will recognize that the pharmaceutically acceptable carrier used in the cell composition does not contain buffers, compounds, cryopreservatives, preservatives, or other agents in amounts that substantially interfere with the viability of the cells delivered to a subject. The cell-containing formulation may include, for example, an osmotic buffer that allows the integrity of the cell membrane to be maintained, and optionally, nutrients that maintain cell viability or enhance engraftment upon administration. Such formulations and suspensions are known to those skilled in the art and / or can be adapted for use with progenitor cells as described herein using routine experimentation.

[0434] In some embodiments, the cell composition may be emulsified or provided as a liposomal composition, so long as the emulsification procedure does not adversely affect cell viability. The cells and any other active ingredients may be mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredients, in amounts suitable for use in the therapeutic methods described herein.

[0435] Additional agents included in the cell compositions can contain pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the polypeptide) formed with inorganic acids such as hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, tartaric acid, or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, or procaine.

[0436] Physiologically acceptable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that contain no active ingredient and water, or buffers such as sodium phosphate at physiological pH, physiological saline, or phosphate-buffered saline. Furthermore, aqueous carriers can contain two or more buffer salts, and salts such as sodium chloride and potassium chloride, dextrose, polyethylene glycol, and other solutes. Liquid compositions can also contain liquid phases in addition to water, and in addition to the exclusion of water. Examples of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions. The amount of active compound used in the cell composition that is effective in treating a particular disorder or condition depends on the nature of the disorder or condition and can be determined by standard clinical techniques.

[0437] kit Some embodiments provide kits that include any of the compositions described above, e.g., a composition for genome editing or a therapeutic cell composition, and one or more additional components.

[0438] In some embodiments, the kit can have one or more additional therapeutic agents that can be administered simultaneously or sequentially with the composition for a desired purpose, e.g., genome editing or cell therapy.

[0439] In some embodiments, the kit can further include instructions for practicing a method using the components of the kit. The instructions for practicing the method are recorded on a suitable recording medium. For example, the instructions can be printed on a substrate such as paper or plastic. The instructions can be present as a package insert, on a label of the kit's container or a component thereof, or the like (i.e., associated with the packaging or subpackaging). The instructions can be present as an electronic storage data file present on a suitable computer-readable storage medium, such as a CD-ROM, diskette, flash drive, etc. In some cases, the actual instructions are not present in the kit, but a means for obtaining the instructions from a remote source (e.g., via the Internet) can be provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions can be recorded on a suitable substrate.

[0440] Other possible treatment approaches Gene editing can be performed using nucleases engineered to target specific sequences. To date, there are four major types of nucleases: meganucleases and their derivatives, zinc finger nucleases (ZFNs), transcription activators like effector nucleases (TALENs), and the CRISPR-Cas9 nuclease system. Because the specificity of ZFNs and TALENs is dependent on protein-DNA interactions, while RNA-DNA interactions primarily guide Cas9, nuclease platforms differ in design difficulty, targeting density, and mode of action. Cas9 cleavage also requires a flanking motif, the PAM, which differs between different CRISPR systems. Streptococcus pyogenes-derived Cas9 cleaves using the NRG PAM, while Neisseria meningitidis-derived CRISPR cleaves at sites with PAMs including NNNNGATT (SEQ ID NO: 101), NNNNGTTTT (SEQ ID NO: 102), and NNNNGCTT (SEQ ID NO: 103). Many other Cas9 orthologs target protospacers adjacent to alternative PAMs.

[0441] CRISPR endonuclease such as Cas9 can be used in various embodiments of the method of the present disclosure.However, the teachings described herein, such as therapeutic targeting site, can be applied to other forms of endonuclease, such as ZFN, TALEN, HE or MegaTAL, or can use a combination of nucleases.However, in order to apply the teachings of the present disclosure to such endonuclease, it will be necessary to engineer proteins that are specifically directed to specific targeting sites.

[0442] Additional binding domains can be fused to the Cas9 protein to enhance specificity. The target site of these constructs maps to the identified gRNA-directed site but requires additional binding motifs, such as zinc finger domains. In the case of Mega-TALs, meganucleases can be fused to the TALE DNA-binding domain. The meganuclease domain enhances specificity and provides cleavage. Similarly, inactivated or dead Cas9 (dCas9) can be fused to a cleavage domain, requiring adjacent binding sites for the sgRNA / Cas9 target site and the fused DNA-binding domain. This would require some protein engineering of dCas9, in addition to catalytic inactivation, to reduce binding without additional binding sites.

[0443] In some embodiments, compositions and methods for editing a genome (e.g., inserting a GOI coding sequence into the albumin locus) in accordance with the present disclosure can utilize or be performed using any of the following approaches:

[0444] Zinc finger nuclease Zinc finger nucleases (ZFNs) are modular proteins with zinc finger DNA-binding domains engineered to bind to the catalytic domain of the type II endonuclease FokI. Because FokI functions only as a dimer, pairs of ZFNs must be engineered to bind to cognate target "half-site" sequences on opposing DNA strands with precise spacing to allow the formation of catalytically active FokI dimers. Dimerization of the FokI domains, which have no sequence specificity themselves, generates a DNA double-strand break between the ZFN half-sites as the initiating step in genome editing.

[0445] The DNA-binding domain of each ZFN typically contains three to six zinc fingers with a Cys2-His2 rich architecture. Each finger primarily recognizes a triplet of nucleotides on one strand of the target DNA sequence, although interstrand interactions with the fourth nucleotide are also important. Amino acid modifications of the fingers at positions that make critical contacts with DNA alter the sequence specificity of a particular finger. Thus, a four-finger zinc finger protein selectively recognizes a 12-bp target sequence. The target sequence is a composite of triplet preferences contributed by each finger, but triplet preferences can be influenced to different degrees by adjacent fingers. A key aspect of ZFNs is that they can be easily retargeted to almost any genomic address simply by modifying individual fingers, although this requires considerable expertise to do successfully. Most applications of ZFNs use proteins with four to six fingers, each recognizing 12 to 18 bp. Thus, a pair of ZFNs will typically recognize a 24 to 36-bp binding target sequence, not including the 5 to 7 bp spacer between half sites. Binding sites can be further separated by larger spacers, including 15–17 bp. Target sequences of this length are likely unique in the human genome, assuming repetitive sequences or gene homologs are excluded during the design process. Nevertheless, ZFN protein-DNA interactions are not absolute in specificity, and off-target binding and cleavage events can occur either as heterodimers between two ZFNs or as homodimers of one or the other ZFN. The latter possibility was effectively eliminated by engineering the dimerization interface of the FokI domain to create "plus" and "minus" variants, also known as obligate heterodimer variants, that can dimerize only with each other, not with themselves. Enforcing obligate heterodimerization prevents homodimer formation. This significantly improves the specificity of ZFNs, as well as any other nucleases that employ these FokI variants.

[0446] A variety of ZFN-based systems have been described in the art, and their modifications are regularly reported, and many references describe the rules and parameters used to guide the design of ZFN.For example, see Segal et al., Proc Natl Acad Sci USA 96(6):2758-63(1999); Dreier B et al., J Mol Biol.303(4):489-502(2000); Liu Q et al., J Biol Chem.277(6):3850-6(2002); Dreier et al., J Biol Chem 280(42):35588-97(2005) and Dreier et al., J Biol Chem.276(31):29466-78(2001).

[0447] Transcription activator-like effector nucleases (TALENs) Similar to ZFNs, TALENs represent another form of modular nuclease in which an engineered DNA-binding domain is linked to a FokI nuclease domain. A pair of TALENs cooperate to achieve targeted DNA cleavage. Their primary difference from ZFNs is the nature of the DNA-binding domain and the associated target DNA sequence recognition properties. The TALEN DNA-binding domain is derived from the TALE protein, originally described in the plant bacterial pathogen Xanthomonas species. TALEs have a tandem array of 33–35 amino acid repeats, each of which recognizes a single base pair in the target DNA sequence, typically up to 20 bp long and with a total target sequence length of up to 40 bp. The nucleotide specificity of each repeat is determined by a repeat variable dipeptide (RVD), which contains only two amino acids at positions 12 and 13. The bases guanine, adenine, cytosine, and thymine are primarily recognized by four RVDs: Asn-Asn, Asn-Ile, His-Asp, and Asn-Gly, respectively. This constitutes a much simpler recognition code than zinc fingers and therefore represents an advantage over the latter in terms of nuclease design. Nevertheless, like ZFNs, TALEN protein-DNA interactions are not absolute in their specificity, and TALENs also benefit from the use of obligate heterodimeric variants of the FokI domain to reduce off-target activity.

[0448] Additional variants of the FokI domain have been created in which catalytic function is disabled. When either half of a TALEN or ZFN pair contains an inactive FokI domain, only single-strand DNA breaks (nicking) occur at the target site, rather than DSBs. The results are comparable to the use of CRISPR / Cas9 / Cpf1 "nickase" mutants in which one of the Cas9 cleavage domains is inactivated. DNA nicks can be used to drive genome editing via HDR, although with lower efficiency than DSBs. A key advantage is that off-target nicks are repaired quickly and accurately, unlike DSBs, which are prone to misrepair via NHEJ.

[0449] A variety of TALEN-based systems have been described in the art, and their modifications are regularly reported.For example, see Boch, Science 326(5959):1509-12(2009); Mak et al., Science 335(6069):716-9(2012) and Moscou et al., Science 326(5959):1501(2009).The use of TALEN based on " Golden Gate " platform or cloning scheme has been described by several groups. See, for example, Cermak et al., Nucleic Acids Res. 39(12):e82(2011), Li et al., Nucleic Acids Res. 39(14):6315-25(2011), Weber et al., PLoS One. 6(2):e16765(2011), Wang et al., J Genet Genomics 41(6):339-47, Epub 2014 Can 17(2014), and Cermak T et al., Methods Mol Biol. 1239:133-59(2015).

[0450] Homing endonucleases Homing endonucleases (HEs) are sequence-specific endonucleases that have long recognition sequences (14–44 base pairs) and often cleave DNA with high specificity at unique sites in the genome. There are at least six known HE families, categorized by their structure, including LAGLIDADG (SEQ ID NO: 6), GIY-YIG, His-Cis box, HNH, PD-(D / E)xK, and VSR-like, derived from a wide range of hosts (including eukaryotes, protists, bacteria, archaea, cyanobacteria, and phages). Similar to ZFNs and TALENs, HEs can be used to create DSBs at target loci as the first step in genome editing. Furthermore, some natural and engineered HEs cleave only a single strand of DNA, thereby functioning as site-specific nickases. The large target sequences of HEs and the specificity they provide make them attractive candidates for creating site-specific DSBs.

[0451] Various HE-based systems have been described in the art, and modifications thereof are regularly reported. For example, see the reviews by Steentoft et al., Glycobiology 24(8):663-80(2014), Belfort and Bonocora, Methods Mol Biol.1123:1-26(2014), Hafez and Hausner, Genome 55(8):553-69(2012), and the references cited therein.

[0452] MegaTAL / Tev-mTALEN / MegaTev As further examples of hybrid nucleases, the MegaTAL and Tev-mTALEN platforms utilize the fusion of a TALE DNA-binding domain and a catalytically active HE, taking advantage of both the tunable DNA binding and specificity of the TALE and the cleavage sequence specificity of the HE. See, for example, Boissel et al., NAR 42:2591-2601 (2014), Kleinstiver et al., G3 4:1155-65 (2014), and Boissel and Scharenberg, Methods Mol. Biol. 1239:171-96 (2015).

[0453] In a further variant, the MegaTev architecture is a fusion of a meganuclease (Mega) with a nuclease domain derived from the GIY-YIG homing endonuclease I-TevI ​​(Tev). The two active sites are positioned approximately 30 bp apart on the DNA substrate, generating two DSBs with incompatible sticky ends. See, for example, Wolfs et al., NAR 42, 8816-29 (2014). It is expected that other combinations of existing nuclease-based approaches will evolve and be useful for achieving the targeted genome modifications described herein.

[0454] dCas9-FokI or dCpf1-Fok1 and other nucleases Combining the structural and functional properties of the above nuclease platforms offers an additional approach to genome editing that can potentially overcome some of their inherent deficiencies. For example, CRISPR genome editing systems typically use a single Cas9 endonuclease to create DSBs. Targeting specificity is driven by a 20- or 22-nucleotide sequence in the guide RNA that undergoes Watson-Crick base pairing with the target DNA (plus, in the case of S. pyogenes-derived Cas9, an additional two bases in the adjacent NAG or NGG PAM sequence). While such sequences are long enough to be unique in the human genome, the specificity of the RNA / DNA interaction is not absolute, and considerable perturbation can be tolerated, particularly in the 5′ half of the target sequence, effectively reducing the number of bases that drive specificity. One solution to this is to retain only the RNA-guided DNA-binding function of Cas9 or to completely inactivate the Cpf1 catalytic function and instead fuse the FokI domain to the inactivated Cas9. See, for example, Tsai et al., Nature Biotech 32:569-76 (2014) and Guilinger et al., Nature Biotech. 32:577-82 (2014). Because FokI must dimerize to be catalytically active, two guide RNAs are required to bring two FokI fusions into close proximity to form a dimer and cleave DNA. This essentially doubles the number of bases at the combined target site, thereby increasing the targeting stringency of CRISPR-based systems.

[0455] As a further example, fusion of a TALE DNA-binding domain to a catalytically active HE such as I-TevI ​​is expected to take advantage of both the tunable DNA binding and specificity of the TALE and the cleavage sequence specificity of I-TevI, further reducing off-target cleavage.

[0456] Details of one or more embodiments of the present disclosure are set forth in the accompanying description below. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, some exemplary materials and methods are described herein. Other features, objects, and advantages of the present disclosure will be apparent from the description. In the description, the singular also includes the plural unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present description shall prevail.

[0457] It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof will be suggested to those skilled in the art and are within the spirit and scope of this application and the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

[0458] Some embodiments of the disclosure provided herein are further illustrated by the following non-limiting examples. [Example]

[0459] Example 1: Identification of gRNAs that direct Cas9 nuclease cleavage in intron 1 of the mouse albumin gene in Hepa1-6 cells in vitro For the purpose of evaluation in relevant preclinical animal models, gRNA molecules directing efficient cleavage by Cas9 nuclease in intron 1 of albumin from relevant preclinical animal species were tested. The mouse model of hemophilia A is well established (Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH, Jr. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. (Nat Genet. 1995;10:119-21. doi:10.1038 / ng0595-119) and represents a valuable model system for testing novel therapeutic approaches for this disease. To identify gRNAs that could cleave intron 1 of mouse albumin, the sequence of the intron was compared to the sequence of interest and all related sequences in the mouse genome to identify NGGs that are potential targets for cleavage by Streptococcus pyogenes Cas9 (spCas9). The PAM sequence was analyzed using an algorithm (e.g., CCTOP; https: / / crispr.cos.uni-heidelberg.de / ) to identify all possible gRNA target sequences. Each gRNA was then ranked based on the frequency of its exact sequence or related sequences within the mouse genome to identify the gRNA with the least theoretical risk of off-target cleavage. Based on this type of analysis, a gRNA designated mALbgRNA_T1 was selected for testing.

[0460] mAlbgRNA_T1 shows homology to only four other sites in the mouse genome, each showing four nucleotide mismatches as shown in Table 2 below. [Table 3]

[0461] To evaluate the efficiency of mALbgRNA_T1 in promoting Cas9 cleavage in mouse cells, we used the mouse hepatocyte-derived cell line Hepa1-6. Hepa1-6 cells were cultured in DMEM + 10% FBS in a 5% CO2 incubator. RNPs consisting of gRNA bound to Streptococcus pyogenes Cas9 (spCas9) protein were preformed by mixing 2.4 μl of spCas9 (0.8 μg / μl) and 3 μl of synthetic gRNA (20 μM) in 7 μl of PBS (1:5 spCas9:gRNA ratio) and incubating for 10 min at room temperature. For nucleofection, a complete nucleofection reagent was prepared by adding an entire vial of SF Supplement Reagent (Lonza) to SF Nucleofector Reagent (Lonza). For each nucleofection, 1 × 10 5 Hepa1-6 cells were resuspended in 20 μl of complete nucleofection reagent, added to the RNP, and then transferred to a nucleofection cuvette (16-well strip) placed in a 4D nucleofection device (Lonza) and nucleofected using program EH-100. Cells were allowed to rest for 10 minutes before being transferred to an appropriately sized plate containing fresh complete medium. 48 hours after nucleofection, cells were harvested, and genomic DNA was extracted and purified using the Qiagen DNeasy kit (cat. 69506).

[0462] To assess the frequency of Cas9 / gRNA-mediated cleavage at the target site in albumin intron 1, a primer pair flanking the target site (MALBF3: 5'TTATTACGGTCTCATAGGGC3' (SEQ ID NO: 11) and MALBR5: AGTCTTTCTGTCAATGCACAC3' (SEQ ID NO: 12)) was used in a polymerase chain reaction (PCR) using an annealing temperature of 52°C to amplify a 609-bp region from genomic DNA. The PCR product was purified using a Qiagen PCR Purification Kit (Cat no. 28106) and directly sequenced using Sanger sequencing with the same primers used in the PCR reaction. Sequence data were analyzed by an algorithm called Tracking of Indels by Decomposition (TIDE), which determines the frequency of insertions and deletions (INDELs) present at the predicted cleavage site of the gRNA / Cas9 complex (Brinkman et al. (2014); Nucleic Acids Research, 2014, 1). The overall frequency of INDEL generation for mAlbgRNA_T1 was 85-95% when tested in three independent experiments, indicating efficient cleavage by gRNA / Cas9 in the genome of these cells. An example of TIDE analysis in Hepa1-6 cells nucleofected with mAlbg RNA-T1 is shown in Figure 3. Most insertions and deletions consist of 1-bp insertions and 1-bp deletions, with the number of deletions being small, up to 6 bp.

[0463] Example 2: Evaluation of the cleavage efficiency of mAlbgRNA_T1 in vivo in mice A lipid nanoparticle (LNP) delivery vehicle was used to deliver Cas9 and mAlbgRNA-T1 to mouse hepatocytes. The sgRNA was chemically synthesized incorporating chemically modified nucleotides to improve resistance to nucleases. An example gRNA is: [ka] The gRNA has t...

Claims

1. A guide RNA (gRNA) comprising a spacer sequence selected from the group consisting of SEQ ID NOs: 22, 21, 28, and 30.

2. The gRNA of claim 1, wherein the spacer sequence is SEQ ID NO:

22.

3. The gRNA of claim 1, wherein the spacer sequence is SEQ ID NO:

21.

4. The gRNA of claim 1, wherein the spacer sequence is SEQ ID NO:

28.

5. The gRNA of claim 1, wherein the spacer sequence is SEQ ID NO:

30.

6. The gRNA of any one of claims 1 to 5, wherein the gRNA sequence comprises a scaffold sequence.

7. The gRNA of any one of claims 1 to 6, wherein the gRNA is a single guide RNA.

8. A lipid nanoparticle comprising a gRNA according to any one of claims 1 to 7.